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1. INTRODUCTION 
1.1. Prostate cancer  
 Adenocarcinoma of prostate gland is the second most frequent cancer and 
sixth leading cause of mortality in males. The growth, development, and 
homeostasis of the prostate gland are under the control of androgens. Androgens, 
dihydrotestosterone (DHT) and testosterone bind with the androgen receptor (AR) 
and stimulate the growth of the prostate gland. The proliferation of the prostate 
gland occurs significantly during the time of puberty and after that, the androgens 
continue to play an important in maintaining the homeostasis of the prostate 
gland. In some men, with increasing age, androgen dependant proliferation of the 
prostate gland resumes, resulting in benign prostatic hyperplasia or malignant 
prostate cancer [1]. The AR antagonists competitively prevent the binding of 
androgens with AR. So, they are used in the treatment of prostate cancer [2].  
1.2. Structure and activation mechanism of AR 
 The AR has 900-920 amino acids and the variations in the amino acid 
number are due to the polymorphism in the length of polyglutamine (CAG 
repeats) and polyglycine (GGN repeats) tracts in the first exon. The AR was also 
divided into 4 regions such as variable N-terminal domain or activation function 1 
(AF - 1), DNA binding domain, hinge region, and ligand binding domain (LBD) 
or activation function 2 (AF - 2) [3]. The ligand binding domain has twelve α 
helixes and two β sheets that fold to form a hydrophobic ligand binding pocket to 
which the androgens bind. The helix-12 of the AR is the highly flexible and 
functions as a gate for the entry of ligands. Helix 3, 4, 5, and 10 are the primary 
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contact sites for androgens. The helix 3, 4 and 12 are the primary contact sites for 
co-activators. The binding of androgens with AR largely remains hydrophobic 
interactions with amino acids Val746, Met742, Gln711, Met745,  Leu707, 
Leu704, and Trp741. The hydrogen bond interactions with amino acids, Arg752, 
Gln711, Asn705, Asn704 and Thr877 also play a critical role in the specific 
binding of androgens to AR [4]. The AR agonists and antagonists bind to the same 
binding pocket but with one major difference between them. The AR antagonists 
were bulkier molecules than the agonist and because of this the AR antagonists 
prevent the closing of the helix-12 towards the ligand binding domain [5]. It 
attains an open and closed conformation in response to antagonist and agonist 
respectively. The closed conformation (agonist) favours interaction with co-
activators. The open conformation (antagonist) prevents the interaction of helix-12 
with co-activators and favours the interaction with co-repressors [6].  
 The Androgen binding causes the helix-12 to lie over the ligand binding 
pocket, which will reveal the domain for intramolecular AF-1 and AF-2 
interaction (N/C terminal interaction). The N/C terminal interaction is specific to 
AR. The N/C terminal interaction will lead to cascade of events like 
phosphorylation, dimerization, nuclear translocation, binding to specific AR 
response elements, co-activator recruitment, and initiation of transcription. Class 1 
family of co-activators such as steroid receptor co-activator - 1 (SRC-1) and 3, 
transcriptional intermediary factor-2 (TIF2) and class 2 family of co-activators 
such as, p300/cAMP (cyclic adenosine mono-phosphate) response element 
binding protein (CREB) regulates the transcriptional activity of AR. The co-
Chapter 1: Introduction 
 
PSG College of Pharmacy, Coimbatore. Page 3 
 
activators de-condense the chromatin and facilitate the binding of RNA 
polymerase for the initiation of transcriptional mechanism [3, 7]. 
1.3. Castration resistant prostate cancer 
 The hormonal therapy largely becomes ineffective and most of the prostate 
cancer relapses after a treatment median of 18-24 months. The relapsed prostate 
cancer is known as castration resistant prostate cancer (CRPC). The CRPC could 
be either androgen dependant or androgen independent prostate cancer (AIPC) [8, 
9]. In case of androgen dependant CRPC, the enzymes involved in the synthesis of 
androgens were over expressed which lead to the increase in the intracrine 
androgen level. The androgen dependant CRPC could be controlled by drugs 
which inhibit the synthesis of androgens [9, 10]. The AIPC doesn't depend on 
androgens for proliferation; instead it adapts various mechanisms to neutralize the 
hormonal therapy. Clinically, AIPC is defined as the ability of the prostate cancer 
cells to grow in the castrated plasma levels of androgen. The occurrence of point 
mutation in the ligand binding domain of the AR was one of the major reasons 
behind the development of AIPC [11]. 
1.4. AR mutations  
The mutation at amino acid Thr877 was frequently expressed in AIPC 
[11]. This mutant AR could be activated by non-androgens such as AR 
antagonists (flutamide, cyproterone acetate and nilutamide) and steroidal 
hormones (estradiol, glucocorticoids, progesterone, etc) [12, 13]. The AR 
antagonist, bicalutamide antagonizes the T877A (threonine to alanine) mutated 
AR but another mutation at amino acid Trp741 was identified among bicalutamide 
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treated patients resulting in relapse. The point mutations were specific to the AR 
antagonists and convert them into an agonist. This leads to the withdrawal of the 
antagonist from the treatment regimen [14, 15]. 
Table 1: AR antagonist and the resistance causing mutation 
S. No Classification AR antagonist Resistance 
1 Steroidal Cyproterone acetate, Megestrol,  
Medroxy progesterone 
T877A 
2. Non-steroidal 1st generation 
Flutamide, Nilutamide 
T877A 
  2nd generation 
Bicalutamide 
W741L 
  3rd generation 
Enzalutamide, 
ARN509 (clinical trials) 
F876L 
 
1.5. AR mediated activation of TMPRSS2-ETS gene fusion 
 The fusion of ETS (erythroblast transformation-specific) genes like ERG 
(ETS-related gene) and ETV1 (ETS translocation variant 1) with TMPRSS2 
(transmembrane protease serine 2) were identified in the significant number of 
AIPC patients. The TMPRSS2 is an AR response element. The ETS family of 
transcriptional factors is oncogenic and stimulates the cell differentiation, cell 
division, metastasis, and angiogenesis [16, 17]. The fusion of ETS genes with AR 
response elements results in the over expression of ETS genes whenever AR is 
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activated [16, 17]. The hormonal therapy decreases the plasma testosterone level 
but the mutated AR which is expressed in AIPC does not require androgen for 
activation. Consequently, the mutated AR could activate the expression of ETS 
genes without androgen. The AR mutation and ETS chromosomal rearrangement 
in conjunction could co-ordinate the AIPC progression and drug resistance for AR 
antagonist and cytotoxic drugs. A novel AR antagonist that resists the mutations 
and decreases the expression of ETS genes could well be the future for prostate 
cancer treatment. 
1.6. Hypothesis generation and work plan 
 At present, there are no AR antagonists in either market or in the clinical 
trials that could tolerate the point mutations. Hence, our aim the study is to 
identify a novel AR antagonist that could efficiently antagonize mutant ARs. The 
mechanism of the antagonist binding to either wild type or mutant ARs was yet to 
be elucidated. This is because there is no antagonist bound AR conformation in 
the protein data bank (PDB). The available co-crystal structures of AR with 
antagonist express mutation which converts them into an agonist. Hence the 
difference in the binding mechanism between the wild and mutant ARs should be 
elucidated for successful identification of the novel AR antagonist.  
 The structure based virtual screening could not be used for hits 
identification due to the lack of AR crystal structure. Hence, the essential 
functional groups (pharmacophore) of the AR antagonist should be derived 
through ligand based drug design methods. We also constructed a homology 
model of AR for docking studies. The homology model was used to visualize the 
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binding conformation of the identified hit molecules. Combining the outputs from 
the ligand and structure based drug design methods we had identified novel AR 
antagonist to treat AIPC. These new chemical entities have 4-nitro-phenyl or 4-
methoxy-phenyl or 4-fluoro-phenyl nucleus bearing bulky β-iminoenamine BF2 
group. In this study we identified the functional groups that are essential for an 
AR antagonist to overcome the resistance with mutant ARs. The anti prostate 
cancer activity of the new chemical entities was also been elucidated through 
various in-vitro techniques.  
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2. AIM AND OBJECTIVES OF THE STUDY 
2.1. Aim 
 To identify novel AR antagonist that could antagonize mutant ARs for the 
treatment of androgen independent prostate cancer. 
2.2. Specific objectives 
 To analyse the ligand/protein interactions between the wild and mutant ARs. 
 To develop a pharmacophore model for wild and mutant AR antagonists and 
to identify difference between the pharmacophore models. 
 Identification of new chemical entities through in-silico drug design 
methods. 
 In-vitro anti prostate cancer activity of the new chemical entities to identify 
the hit molecules. 
 To elucidate the anti-cancer mechanism of action of the best active 
molecule. 
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3. LITERATURE REVIEW 
3.1. Prostate cancer 
 Adenocarcinoma of prostate gland is the second most frequent cancer and 
sixth leading cause of mortality in males. The occurrence rate of prostate cancer is 
high in developed countries and the occurrence rate is lower in the central Asian 
countries. In the recent past, the death rates in the western countries were reduced 
due to improved diagnostic and treatment techniques [18]. The prostate gland is a 
heart shaped organ that surrounds the neck of the urethra which is presented 
immediately inferior to the bladder. The prostate gland empties the prostatic fluid 
into the urethra. The secretary portion of the gland is of epithelial cells, which are 
supported by fibro muscular stromal cells. The cancer develops in the epithelial 
cells and the stromal cell may aid in cancer progression and metastasis [19]. The 
risk factors for the prostate cancer are diverse and depends on  
1. Higher age 
2. Ethnicity  
3. Life style and  
4. Environmental factors.  
 The Japanese men have lower risk for prostate cancer because they have 
reduced 5α-reductase enzyme activity. This enzyme catalyzes the conversion of 
testosterone to dihydrotestosterone in the prostate cells. The pollutants like 
bisphenol A and other hormone disruptors also increase the risk of prostate 
cancer. The chemical, bisphenol A was present in plastics. Overweight and 
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consumption of animal products also increases the risk while intake of soy 
products decreases the risk [20].  
 The growth and development of prostate gland is under the control of 
androgens, dihydrotestosterone, testosterone and adrenal androgens. Androgen 
dependent growth of the prostate gland occurs significantly during the time of 
puberty and after that androgens continue to play an important role in its 
homeostasis. In some men with increasing age androgen dependent hyper-
proliferation of the prostate gland resumes resulting in benign prostatic 
hyperplasia or malignant prostate cancer [21]. Dihydrotestosterone is the major 
androgen and will be synthesized from testosterone in-vivo by an enzyme called 
5α-reductase. Dihydrotestosterone have more binding affinity for AR than the 
testosterone. Adrenal androgen also gets converted into dihydrotestosterone inside 
prostate cells by prostatic enzymes [22]. 
 The occurrence of prostate cancer could be either hereditary or sporadic. 
The mutation or variations in the hereditary prostate cancer loci are responsible 
for the pathogenesis of hereditary prostate cancer. In the hereditary prostate cancer 
the chances of prostate cancer occurrence is very high and occurs at young age. 
The genes that codes for proteins which are involved in cell division, cell repair 
and apoptosis are distorted [23]. Mutations of genes ribonuclease L, macrophage 
scavenger receptor 1, nibrin 1, checkpoint kinase 2, breast cancer type 2 
susceptibility protein, ElaC Ribonuclease Z 2, mismatch repair, and homeobox 
protein 13, p21, p27 and p53 are some of the reasons for the occurrence for of 
hereditary prostate cancer [24 - 30]. The sporadic prostate cancer is the most 
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common and widely occurring one. This depends on increasing age, ethnicity, 
environmental factors and life style. The metastatic potential to the cancer cells 
were guided by the down regulation of E-Cadherin. This results in epithelial 
mesenchymal transition and over expression of N-Cadherin which increases the 
heterotypic cell adhesion. This mechanism provides the metastasis and 
invasiveness to prostate cancer cells [31].  
 Prostate specific antigen (PSA) is a prostate cancer bio-marker and their 
serum level is an indicator for prostate cancer patients. Higher levels of PSA 
possess greater risk of prostate cancer occurrence. However, there is no prescribed 
PSA level below which the men can be assured no risk of prostate cancer. Prostate 
cancer antigen 3 (PCA3) and TMPRSS2-ERG fused genes are the new bio-
markers for prostate cancer patients. The new biomarkers have higher specificity 
and sensitivity for prostate cancer detection [32]. The major clinical symptoms 
experienced by prostate cancer patients are difficultly in urination, painful 
urination, loss of control over urination, low back pain, painful ejaculation, 
urethral dysfunction, and cord compression etc. 
3.2. Treatment for prostate cancer                                                                                                                                                                                      
3.2.1. Localized prostate cancer 
 Radical prostatectomy which involves the surgical removal of prostate 
gland, image guided radiotherapy which includes three-dimensional conformal 
radiotherapy and intensity modulated radio therapy are widely used to treat 
localized prostate cancer [33]. 
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3.2.2. Metastatic prostate cancer  
 The treatment was aimed at reducing the circulating PSA and androgen 
level. This can be achieved by androgen deprivation therapy and combined 
androgen blockade therapy.  
The androgen deprivation therapy includes, 
 Surgical castration: Bilateral orchiectomy (removal of both the testes) and 
the standard plasma castrate level of testosterone (≤ 20 ng/dL) would be 
achieved within 12 hours.  
 Pharmacological castration: Gonadotropin releasing hormone receptor 
agonist or gonadotropin releasing hormone receptor antagonist (Table 2) 
are used for pharmacological castration. There will be an initial rise in the 
testosterone concentration while using gonadotropin releasing hormone 
receptor agonist. However, after 2 to 4 weeks the castration level of 
testosterone will be achieved.  
In the combined androgen blockade therapy, in addition to castration (surgical or 
pharmacological) AR antagonist were used to prevent the activation of the AR by 
adrenal androgens [34, 35].  
3.2.3. Recurrence of prostate cancer after treatment   
 The androgen deprivation therapy or the combined androgen blockade 
therapy initially has beneficial effects in significant number of patients. However, 
after a median of 18-24 months treatment most of the prostate cancer relapse into 
more aggressive form of the disease known as CRPC. The CRPC could be either 
androgen dependant or AIPC. In androgen dependant ones, tumor growth depends 
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on androgen for proliferation and so it responds to hormonal therapies. The 
androgens were synthesized inside the prostate cancer cells from steroids like 
cholesterol, androstenedione, dehydroepiandrostenedione, pregnenolone, 
progesterone, etc. This is because of the over expression of the enzymes involved 
in synthesis of dihydrotestosterone was elevated [36, 37]. The synthesis of 
dihydrotestosterone can be inhibited by abiraterone acetate and ketoconozole. 
Hence the androgen dependent prostate cancer cell proliferation could be 
controlled by CYP17 inhibitors. The cells of AIPC do not dependent on androgens 
for proliferation and could not be treated with CYP17 inhibitors. The cytotoxic 
agent docetaxel and paclitaxel is the stable treatment regimen for AIPC [34, 35].  
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Table 2: Classification of drugs used to treat prostate cancer 
1. Hormonal therapy 
GnRH agonist                     Leuprolide, Goserilin, Triprorelin, Histrelin, Busrelin 
GnRH antagonist               Abarelix, Degarelix, Cetrorelix, Ganirelix 
Non-steroidal AR 
antagonist 
1st generation: Flutamide and Nilutamide.  
2nd generation: Bicalutamide 
3rd generation: Enzalutamide 
Steroidal AR 
antagonist  
Cyproterone acetate, Megesterol, Medroxyprogesterone, 
Diethylstilbesterol 
CYP17 inhibitors Ketoconazole, Abiraterone acetate 
5α reductase 
inhibitors 
Finasteride, dutasteride 
2. Non hormonal therapy 
Cytotoxic agents                 1. Taxane derivatives: Cabazitaxel, Docetaxel, Paclitaxel 
2. Anti-tumor antibiotic: Mitoxantrone hydrochloride 
Miscellaneous Sipulencel - T (Immunotherapy), Radium 223 dichloride 
(Radiopharmaceutical), Denosumab (Monoclonal antibody), 
Corticosteroid and Zoledonic acid. 
GnRH: Gonadotropin releasing hormone; AR: androgen receptor.
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Table 3: Drugs in clinical trials for the treatment of prostate cancer 
Phase Disease status Treatment Mechanism of action 
Phase 1 Metastatic prostate cancer PrCa VBIR Vaccine based immunotherapy 
Phase 1 Advanced prostate cancer  AZD8186 + Abiraterone PI3K inhibitor + CYP17 inhibitor 
Phase 1 Recurrent metastatic CRPC  EC1169 Chemotherapy agents similar to taxanes 
Phase 1 Metastatic solid tumours Durvalumab + Monalizumab  mAb to Programmed death ligand-1 + mAb to NKG2A 
Phase 1 Metastatic CRPC TAS3681 AR antagonist 
Phase 1 Advanced prostate cancer IMC-CS4 Triggers immune response against prostate cancer cells 
Phase 1 Advanced prostate cancer 131I-MIP-1095 Radiopharmaceutical - Attaches to PSMA protein of 
prostate cancer cells and delivers radioactive iodine 
Phase 1 Advanced prostate cancer ZEN003694 Inhibits bet family of proteins 
Phase 1  Metastatic prostate cancer ZEN003694 + Enzalutamide Inhibits bet family of proteins + AR antagonist 
Phase 1b Metastatic prostate cancer Atezolizumab + Radium - 223 mAb to programmed cell death ligand + radiotherapy 
Phase 1b Metastatic CRPC  CC-115 + enzalutamide mTOR inhibitor + AR antagonist 
Phase 2 Metastatic CRPC Abiraterone + cabazitaxel CYP 17 inhibitor + Cytotoxic agent 
Phase 2 Localized high risk prostate ARN509 + Abiraterone + AR antagonist + CYP 17 inhibitor + GnRH receptor 
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cancer leuprolide + hyperfractioned 
radiotherapy 
agonist 
Phase 2 Metastatic prostate cancer Rucaparib PARP inhibitor 
Phase 3 Metastatic prostate cancer Abiraterone + predinsone + 
ARN509 
CYP17 inhibitor + Anti-inflammatory + AR antagonist 
Phase 3 Localized high risk prostate 
cancer 
Enzalutamide + Leuprolide AR antagonist + GnRH receptor agonist 
Ref: (Memorial Sloan Kettering cancer centre, 2017); PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase; mAb: Mono colonel antibody; AR: AR; 
PSMA: prostate specific membrane antigen; MTOR: mechanistic target of rapamycin; PARP: Poly ADP ribose polymerase; CRPC: castration resistance 
prostate cancer.
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Figure 1: Recently identified AR antagonist hit molecules [38] 
 
3.3. Castration resistant prostate cancer (androgen dependant) 
The pathogenesis involved in the aggressive form of prostate cancers such 
as androgen dependant and AIPC are different. In androgen dependant prostate 
cancer, the prostate cancer cells depend on androgen for proliferation. The 
expression of AR was elevated to utilize the residual androgen efficiently [37]. 
Additionally, the enzymes involved in the synthesis of dihydrotestosterone are 
over expressed and the enzymes involved in the catabolism of dihydrotestosterone 
were down regulated (Figure 2). The above mechanisms work together to the 
increase the intracraine androgen level [39]. In case of AIPC the prostate growth 
does not depend on androgens for proliferation. There are many mechanisms 
behind the development of AIPC. 
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Figure 2: De-novo synthesis of androgen 
 
The figure 2 represents the synthesis of androgen from cholesterol inside the prostate 
cancer cells. The androgen synthesis inhibitors could be used to control the aberrant rise 
in intracrine androgen level. 
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3.4. Castration resistant prostate cancer (androgen independent) 
 The AIPC does not depend on androgen for proliferation and the AIPC 
cancer cells adapt various mechanisms to evade hormonal therapy. The reasons 
for prostate cancer cells switching from androgen dependant to independent stage 
are diverse.  In the following section we consider the various reasons behind the 
AIPC relapse after hormonal therapy failure and new drug discovery strategies for 
AIPC.  
3.4.1. Mutations in the ligand binding domain of AR 
 The Mutation in the ligand binding domain of the AR is one of the major 
reasons behind the development of AIPC [40]. The mutations are mostly somatic 
point mutations which broadens the ligand specificity. The mutation occurs due to 
the stress given to the AR by antagonist. The somatic point mutations can be 
broadly classified into three types, 
 Mutations expressed in flutamide treated patients 
The mutations, T877A (threonine to alanine), T877S (threonine to serine), 
V715M (valine to methionine), A721T (alanine to threonine), N756D 
(asparagine to aspartic acid), and H874Y (histidine to tyrosine) were 
identified in AIPC patients who underwent flutamide containing therapy. 
These mutations causes resistance to flutamide treatment and these mutant 
ARs were activated by flutamide [41 - 43]. 
 Mutations expressed in bicalutamide treated patients 
The mutations, W741C (tryptophan to cysteine), W741L (tryptophan to 
leucine), and D879G (aspartic acid to glycine) were identified in AIPC 
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patients who underwent bicalutamide containing therapy. These mutations 
were responsible for bicalutamide resistance and these mutant ARs were 
activated by bicalutamide [44, 45].  
 Mutations expressed in enzalutamide treatment 
F876L (Phenyl alanine to leucine) mutant AR was identified in AIPC cell 
lines after the treatment with enzalutamide. This mutation converts the 
enzalutamide into an agonist and causes resistance [45] 
The most widely studied mutation and frequently occurring one was 
T877A mutant AR (Table 4). The replacement with alanine provides additional 
space within the ligand binding pocket which allows the receptor to bind with 
variety of ligands. This mutation is specifically expressed in patients who 
underwent combined androgen blockade therapy in which flutamide is as an AR 
antagonist [46]. The T877A is activated by non-androgens like cyproterone 
acetate, hydroxy-flutamide (active form of flutamide), estrogens, glucocorticoids, 
and progesterone. The bicalutamide antagonizes T877A mutant AR [47, 48]. The 
crystal structure for T877A mutant AR's ligand binding domain was available 
(PDB: 2AX6, 2OZ7). This mutated AR was expressed in human prostate cancer 
LNCaP cell line [49].  
 The T877S mutant AR was identified in patients who underwent combined 
androgen blockade therapy in which flutamide is as an AR antagonist [50]. 
Similar to that of T877A mutant the T877S mutant was also activated by estradiol, 
progesterone, hydroxy-flutamide, nilutamide and androstenedione. Bicalutamide 
antagonizes this mutant AR [50]. The W741C/L mutation was identified in 
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patients who underwent combined androgen blockade therapy in which 
bicalutamide is as an AR antagonist. This mutant AR is antagonized by flutamide, 
cyproterone acetate and nilutamide [42, 44]. The crystal structure of W741L 
mutant AR's ligand binding domain has been elucidated (PDB: 1Z95). 
Table 4: Frequency of AR mutations in AIPC 
S. No Treatment AR mutation Frequency identified 
1.  Orchiectomy Q902R 1 
2.  Orchiectomy Wild type 9 
3.  Orchiectomy AR negative 2 
4.  Orchiectomy + F Wild type 1 
5.  Orchiectomy + F  AR negative 1 
6.  GnRH Wild type 6 
7.  GnRH AR negative 2 
8.  GnRH D890N 1 
9.  DES AR negative 1 
10.  GnRH + F (CAB) Wild type 10 
11.  GnRH + F (CAB) T877A 18 
12.  GnRH + F (CAB) T877S 2 
13.  GnRH + F (CAB) V715M 2 
14.  GnRH + F (CAB) H874Y 2 
15.  GnRH + F (CAB) A721T 1 
16.  GnRH + F (CAB) N756D 1 
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17.  GnRH + B (CAB) W741C 1 
18.  GnRH + B (CAB) D879G 1 
19.  GnRH + B (CAB) W741L 1 
GnRH - Gonadotrophin releasing hormone agonist or antagonist; CAB - Combined 
androgen blockade therapy; F - Flutamide; B - Bicalutamide; DES - Diethylstilbesterol. 
 
3.4.2. TMPRSS2-ERG gene fusion 
 Another major identification in CRPC was the discovery of the TMPRSS2 
- ETS gene rearrangements. The TMPRSS2 - ETS gene rearrangements were 
identified in 50% to 70% prostate cancer patients [51]. The ETS families of 
transcriptional factors are oncogenic and control the cell differentiation, cell 
division, metastasis and angiogenesis. The fusion between ETS and TMPRSS2 an 
AR responsive element leads to the over expression of ETS genes. For the ETS to 
over-express, it requires AR activation because since it was fused with an AR 
response elements [52]. The hormonal therapy decreases the plasma testosterone 
level but the mutated AR which is frequently expressed in AIPC does not require 
androgen for activation. Consequently, the mutated AR could activate the 
expression of ETS genes without androgen. The AR mutation and ETS 
chromosomal rearrangement in conjunction could co-ordinate the AIPC 
progression and drug resistance for AR antagonist and cytotoxic drugs.  
3.4.3. AR/TMPRSS2-ETS/PTEN/PI3K/AKT 
 The TMPRSS2 - ETS gene rearrangements results in the loss of the 
expression of PTEN (Phosphatase and tensin homolog). About 40% of TMPRSS2 
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- ETS gene expressing specimens were associated with the loss of PTEN [53]. 
This information bring in that the PTEN loss and ETS rearrangements were 
associated proceedings that act together to uphold the prostate cancer progression. 
The ETS genes were transcriptional regulators which regulate the transcriptions of 
the downstream check point genes concerned with promoting cellular 
proliferation, cell death, and survival. The PTEN is a tumour suppressor gene and 
has control over PI3K/AKT (Phosphatidylinositol 3-kinase/ Protein kinase B) 
pathway. Loss of PTEN means the control over the PI3K/AKT pathway was lost 
that result in the constitutive activation of AKT [53].  
The AKT inhibitors decrease the PSA transcription by AR. The AKT 
phosphorylates the serine residues 213 and 791 of the AR. Phosphorylation of AR 
by AKT enhances the interaction of AR with the co-activators and increases PSA 
transcription many fold [54, 55]. Apart from phosphorylation of AR, the AKT is a 
key signalling protein involved in cell survival and proliferation. They activate the 
transcription of many proteins necessary for cell survival, proliferation and 
division. The AKT role in the advancement of cancer has been studied widely. 
The AKT modulates the effect of wide variety of intracellular proteins by 
phosphorylation (Figure 3).  
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Figure 3: AR/AKT interaction in prostate cancer 
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3.4.4. AR/TMPRSS2-ETS/PTEN/PI3K/AKT/GSK3β/β-catenin 
 Cross talk between the PI3K/AKT pathway, wnt pathway and AR has been 
confirmed in prostate cancers (Figure 4) [56]. This was because of the TMPRSS2-
ETS gene fusion which results in the subsequent over-expression of ETS genes in 
AIPC. The ETS genes suppress the expression of the tumour suppressor gene 
PTEN. Loss of PTEN relieves the control over PI3K/AKT pathway and the 
pathway becomes constitutively active. A study using synthetic PI3K inhibitor in 
the transgenic mice expressing PTEN null mutation has indicated that the 
mechanism indeed involves the GSK3β/β-catenin pathway. The GSK3β/β-catenin 
pathway is a downstream effecter of PI3K/AKT pathway. This indicates that the 
Wnt pathway was also involved in the prostate cancer progression through PTEN 
and PI3K/AKT pathway [57]. 
The central particle in the PI3K/AKT/GSK3β/β-catenin pathway is the 
protein β-catenin [58]. The β-catenin is responsible for cell proliferation, 
angiogenesis and metastasis. The β-catenin exists in cell membrane, cytoplasm 
and nucleus. In the cytoplasm the β-catenin exists as multi-protein complex. Any 
free β-catenin was phosphorylated by GSK3β and degraded by ubiqutin. The 
complex was formed by proteins, GSK3β (active form), APC (adenomatous 
polyposis coli), axin and β-catenin [57, 58]. The PI3K/AKT pathway prevents the 
degradation of β-catenin through inactivating the GSK-3β. The inactive GSK3β 
does not cleave the β-catenin and so the free cytoplasmic β-catenin level 
increases. The free β-catenin translocates from the cytoplasm into the nucleus and 
interacts with the T-cell factor (TCF) and lymphoid enhancer factor 1 (LEF1) 
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family of transcriptional factors [58, 59]. LEF1 is found to be over expressed in 
AIPC and hence it has a dominant role in AR over expression. The AR over 
expression also activates the wnt pathway and sets up a positive feedback for the 
further expression of AR creating a positive feedback mechanism [60]. The β-
catenin–TCF/LEF induces the mRNA transcription of oncogenes like c-myc, 
cyclin D1 and also increases the ligand dependant AR mediated cellular 
proliferation (Figure 4). 
Figure 4: AR/GSK3β/β-Catenin signalling in prostate cancer 
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3.4.5. AR co-regulators 
 Altered function and over expression of co-regulatory proteins has been 
implicated in the development of resistance to hormonal therapies leading to 
prostate cancer relapse. Expression of certain co-regulatory proteins alone confers 
the activation of AR by anti-androgens. The over expression of class 1 co-
activators such as p160/SRC, SRC-1, TIF2 have been well studied [61]. The SRC-
1 has histone acetyltransferase activity and relaxes the promoter region of the 
response elements and increases the transcriptional activity. TIF2 is shown to be 
regulated by IL-6 and has active role in the development of bicalutamide 
resistance. The class 2 CBP/p300 family of co-activators are also implicated in 
AIPC and is involved in the activation of AR in androgen depleted state [62].  
 The ARA70 is an AR specific response element. The ARA70 was found to 
activate the androgen deprived cell line in the presence of AR antagonist. This 
results in the development of resistance towards AR antagonist. Hence it may 
augment the anti-androgen withdrawal syndrome [63]. The Co-repressors 
NcoR/SMRT represses the transcriptional activity of androgens in the presence of 
anti-androgens in normal prostate cells. In relapsed prostate cancers the above 
mentioned co-repressors are over-expressed and function as a co-activator 
increasing the transcription of AR response elements [64]. 
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3.5. Rationale for target selection 
Figure 5: AR as central dogma in androgen independent prostate cancer 
 
T887A AR: T877A mutated AR; TMPRSS2: Transmembrane protease, serine 2; ETS: 
erythroblast transformation-specific: ERG: ETS related genes; ETV1: ETS variant 1. 
 
From the evaluation of the molecular pathogenesis of prostate cancer we 
selected the mutant AR as the target for AIPC. This was because the mutant AR 
was involved directly or indirectly in the activation cell survival pathways (Figure 
5). 
 The mutation in AR seems to be the central dogma of AIPC. 
 The AR was over expressed and expresses mutation in most of the AIPC. 
 The mutant AR was specifically expressed in AIPC cells. 
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 The mutant AR was responsible for the over expression of TMPRSS2-ETS 
gene transcripts. This is because the TMPRSS2 is an AR response 
element. 
 The increased transcripts of ETS were then further responsible for the loss 
of function of PTEN. 
 Loss of PTEN results in the constitutive activation of PI3K/AKT pathway 
which is a survival pathway. This prevents the prostate cancer cells from 
apoptosis. 
 The PI3K/AKT pathway also inhibits the GSK3β. The inhibition of 
GSK3β increases the activity of β-catenin which increases the expression 
of oncogenes c-myc, cyclin D1 etc, which leads to increased survival of 
the AIPC cells. 
 Directly targeting the pathways might not be a rational approach because, 
the enzymes in the pathways are also expressed in non-cancerous cells and 
could lead to unwanted side effects and toxicity. 
 The co-activators of the AR were also an attractive target but there is no 
crystal structure or any other inhibitors in the clinical or in the clinical 
trials. Hence it becomes difficult to design novel molecules to specifically 
inhibit the co-activators.  
 Hence to inhibit the TMPRSS2-ETS mediated PI3/AKT activation and to 
further modulate the GSK3β/β-catenin pathway a potent AR antagonist 
that could target mutant AR will be a right choice. 
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3.6. AR structure and function 
3.6.1. AR gene location 
 The AR is a nuclear receptor encoded by a single gene located on human 
X-chromosome at Xq11-12 region that spans more than 90kb and contains 8 
exons (Figure 6). The human AR is made of 900-920 amino acids. The variations 
in the amino acid length are due the polymorphism in the length of polyglutamine 
(CAG repeats) and polyglycine (GGN repeats) tracts of the first exon [65].  
Figure 6: Functional domains of AR 
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The AR 4 functional regions  
1. Variable N-terminal domain (NTD) or Activation function 1(AF1),  
2. DNA binding domain (DBD)  
3. Hinge Region  
4. Ligand binding domain (LBD) / Activation function 2 (AF2).  
There are two isoforms of AR namely AR-A and AR-B. The AR-A and AR-B  
isoforms are expressed in humans. The N-terminal of the AR-A isoform is 
produced by translation initiation at alternate site (Met188) and so the amino acid 
starts from Met188. The AR-B isoform is predominantly expressed one and the 
ratio of AR-B isoform to AR-A isoform is 10:1 [66].  
3.6.2. Structure and function of AR N-terminal domain (NTD) 
 The first exon codes for NTD. The NTD approximately makes up half of 
the molecule of AR and is required for full transcriptional activity. Poly glutamine 
tract (CAG) in the NTD varies from 8 to 33 repeats in normal individual. A rare 
neuromuscular disorder namely Kennedy’s disease is caused by increased CAG 
repeats [67]. Increased CAG repeats decrease the transactivation potential of AR 
by p160/SRC family of co-activators. Shorter CAG repeats increase the 
transcriptional activity of AR but their risk associated with prostate is variable. 
Recent studies stated that there is no relation between CAG tract length and 
prostate cancer but a CAG tract length ≤ 21 may have a protective role against 
prostate cancer [68].  
 The activity of AR depends on various transactivation domains within the 
NTD. The NTD of AR contains two activation domains namely TAU-1 and TAU-
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5. TAU-1 (1 to 485) appears to be important in ligand dependant activation and 
TAU-5 (360 to 528) is responsible for constitutive ligand dependant activation of 
AR. The 
23
FQNLF
27 
motif is involved in the ligand dependant intramolecular N/C 
(amino/carboxyl) terminal interaction which is essential for full activation of AR 
(Figure 6) [69].  
This N/C interaction leads to 
 Receptor stabilization,  
 Prevent the dissociation of ligand from AR  
 Increases the binding affinity for DNA 
 Creates the surface area for recruitment of the co-activators. 
 The ligand dependant N/C terminal interaction occurs between the FXXLF 
motif of NTD with helixes 3, 4 and 12 of AF-2 domain. In addition of mediating 
intra-molecular interaction, the FXXLF motif also binds to X-chromosome linked 
melanoma antigen gene product (MAGE-11). MAGE11 is an AR co-activator 
which enhances the transcriptional activity by allowing the interaction of 
SRC/p160 family of co-activators with AF-2 domain [70]. The second motif 
WXXLF is responsible for constitutive activation of AR in the absence of ligand 
or ligand binding domain. The 
433
WXXLF
437
 motif interacts with ligand binding 
domain outside of AF-2 domain [70, 71]. The truncated AR lacking ligand 
binding domain is constitutively activated and has 3/4
th
 of the total transcriptional 
activity compared to full length AR. These 2 motifs resemble like LXXLF motif 
in p160 family of co-activators and compete with co-activator binding to carboxyl 
terminal domain (CTD) or ligand binding domain [71].  
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3.6.3. Structure and Function of AR DNA binding domain (DBD)  
 The DBD is coded by exons 2 and 3. The DBD of AR is highly conserved 
and plays a major role in  
1. AR nuclear localization  
2. AR dimerization and 
3. DNA binding  
The DBD is made of 3α helixes having 2 zinc finger motifs and a short C - 
terminal extension (Figure 6) (CTE). Each zinc finger consists of 4 cysteine 
residues and a Zn
-1
 ion [72]. The first zinc finger (P-box) is involved in the 
sequence recognition and directly binds to major grove of hormone response 
element (HRE) in the DNA. The HRE consists of the core DNA sequence is 5’-
TGTTCT-3’. The class 1 nuclear receptor which includes glucocorticoid, 
mineralocorticoid and progesterone receptors recognize the inverted repeats of the 
core sequence separated by 3 nucleotides [73]. A missense mutation in the p-box, 
K580R resulted in androgen insensitivity syndrome explaining the importance of 
p-box in AR's transcriptional activity [74]. The second zinc finger (D-box) is 
responsible for the stabilization of DNA bound AR interactions and mediate DNA 
dependant intermolecular protein-protein interactions (homo dimerization) [75]. 
 The entire class 1 nuclear receptors bind to the same HRE, the specific 
physiological function of AR is elicited by carboxyl terminal extension (CTE) 
amino acids. In AR, CTE amino acids (625 - 636) provide an additional dimer 
interface along with second zinc finger that is required for selective and high 
affinity binding of AR to specific AR response elements [76].  Zhong and co-
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workers revealed that the CTE amino acids 617 - 633 have two nuclear targeting 
sequences (RKCYEAGMTLGARKLKK) which import the AR to its nucleus and 
is called nuclear localization signal (NLS) [77]. 
3.6.4. Structure and functions of hinge region 
 The hinge region is coded by exons 4 and a part of 5. It is flexible and 
separates the DBD from ligand binding domain. The hinge region of AR has a 
transcriptional inhibiting motif made of highly basic amino acids [629-
RKLKKLGN-636] and has an attenuating effect on AF-2 activity by interfering 
with the recruitment of co-activators. Deletion of the inhibiting motif enhances the 
intramolecular N/C terminal interaction which is necessary for AR transcriptional 
function as discussed in the NTD. However, this impairs the hormone dependant 
nuclear translocation because of the deletion of NLS and also affects DNA 
binding and receptor stability [78]. The AR is preferentially acetylated by 
p300/CBP, Tip60 co-activators in its hinge region of the lysine residues K630, 
K632, K633 and regulates transcriptional activity [79]. The mutational studies on 
those amino acids showed that the acetylation enhances the transcriptional activity 
of the AR. Two missense somatic point mutations R629Q and K630T are 
identified in prostate cancer patients and have higher transcriptional activity than 
wild type AR [80]. 
3.6.5. Structure and function of ligand binding domain 
 The ligand binding domain of AR is coded by exons 6, 7, 8 and C-terminal 
part of 5. The crystal structures of human AR’s ligand binding domain have been 
elucidated and are available in the PDB. The ligand binding domain of AR 
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consists of 12 α-helixes and 2 β-sheets that fold to form triple layered alpha 
helical sandwich which creates a hydrophobic ligand binding pocket to which the 
ligand binds [81]. The AR ligand binding domain has a nuclear export signal 
(NES) in amino acids 742 to 817. This NES keeps the unbound AR in the cytosol. 
The NES is dominant over nuclear localization signal in the resting state [82].  
Figure 7: Ligand binding domain of the AR 
 
The ligand binding domain interacts weakly with LXXLF motifs of co - 
activators but preferentially with FXXLF and WXXLF motifs in the NTD [83]. 
Agonist binding to the ligand binding domain causes helix-12 to lie over the 
ligand binding pocket and exposes the groove necessary for intramolecular N/C 
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interaction. Antagonist binding displaces the helix-12 away from ligand binding 
pocket and unveils the binding surface for co-repressor NcoR/SMRT interaction 
and inhibition of AR transcriptional activity [84]. 
The Helix 4, 5 and 10 are the primary contact sites for androgen. The 
binding of androgens to AR majorly involves hydrophobic interactions with 
amino acids Val746, Met742, Gln711, Met745, Leu707, Leu704, Leu707 and 
Trp741. The Hydrogen bond interactions between ligand/receptor also play a key 
role in specific binding of ligands to AR. The keto group in the ring A of DHT 
forms H-bonds with Gln711, Arg752  while the 17β-OH  group in the D ring 
forms H-bond with Thr877 and Asn705 (Figure 7). The AR antagonists also bind 
to the same ligand binding pocket and prevent the androgens from binding to and 
activating AR. 
3.6.6. Ligand dependant genomic AR activation 
 The ligand dependant activation is required for the maximum activation of 
full length AR. Upon binding of androgens to the AR,  
1. The AR dissociates from the heat shock proteins (HSP), 
2. Undergoes ligand dependant intramolecular N/C terminal interaction,  
3. Phosphorylation,  
4. Weakening of NES and increase in Nuclear translocation signal,  
5. DNA dependant homodimerization,  
6. Co-activator recruitment,  
7. Binding to specific AR response elements and initiation of transcription 
(Figure 8). 
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Figure 8: Activation of AR by androgens
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 The AR resides predominantly in cytoplasm and is associated with HSP 
and chaperons. HSP also have active role in transcriptional activation of the AR 
because HSP90 binds to the AR and keeps it in an active conformation for 
androgen binding. Androgen binding to AR results in the dissociation of HSP 
from AR. The helix 12 folds over the ligand binding pocket and encloses the 
ligand. This results in the unmasking of the necessary grooves to undergo 
intramolecular N/C interaction, dimerization and phosphorylation [85]. 
Phosphorylation of the AR also plays an important role in transcriptional activity.  
The newly translated AR is phosphorylated at serine residues 506, 641, 
653 as a post-translational modification which increase the ligand acquiring 
properties. Treatment of LNCaP cells with a synthetic agonist resulted in the 
phosphorylation of serine residues at 16, 81, 94, 256, 308, 424 and 650 [86]. The 
phosphorylation of serine 650 is required for full transcriptional activity. 
Antagonist binding does not enhance receptor phosphorylation. After 
translocation into the nucleus, the AR undergoes DNA dependant intermolecular 
homo dimerization. The D-box mediate DNA dependant dimerization and the 
CTE amino acid provide an additional dimer interface to bind specific AR 
response elements [87]. 
 Co-activators decondense the chromatin and facilitate the binding of RNA 
polymerase holoenzyme for initiating transcriptional activity. Class 1 family of 
co-activators such as SRC-1, TIF2, SRC-3 and class 2 families of co-activators 
such as p300/ CBP regulate the transcriptional activity of AR [88]. Interaction 
with NTD seems to be responsible for activation rather than interaction with AF-
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2. The SRC1 interacts with NTD of the AR via a glutamine rich region [1053 – 
1123] and mutants lacking this glutamine region are inactive [89].  
3.6.7. Ligand dependant non-genomic AR activation 
The activated AR in the cytoplasm could also interact with several 
signalling pathways such as Ras-Raf-1, PI3K/Akt, Src, and protein kinase C 
(PKC). The mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK) where activated which leads to the proliferation of 
prostate cancer cells (Figure 9) [90]. 
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Figure 9: Ligand dependant non-genomic pathway of AR 
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3.7. AR antagonist 
Figure 10: Classification of non steroidal AR antagonist
 
The AR antagonists were broadly classified into steroidal and non-
steroidal agents based on the ligand chemistry. Steroidal ligands have steroidal 
nucleus. The non steroidal ligands possess a similar anilide pharmacophore 
(Figure 10). The limitations of steroidal anti-androgens are well known because of 
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their toxicity. For long term treatment like prostate cancer, the steroidal anti-
androgens were not suitable. The 1st generation antagonist, nilutamide and 
flutamide had developed resistance with mutant ARs. The nilutamide and 
fluatmide functions as an agonist to T877A mutant AR and stimulates the 
proliferation of prostate cancer cells. The second generation AR antagonist 
bicalutamide also experiences resistant with W741L/C mutant AR antagonist. The 
development of resistance among the 1st and 2nd generation AR antagonist lead 
to the preclinical identification of third generation antagonist, enzalutamide and 
apalutamide (ARN-509). The ARN-509 and enzalutamide in clinical trials was 
also found to be resistant to F876L mutation [91]. At present there is no AR 
antagonist in the clinical trials or in the market without developing resistance 
against mutant AR. Hence it is essential to develop an novel AR antagonist that 
could antagonize mutated AR. 
The presently available 1
st
, 2
nd
 and 3
rd
 generation of AR antagonists have 
common structural features such as an anilide scaffold (Figure 10). In compounds 
such as nilutamde, enzalutamide and ARAN509 the amide group of the anilide 
was part of either hydantoin or thiohydantoin. A trifluoromethyl substitution 
(meta) and either nitro- or nitrile (para) substitution was present in the benzene 
ring of the anilide group in all the AR antagonists. Hence there is no diverse 
structural element in the marketed AR antagonist. Hence there is possibility of 
cross resistance within the molecules and because of that the entire AR antagonist 
had developed resistance for one or another mutation. Structurally diverse AR 
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antagonist could possibly resist those mutations that occur during the course of 
treatment. 
3.8. In-silico drug design and discovery 
The drug design methods could be classified into two types 
 Structure based drug design (SBDD) 
 Ligand based drug design (LBDD) 
3.8.1. Structure based drug design 
 In this, the crystal structure of the target (protein) should be available. The 
hit molecules will be identified based on the binding conformation, binding 
energy and interactions with the target. The interactions between the ligand and 
target were particularly important because it decides the affinity and binding 
energy. Following are some of the major interactions between the ligand and 
target [92]. 
 Covalent bond (Irreversible) 
 H-Bond interaction 
 Hydrophobic interaction 
 Ionic interaction 
 π-π interaction 
The structure of the protein could also be generated by using homology 
modelling. Here there should be a presence of a template crystal structure that has 
close similarity with the target protein (Figure 11) [93]. 
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Figure 11: Computer aided drug design methods 
 
3.8.2. Ligand based drug design 
 The LBDD is divided into ligand and structure based. In the ligand based, 
the information about the binding site of the target was not available. In this case a 
correlation will be obtained between the well-known structures of the ligands and 
their biological activity. The aim is to construct a pharmacophore (3D-QSAR) 
which could be used to find matches in the existing chemical databases like, 
SPECS, ZINC, Cambridge and synthesized molecules. The major drawback in 
here is the researcher will be unsure of the bio active conformation. The second 
drawback was to superimpose the different scaffolds of ligands [94]. Hence, a 
structure based identification of pharmacophore generation is better because this 
approach will consider the actual binding conformation of the ligand in the 
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binding site. Based on bio active binding conformation, a 3D-QSAR 
(pharmacophore) will be generated. The generated pharmacophore could be used 
to screen chemical databases for the identification of matches (Figure 12) [94]. 
Figure 12: Virtual screening workflow for the identification of HIT molecules 
 
The rational drug design had led to the identification of many 
therapeutically useful drugs. The rational drug design had led to the identification 
of imatinib. The imatinib is a tyrosine kinase inhibitor and used in treating 
leukaemia. The successful application of structure based drug design guided to the 
identification of dorzolamide which is a carbonic anhydrase inhibitor [95 - 99].   
Additional examples include: 
 Identification of atypical antipsychotics 
 Identification of cimetidine which is the prototype of H2-receptor 
antagonist which later lead to the identification of many drugs in that 
series. 
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 Selective COX-2 inhibitors which decreased the side effects of COX1 
inhibitors. 
 Enfuvirtide which is a HIV entry inhibitor for the treatment of AIDS.  
 Nonbenzodiazepines like zolpidem and zopiclone 
 Zanamivir is an neuraminidase inhibitor for the treatment of influenza 
 HIV integrase inhibitor raltegravir for the treatment of AIDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Plan Of Work 
 
PSG College of Pharmacy, Coimbatore. Page 46 
 
4. PLAN OF WORK 
Phase 1: To analyse the ligand/protein interactions between the wild and 
mutant ARs 
 Collection of wild and mutant androgen receptors form PDB 
 Identification of 3D structural difference between wild and mutant ARs 
 Analysis of the ligand binding pocket of wild and mutant ARs 
 Elucidation of possible ligand/receptor interactions for AR antagonists  
Phase 2: To develop a pharmacophore model for wild and mutant AR 
antagonists and to identify difference between the pharmacophore models 
 Dataset preparation for wild and mutant AR antagonists 
 Pharmacophore generation and validation of the models 
 Elucidation of difference in the pharmacophore between wild and mutant 
ARs 
Phase 3: Identification of new chemical entities through in-silico drug design 
methods 
 Identification of novel scaffolds through ligand based drug design 
 Evaluation of the ligand/receptor interactions of the hit molecules 
Phase 4: In-vitro anti prostate cancer activity of the new chemical entities to 
identify the hit molecules 
 In-vitro anti-proliferation assay for selected hit molecules in LNCaP 
(T877A AR), MCF-7 (Wild type AR), MDA MB 453 (Q865H AR), PC3 
(AR negative) and 3T3 (non-cancerous) cell lines 
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 Screening for prostate cancer biomarkers (PSA and TMPRSS2) for potent 
compounds in-vitro 
Phase 4: Elucidation of the anti-cancer mechanism of action for the best 
active molecule 
 Gene expression studies for oncogenes such as c-myc, cyclin D1, ETV1, 
PS2 and AR through qPCR 
 Protein expression studies for AR, p-AR213, AKT, and p-AKT473 through 
western blotting 
 Elucidation of apoptotic mechanism through BAX/bcl2 mRNA ratio, 
procaspase 3 protein expression and caspase 3 activity 
 Confirmation of apoptosis through Ethidium bromide/Acridine orange 
staining  
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5. MATERIALS 
5.1. Materials used in this study 
Following are the list of materials used in this study (Table 5) 
Table 5: Materials list 
Chemicals/Softwares/Instruments Manufacturer 
Ligprep, Maestro, Glide XP and SP, PRIME, PHASE and 
PyMOL  
Schrödinger 
Chem Draw ultra Cambridge  
ChemSketch ACD Labs 
BIOVIA Discovery Studio Accelrys 
Compounds (ARA1 to ARA9), 9 compounds Shasun Research 
Centre 
R-Bicalutamide SantaCruz 
Polystyrene culture plates - 96, 24 and 6 well plates, 100mm 
tissue culture dish, T-25 and T-75 culture flask. 
Sigma Aldrich 
Cell Bind tissue culture T-25 flask and 96 well plates Sigma Aldrich 
ATCC modified RPMI medium, RPMI, PBS and Fetal 
bovine serum 
Gibco 
Trypsin 1X, DHT, Testosterone, TRIZOL, Poly - L - Lysine Sigma Aldrich 
Phosphatase and protease inhibitor cocktail, DEPC water, 
High capacity cDNA conversion kit. 
Thermo Scientific 
Primary antibodies and secondary antibodies SantaCruz 
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Primers - PSA, TMPRSS2, GAPDH, PS2, C-Myc, Cyclin 
D1, ETV1 
Sigma Aldrich 
Primers - BAX, Bcl2 Bioline 
MTT, Ethanol, DMSO Hi-Media 
Caspase 3 assay kit BIOVISON 
SYBR green, ROX dye Takara 
SDS, TEMED, Agarose, Ammonium per sulfate  Sigma Aldrich 
Protein assay kit BIO-RAD 
Class II bio-safety cabinet ESCO 
CO2 Incubator, Multimode ELISA reader, Thermal cycler Thermo Scientific 
Step oneplus real time PCR Applied 
Biosystems 
Semi dry blotting Hoefer 
GEL DOC Syngene 
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6. EXPERIMENTAL METHODS 
6.1. Phase 1 - To analyse the ligand/protein interactions between the wild and 
mutant ARs 
6.1.1. Root Mean Square deviation between wild and mutant ARs  
 The AR proteins, wild (PDB ID: 2AMA), T877A (PDB ID: 2AX6) and 
W741L (PDB ID: 1Z95) were downloaded from PDB. The alignment between the 
proteins were done using protein alignment tool in Maestro (v9.8), Schrödinger 
[100]. Each of the mutant proteins were aligned with wild type AR and the root 
mean square deviation (RMSD) was calculated for the protein backbone. The 
alignment score was used to validate the RMSD calculation [101].  
6.1.2. Analysis of the ligand binding pocket of wild and mutant ARs 
6.1.2.1. Ligand preparation  
 The AR ligands such dihydrotestosterone, testosterone, flutamide, 
bicalutamide and enzalutamide were downloaded from chemspider. The ligands 
for docking studies were prepared using LigPrep (v3.1), Schrödinger [102]. The 
LigPrep does the tasks such as conversion of 2D to 3D structure, energy 
minimization, addition of missing hydrogen atoms, generation of different 
ionization state, generation of stereoisomer, neutralization of the charged 
structures, and generation of potential ionization state at a definite pH of 7.2 ± 2. 
The selection of wide pH range (5.2 to 9.2) was essential because of the different 
pharmacokinetic environment that the ligands undergo in biological system. This 
wide range of pH led to protonation of certain molecules especially those who 
have nitro or carboxyl functional groups [103].  
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6.1.2.2. Protein preparation 
 The AR proteins, wild (PDB ID: 2AMA), T877A (PDB ID: 2AX6) and 
W741L (PDB ID: 1Z95) were downloaded from PDB. The crystal structures of 
the proteins were prepared using Protein Preparation Wizard in Maestro (v9.8), 
Schrödinger [100]. Preprocessing of the proteins were essential because, the 
crystal structure of the protein may have multiple chains, missing hydrogen atoms, 
alternate positions for certain amino acids like histamine and glutamine. In the 
preprocessing step of the protein, the identical chains were deleted, polar 
hydrogens were added, water molecules were deleted except those were within 5 
Å from the ligand binding site. The tautomers were generated using pH value of 
7.2 ± 0.2. This pH 7.2 ± 0.2 was considered because it is the physiological pH 
[104].  
6.1.2.3. Homology modelling 
 The homology model was prepared by using PRIME (v3.7), Schrödinger 
[105]. PRIME was used for  
 Protein structure prediction,  
 Side chain optimization,  
 Loop prediction,  
 Active site refinement and  
 Energy minimization.  
 The amino acid sequence of the T877A mutant AR was obtained from 
NCBI. The T877A mutant AR (PDB ID: 2OZ7) was used as the template. This 
was co-crystallized with antagonist cyproterone acetate and has a resolution of 
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1.80 Å. In the homology modelled AR, the ligand binding domain has 671-881 
amino acids instead of 671-919 amino acids [106]. The homology modelled AR 
thereby lacks the helix-12 amino acids. The alignment between the target and 
template sequence was carried out by Clustalw method. The sequence identity 
between the target and template was 100%. The ligand (cyproterone acetate) and a 
water molecule (HOH-108) were retained in the final model. The prepared 
homology model were optimized for energy minimization using OPLS 2005 and 
the active site was further refined.  
6.1.2.4. Docking 
 The docking studies were carried out using GLIDE XP (extra precision) 
(v3.3), Schrödinger. The glide docking considers the ligands as a fully flexible 
unit and the receptor as a rigid grid representation. The grid space within the 
protein was generated using receptor grid generation using default parameters. 
The co-crystal ligand was applied as the central of the docking box with a volume 
competent of binding with ligands with a length of ≤ 20Å. The processed proteins 
were only used to generate the grid space by considering the co-crystal ligand as 
the centroid of the grid space. The ligands were ranked by Glide Score (G Score). 
The least energy is the best ligand [107]. 
G Score = (a x vdW) + (b x Coul) + Lipo + Hbond + Metal + BuryP + RotB + Site 
Where,  
vdW – van der Waal energy, Coul – Coulomb energy, Lipo – Lipophilic contact 
term, Hbond – Hydrogen bond, Metal – Metal binding term, BuryP – penalty for 
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buried polar groups, RotB – penalty for freezing rotatable bonds, Site – polar 
interaction of the active site. 
6.1.2.5. Validation 
 The docking studies were validated by superimposing and calculating the 
RMSD between the bound conformation and docked conformation of the co-
crystallized ligand. The deviation should be less than 2Å. This is because; the 
crystal structures in the PDBs have an average deviation of approximately 2Å 
[108]. The homology model was validated by the structural analysis and 
verification server (SAVES). The amino acids in the favourable, allowed and 
disallowed regions were calculated by Ramachandran plot. The stereochemistry of 
the amino acids in the homology model was evaluated by PROCHECK. The 3D 
compatibility of the homology model was validated by VERIFY_3D. The docking 
was carried out as explained in the previous section [109].  
6.1.3. Elucidation of the binding mechanism of AR antagonist 
 The AR antagonists such as flutamide, bicalutamide and enzalutamide 
were docked with various types of AR proteins. The AR proteins such as wild 
type (PDB ID: 2AMA), T877A mutant (PDB ID: 2AX6), W741L (PDB ID: 
1Z95) and homology model (truncated helix-12) were used for docking studies. 
Then the docked conformation of the ligands in the mutant ARs were aligned and 
superimposed with the conformation in the truncated AR. The difference in the 
binding conformation was elucidated visually and interpreted.  
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6.2. Phase 2 - To develop a pharmacophore model for wild and mutant AR 
antagonists and to identify difference between the pharmacophore models 
6.2.1. Data set preparation for wild, T877A and full antagonists 
 The molecules for the datasets were obtained from literatures [110 - 114]. 
The ligands were then grouped into three datasets. The first dataset consists of 
ligands that antagonize the wild type AR. The second dataset consists of ligands 
that antagonize the T877A mutant AR. The third dataset consists of ligands that 
antagonize both wild and T877A mutant ARs without any agonist / partial agonist 
effect on either of these receptors (full antagonist). The methods adopted in these 
papers were the same and the experiments were conducted in the same laboratory. 
 The dataset for wild type has 122 molecules and was randomly split into 
training (75%) and test (25%) sets [115]. The molecules having IC50<4μM were 
designated as actives and molecules having IC50>50μM were designated as 
inactives. The dataset for T877A AR has 132 molecules and the dataset was 
divided randomly into training (75%) and test (25%) sets. The molecules having 
IC50<3μM were designated as actives and molecules having IC50>32μM were 
designated as inactives. The molecules in the wild and T877A mutant ARs dataset 
represent similarity with AR antagonists, enzalutamide and bicalutamide (Figure 
13). The dataset for full antagonist has 42 molecules and the dataset was randomly 
divided into training (75%) and test (25%) sets. The molecules in the dataset have 
different types of basic nucleus comprising, 1-arylmethyl-4-phenylpyrrole, 4-
arylmethyl-1-phenylpyrazole, 4-aryloxy-1-phenyl pyrazole, and 3-aryl-3-hydroxy-
1-phenylpyrrolidine derivatives (Figure 13). The ligands having IC50<0.10μM 
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were designated as actives and ligands having IC50>3μM were designated as 
inactives. 
Figure 13: Scaffolds of the dataset molecules for pharmacophore modelling 
 
 The biological activity of each dataset was obtained in different cell lines. 
Hence, there is a difference in the biological activity range among the datasets. 
The active and inactive molecules were selected depending on the activity range 
among the dataset molecules. The active molecules are the ones which will have 
the least IC50 and the inactive molecules will have the higher IC50 values among 
the dataset molecules. Hence, the inactive molecules are less active rather than 
absolutely inactive. This method of selection yields an optimal numbers of active 
and inactive molecules in the training and test set. This is absolutely essential for 
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validating the 3D-QSAR with an external test set which should have equal activity 
distribution like training set. 
6.2.2. Ligand preparation 
 The ligands were drawn using Maestro (v9.8), Schrodinger [100]. The 
LigPrep does the tasks such as conversion of 2D to 3D structure, energy 
minimization, addition of missing hydrogen atoms, generation of different 
ionization state, generation of stereoisomer, neutralization of the charged 
structures, and generation of potential ionization state at a definite pH of 7.2 ± 2. 
The selection of wide pH range (5.2 to 9.2) was essential because of the different 
pharmacokinetic environment that the ligands undergo in biological system. This 
wide pH range led to protonation of certain molecules especially those who have 
nitro or carboxyl functional groups. The conformational space for the ligands was 
explored using a combination of Monte-Carlo Multiple Minimum (MCMM) and 
Low Mode (LMOD) with a maximum number of conformers set to 1,000 
conformers per structure. The energy minimization was performed by OPLS 
2005. Each of the energy minimized conformer was filtered by a relative energy 
window of 10 kJ mol
−1
. The minimum atomic deviation allowed was set at 1.00 
Å. The conformers that had higher energy than the 10 kJ mol
−1 
thresholds were 
discarded. For the consideration of identical conformers, the distances between the 
corresponding heavy atoms should be less than 1.00 Å [103]. 
6.2.3. Pharmacophore generation for wild, T877A and full antagonists  
 Common pharmacophore hypotheses (CPH) identification and 3D-QSAR 
model were constructed using PHASE, Schrödinger (v3.9) [116]. PHASE give us 
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a maximum of 7 pharmacophore site points in the 3D-QSAR. The pharmacophore 
site points includes  features such as hydrogen bond acceptors (A), hydrogen bond 
donor (D), hydrophobicity (H), aromatic rings (R), positively ionisable groups (P), 
negatively ionisable groups (N) and user defined X, Y, and Z. The Common 
pharmacophore hypotheses were generated by using a box with a size of 1 Å. All 
of the common pharmacophore hypotheses were effectively scored by correlating 
the observed and predicted activity of the training and test sets using partial least 
squares (PLS) method. The maximum number of partial least square (PLS) factors 
that could be used for calculations was N/5, where N is the number of molecules 
in the training set. A PLS factor value of 5 was used to validate the wild and 
T877A mutant AR antagonist. A PLS factor value of 3 was used for full 
antagonist. Atom based 3D-QSAR method was followed by applying default 
parameters [117].  
6.2.4. Selection and Validation of the Models  
 The best 3D-QSAR model was selected based on high correlation between 
the predicted and observed activity (R
2
), predictive ability of the model (Q
2
), low 
standard deviation (S.D), and the probability of getting an actual result (P value) 
of the training set [118]. The model was also validated by predicting a test set 
having wide range of biological activity. The correlation between the observed 
and predicted activity of the test set (R
2
), Pearson-R, Predictive R
2
 (R
2
pred), and 
the correlation between the observed and predicted activity of the test set with 
intercept set at zero (r
2
m) were used to evaluate the predictive power of the 
models. The models having the highest (at least>0.5) value for Q
2
, R
2
pred, and 
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r
2
m were considered for selection [119]. From this selection, the model that had 
the highest R
2 
value for training and test set molecules, Q
2
, R
2
pred, and r
2
m was 
considered as the best. 
6.3. Phase 3 - Identification of new chemical entities through in-silico drug 
design methods 
6.3.1. In-silico virtual screening (Pharmacophore matching and docking) 
 The generated pharmacophore was used to find matches in the SPECS 
database and synthesized compounds from Shasun Research Centre, Chennai. The 
pharmacophore matching was performed by using PHASE (v3.9), Schrodinger 
[116]. PHASE searches database using sites and geometric arrangements to find 
molecules that match the hypothesis and then retrieve the relevant conformers 
from the database for alignment to the hypothesis. The compounds having 
matching thershold of 2 out of 3 were further processed by docking studies [120].  
 The AR proteins (PDB ID: 2OZ7) and homology model (helix-12) were 
used for docking calculations. The Glide SP (standard precision), Schrödinger was 
followed for docking calculations [107]. The SP method significantly reduces the 
time taken for docking and hence large number of database ligands could be 
screened.     
6.4. Phase 4: In-vitro anti prostate cancer activity of the new chemical entities 
to identify the hit molecules 
6.4.1. In-vitro anti-proliferation assay 
 The cell lines, LNCaP-FGC, MDA-MB-453, MCF-7, PC3, and 3T3 were 
purchased from NCCS, Pune. The PC3 and 3T3 cells were cultured in RPMI 
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medium supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine. 
The MDA MB 453 cells were cultured in DMEM F12 medium supplemented with 
10% FBS and 2 mM glutamine. The LNCaP cells were cultured in ATCC 
modified RPMI medium which was supplemented with 10% FBS, 4.5 g/L D-
Glucose, 2.383 g/L HEPES buffer, 2M L-Glutamine, 1.5g/L sodium bicarbonate 
and 110 mg/L sodium pyruvate and. The PC3, MDA MB 453 and 3T3 cells were 
grown in polystyrene surface (T25 flask & 96 well plate). The LNCaP cells were 
grown in corning CellBIND surface (T25 flask & 96 well plate). The cells were 
incubated at 37 °C with 5% CO2. 0.25 % trypsin was used for detachment of the 
cells [121, 122]. 
 The entire cell lines were cultured in their respective medium 
supplemented with charcoal stripped 10% FBS for the proliferation and anti-
proliferation assays. The screening was done in a 96 well plate. Each of the 96 
wells was seeded with approximately 2000 cells. The anti-proliferative activity 
was measured by adding standard and test compounds (0.1 μM to 100 μM) in the 
presence of 1 nM DHT. The proliferative activity of the standard and test 
compounds (1 μM) was evaluated without 1 nM DHT [123]. The toxicity of the 
compounds (0.1 μM to 100 μM) was measured in non-cancerous 3T3 cell line. 
The cells were treated for 48 hours. Post treatment, the culture medium was 
drained and replaced with fresh medium supplemented with 10 μl of MTT (5 
mg/ml) and incubated for 4 hours. The formazon crystals that were formed were 
dissolved in 100 μl of DMSO/well. The optical density was measured at 570 nm. 
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The IC50 was calculated by plotting a dose response curve by taking percentage 
cyto-toxicity in y axis and log dose in x axis. 
Percentage toxicity = {1 – [(At-Ab)/ (Ac-Ab)]} x100 
Where,  
At = Absorbance value of test compound, 
Ab = Absorbance value of blank and  
Ac =Absorbance value of control.  
6.4.2. Screening for prostate cancer bio-markers 
6.4.2.1. RNA Isolation 
 The prostate specific antigen (PSA) and TMPRSS2 were the biomarkers 
for prostate cancer. The gene expression of the prostate specific antigen and 
TMPRSS2 were evaluated in LNCaP cell lines by qPCR. The LNCaP cells were 
cultured in RPMI medium supplemented with charcoal stripped 10% FBS. The 
cells were treated for 24 hours with bicalutamide (10 µM) or ARA3 (1 µM) in the 
presence of 1 nM DHT [124]. The total RNA was isolated using trizol (sigma). 
The treated cells were lysed in the culture plate by using trizol reagent. The 
quantity of trizol used was 1ml per 10cm
2
 of the surface area. The lysed cells were 
allowed to rest for 5 minutes at room temperature for the dissociation of 
nucleoproteins from the RNA. Then, 200µl of chloroform was added to the lysed 
cells for 1 ml of trizol used. The mixture was shaken intermittently for 15 
seconds. Then the samples were allowed to stand for 2–15 minutes. The samples 
were phase separated by centrifugation at 12,000 × g for 15 minutes at 2–8 °C.  
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The centrifugation procedure divides the mixture into 3 phases:  
 The red colored organic phase contains protein,  
 The white ring in the inter phase contains DNA and,  
 The colorless supernatant has total RNA.  
 The supernatant was carefully transferred without disturbing the other 
layers into a fresh tube. Then, 0.5 ml of 2-propanol was added to the supernatant 
for 1ml of trizol that was added previously. The supernatant mixture was allowed 
to stand for 5– 10 minutes. The precipitate RNA is visible in this step. The 
precipitated RNA was obtained by centrifuging the samples at 12,000 × g for 10 
minutes at 2–8 °C. The RNA precipitate was then washed with 1 ml of 75% 
ethanol. The sample was vortexed and then centrifuged at 7500 × g for 5 minutes 
at 2–8 °C. The quantity and the quality of the total RNA was identified using 
Nanodrop (Thermal scientific). The ratio, A260/A280 and A260/A230 of the total 
RNA was used to assess the quality of the RNA. The RNA samples which had the 
ratio of >2 were used for gene expression studies [125].  
6.4.2.2. Real time PCR (qPCR)  
 The cDNA was converted from 1 μg of the total RNA using high capacity 
cDNA conversion kit (Applied Bio-systems). The thermal cycling condition for 
cDNA synthesis was given in table 6. The amplification of the cDNA and 
subsequent expressions of the genes were measured using SYBR green master 
mix (Takara) and step one plus qPCR (Applied Bio-systems). The ROX dye was 
used as an internal control for SYBR green. The primers were designed by primer 
3 software (Table 7). The thermal cycling condition for qPCR was given in table 
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8. The relative mRNA expression of the test genes (PSA and GAPDH) to GAPDH 
was calculated by comparative Ct method. The product (amplicon) was confirmed 
by evaluating the Tm temperature of melt curve [126]. 
Table 6: Thermal conditions for cDNA synthesis 
Settings Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 minutes 120 minutes 5 minutes infinity 
 
Table 7: Primers for prostate cancer biomarkers 
Gene Primers NCBI Tm ºC 
GAPDH F: 5'-CCATCTTCCAGGAGCGAGATCCC-3', 
R: 5'-CCCAGCCTTCTCCATGGTGG-3' 
NM_0020
46.5 
85.85 
PSA F: 5'-CCGGAAGTGGATCAAGGACA-3',  
R: 5'- GGCCTGGTCATTTCCAAGGT-3', 
NM_0016
48.2 
82.92 
TMPRSS2 F: 5'-GCTTCCCCGTGCATGATTTA-3',  
R: 5'-ATGGCAGAGAGTGCCAAAGC-3', 
NM_0011
35099.1 
79.35 
 
Table 8: Thermal conditions for qPCR 
Settings Initial denaturation PCR condition (40 cycles) 
Denaturation Annealing and Elongation 
Temperature 95°C 95°C 60°C 
Time 30 seconds 5 seconds 30 seconds 
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6.5. Phase 4 - Elucidation of the mechanism of action of the best active 
molecule 
6.5.1. Gene expression 
 The mRNA expression of androgen stimulated oncogenes (ETV1, C-MYC 
& Cyclin D1), AR and oestrogen receptor response element (PS2) were measured 
in LNCaP cells by qPCR. For the quantification of oncogenes the LNCaP cells 
were cultured in RPMI medium supplemented with charcoal stripped 10% FBS. 
The cells were treated for 24 hours with bicalutamide (10 µM) or ARA3 (1 µM) 
in the presence of 1 nM DHT. For the quantification of AR and PS2, the LNCaP 
cells were treated for 24 hours with bicalutamide (10 µM) or ARA3 (1 µM) in the 
absence of 1nM DHT. The primers were designed by primer 3 software (Table 9). 
The thermal cycling condition for qPCR was given in table 10. The relative 
mRNA expression of the test genes to GAPDH was calculated by comparative Ct 
method. The product (amplicon) was confirmed by evaluating the Tm temperature 
of melt curve. 
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Table 9: Primers of oncogenes 
Gene Primers NCBI Tm ºC 
GAPDH F: 5'-CCATCTTCCAGGAGCGAGATCCC-3', 
R: 5'-CCCAGCCTTCTCCATGGTGG-3' 
NM_00204
6.5 
85.85 
C-MYC F: 5'-TAGTGGAAAACCAGCAGCCTCC-3',  
R: 5'-CGTCGCAGTAGAAATACGGCT-3', 
NM_00246
7.4 
85.32 
Cyclin 
D1 
F: 5'-GCTGCGAAGTGGAAACCATC-3',  
R: 5'-CCTCCTTCTGCACACATTTGA-3', 
NM_05305
6.2 
90.02 
ETV1 F: 5’-TTAGCCGTTCACTCCGCTAT-3’ 
R: 5’-TATCTGGAAAGGCCATGGAG-3’ 
NM_00495
6.4 
80.83 
AR F: 5’-GCTGCATCAGTTCGCTTTTG-3’ 
R: 5’-CTTGGGCACTTGCACAGAGA-3’ 
NM_00004
4.3 
83.15 
PS2 F: 5’-GCCCTCCCAGTGTGCAAATA-3’ 
R: 5’-TGGAGGGACGTCGATGGTAT-3’ 
NM_00322
5.2 
84.23 
 
Table 10: Thermal conditions for qPCR 
Settings Initial denaturation PCR condition (40 cycles) 
Denaturation Annealing and Elongation 
Temperature 95°C 95°C 60°C 
Time 30 seconds 5 seconds 30 seconds 
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6.5.2. Protein expression of AR and AKT1 
 The LNCaP cells were cultured in medium supplemented with 10% 
charcoal stripped FBS. The cells were treated for 24 with ARA3 (1 µM) or 
bicalutamide (10 µM) in the presence of 1 nM DHT. The proteins were extracted 
by adding RIPA buffer supplemented with protease and phosphatase inhibitor 
cocktail. Protein concentration was determined by Bio-Rad Bradford reagent 
(Bio-Rad Laboratories, Hercules, CA). The lysate was centrifuged at 16000 g for 
20 min. Supernatant equivalent to 40µg of protein was subjected to SDS PAGE 
gel electrophoresis. The antibodies were given in table 11. The resolved proteins 
were transferred to a PVDF membrane. The transferred proteins were hybridized 
with primary antibodies. Expression of β-actin was measured as an internal 
control using β-actin antibody (ab8227). The proteins were detected by 
horseradish peroxidase labeled anti rabbit or anti-mouse IgG monoclonal or 
polyclonal antibody and a chemi-luminescence detection kit (ECL, GE healthcare) 
[127]. The fold expression was calculated by using the formula,  
Fold ratio =  Ratio of amount of target protein (treated) normalized with control 
Ratio of amount β-actin (treated) normalized with control 
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Table 11: List of antibodies for western blot 
S. No Antibody Molecular weight KDa Dilution 
1 AR (sc816) 110 1:1000 
2 p-AR
213
 (sc135635) 110 1:1000 
3 akt1 (sc5289) 62 1:1000 
4 p-akt1
473
 (sc293125) 60 1:1000 
5 β-actin 41 1:1000 
 
6.5.3. Apoptosis assays 
 The apoptosis was confirmed in LNCaP cells by quantifying the 
BAX/Bcl2 mRNA ratio, procaspase-3 protein level, caspase-3 enzyme activity, 
and ethidium bromide/acridine orange (EB/AO) staining. 
6.5.3.1. Gene expression of bax/bcl2  
 The mRNA expression of BAX and Bcl2 was quantified in LNCaP cells. 
The LNCaP cells were cultured in RPMI medium supplemented with 10% 
charcoal stripped FBS. The cells were treated for 48 hours with ARA3 (1 µM) or 
bicalutamide (10 µM) in the absence of 1nM DHT. The cDNA was converted 
from 1μg of the total RNA using high capacity cDNA conversion kit (Applied 
Bio-systems). The amplification of the cDNA and subsequent expressions of the 
genes were measured using SYBR green master mix (Takara) and step one plus 
qPCR (Applied Bio-systems). The ROX dye was used as an internal control for 
SYBR green. The primers were designed by primer 3 software (Table 12). The 
thermal cycling conditions for the qPCR were given in table 13. The relative 
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mRNA expression of the test genes to GAPDH was calculated by comparative Ct 
method. The product (amplicon) was confirmed by evaluating the Tm temperature 
of melt curve. 
Table 12: Primers for apoptosis biomarkers 
Gene Primers NCBI Tm ºC 
GAPDH F: 5'-CCATCTTCCAGGAGCGAGATCCC-3', 
R: 5'-CCCAGCCTTCTCCATGGTGG-3' 
NM_002
046.5 
85.85 
BAX F: 5’-GGGGACGAACTGGACAGTAA-3’ 
R: 5’-CAGTTGAAGTTGCCGTCAGA-3’ 
NM_001
291428.1 
85.45 
Bcl2 F: 5’- CAGGATAACGGAGGCTGGGATG-3’ 
R: 5-GACTTCACTTGTGGCCCAGAT-3’ 
NM_000
633.2 
86.94 
 
Table 13: Thermal conditions for qPCR 
Settings Initial denaturation PCR condition (40 cycles) 
Denaturation Annealing and Elongation 
Temperature 95°C 95°C 60°C 
Time 30 seconds 5 seconds 30 seconds 
 
6.5.3.2. Caspase 3 activity  
 The protein expression of procaspase was measured as discussed in the 
earlier section. The LNCaP cells were treated for 48 hours with ARA3 (1 µM) or 
bicalutamide (10 µM) in the absence 1 nM DHT. The caspase-3 activity was 
measured in LNCaP cells by a colorimetric caspase assay kit (Bio Vision). Assay 
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was performed according to instructions given by the manufacturer. The cells 
were harvested and lysed in 50 µl of lysis buffer by incubating on ice for 10 
minutes. Centrifugation was done to remove cell debris at 10,000 x g for 2 min. 
This supernatant extract was taken and protein measurement was done by 
Bradford’s method. Total protein (100 µg) was used in 50 µl of cell lysis buffer. 
To that 50 µl of 2X reaction buffer containing 10 mM DTT and 5 µl of 4 mM of 
DEVD-pNA (caspase-3 substrate) was added and incubated at 37
o
C for 90 min. 
Absorbance was measured at 405nm by Multiskan™ GO multiplate reader 
(Thermo Scientific, Waltham, USA). Relative change in enzyme activity was 
measure  
6.5.3.3. Ethidium bromide/Acridine orange (EB/AO) staining 
 The LNCaP cells were cultured in RPMI medium supplemented with 10% 
charcoal stripped FBS. The cells were treated for different time points (4 hour, 16 
hour and 24 hour) with ARA3 (1 µM) or bicalutamide (10 µM) in the absence of 
1nM DHT. The method for EB/AO staining was followed as explained in Ribble 
and co-workers [128]. The cells were cultured in 24well plates. After the 
treatment period, the EB/AO solution (each 100 µg/ml) in PBS buffer was added 
to the wells. The fluorescence was visualized within 10 minutes using Nikon 
fluorescence microscope and photographed. 
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7. RESULTS and ANALYSIS 
7.1. Phase 1 - To analyse the ligand/protein interactions between the wild and 
mutant ARs 
7.1.1. Purpose of the study 
 The purpose of the study is to identify the difference between the wild and 
mutant ARs. The difference in the structure of the wild and mutant AR was 
identified by computing the root mean square deviation (RMSD) between the 
protein backbone atoms. The difference in the binding characters of wild and 
mutant AR was studied using docking studies. The difference in the ligand 
binding pocket was identified through manual visualization. The entire ARs in the 
PDB are in agonist conformation. We observed that the bulkiness and rigidity had 
increased with newer generation of AR antagonist. As discussed earlier, the helix-
12 of the AR extends from the ligand binding pocket upon binding with AR 
antagonist. Hence it may not possible for bulky AR antagonist to fit in the AR in 
agonist conformation. For the same, we modelled a helix-12 negative AR to fit the 
bulkier AR antagonist.  
7.1.2. Root Mean Square deviation between wild and mutant ARs 
The RMSD was calculated between wild and mutant ARs (T877A and 
W741L) mutant AR's ligand binding domain. The mutant AR proteins (T877A 
and W741L) were individually aligned with the wild type AR. The wild type AR 
was in agonist conformation because it was bound with DHT. The mutated ARs 
were also in agonist conformation but were bound with antagonist (Table 14). The 
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RMSD of <1 Å indicates that the structures of the mutated ARs are not 
significantly differ from the wild type AR.  
Table 14: RMSD between wild and mutant ARs 
AR mutation  RMSD with wild type AR in Å  Alignment score  
T877A  0.399  0.006  
W741L  0.276  0.003  
 
7.1.3. Analysis of the ligand binding pocket of wild and mutant ARs 
 The difference in the ligand-receptor interactions between wild and mutant 
(T877A and W741L) ARs were evaluated through docking studies. The standard 
AR agonist such as DHT and testosterone and standard AR antagonist such as 
bicalutamide, flutamide and enzalutamide were docked with wild, T877A, W741L 
and homology model (helix-12 negative) ARs (Table 15). 
7.1.3.1. Androgen 
The androgen DHT has binding affinity towards all the ARs (Table 15). 
The DHT and testosterone have similar type H-Bond interactions with wild type 
AR (Figure 14). The ketone group of DHT and testosterone formed H-Bond 
interaction with Arg752, while the 17β hydroxyl group formed H-Bond 
interaction with Asn705 and Thr877. Testosterone did not bind with the T877A 
mutated AR and didn't form any H-Bond interaction with W741L mutated AR. 
The binding energy of the androgens was less in the mutated ARs than the wild 
type AR. The DHT has a dock score of -10.80 kcal/mol with wild type AR but the 
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dock score had decreased with T877A (-7.84 kcal/mol) and W741L (-6.71 
kcal/mol) mutated ARs. Similarly the testosterone has a dock score of -10.68 
kcal/mol with wild type AR but the dock score had decreased with T877A (no 
binding) and W741L (-5.95 kcal/mol) mutated ARs. We observed that the AR 
mutation decreases the binding affinity of the androgens with AR. 
Figure 14: Binding interactions of androgens with AR 
DHT forms H-Bond interaction with Arg752, Asn705 and Thr877 with wild type AR. 
Testosterone forms H-Bond interaction with Arg752, Asn705 and Thr877 with wild type 
AR
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Table 15: Docking score and H-Bond interaction of AR standard ligands 
Ligands Wild type T877A W741L Truncated 
Dock 
Score
1 
H-Bond Dock 
Score 
H-Bond Dock 
Score 
H-Bond Dock 
Score 
H-Bond 
DHT -10.80 Arg752, 
Asn705, 
Thr877 
-7.84 Arg752, Gln711, HOH108 -6.71 Arg752, Gln711, 
Thr877, HOH108 
-7.26 HOH108, Asn705 
Testosterone -10.68 Arg752, 
Asn705, 
Thr877 
  -5.95  -7.17 HOH108, Asn705 
Flutamide -7.76 Asn705, 
Thr877 
-8.25 Arg752, Gln711, Asn705, 
Leu704, HOH108
*
, 
HOH213
#
 
-7.22 Arg752, Gln711, 
Leu704, Asn705, 
HOH108 
-6.22 Arg752, Gln711, 
Asn705, HOH108 
Bicalutamide -2.54    -10.27 Arg752, Gln711, 
Leu704, Asn705, 
HOH108 
-7.62 Arg752, Gln711, 
Asn705 
Enzalutamide       -8.42 Arg752, Gln711 
1
Dock score in kcal/mol, *HOH108 could form bridged H-Bond interactions with Arg752, Gln711 and Met745, 
#
HOH213 could 
form bridged H-Bond interaction with Leu873 
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7.1.3.2. Flutamide 
 Flutamide has binding affinity for all the AR types used in this study. 
Flutamide has the highest binding energy with T877A mutated AR (dock score = -
8.25 kcal/mol). Flutamide has a dock score of -7.76 kcal/mol and -7.22 kcal/mol 
with wild and W741L mutated ARs respectively. In wild type AR, the hydroxyl 
group of flutamide forms H-Bond interactions with Thr877 and Asn705 (Figure 
15). In T877A mutated AR, the nitro group of flutamide formed H-Bond 
interactions with Gln711, Arg752, HOH108, and Met745. The hydroxyl group of 
flutamide, in the absence of Thr877 amino acid, formed H-Bond interaction only 
with Asn705. The keto group of the amide formed H-Bond interaction with 
Leu873 mediated through a water molecule (HOH213) and the amino group of the 
amide formed H-Bond interaction with Leu704. We could observe that the size of 
the ligand binding pocket in T877A was bigger than the wild type AR (Figure 15). 
The flutamide displayed two different binding conformations with wild and 
T877A mutated ARs respectively. Flutamide attained a bent conformation with 
T877A mutated AR.  
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Figure 15: Interactions of flutamide with wild and T877A mutant ARs 
 
Flutamide forms H-Bond interaction with Thr877, Asn705 and forms ionic interaction 
with Arg752 in wild type AR. Flutamide forms H-Bond interactions with Arg752 (ionic 
and H-Bond), Gln711, Leu704, Leu873 (bridged through HOH) and Met745 (bridged 
through HOH) in T877A mutant AR. Note that the volume of the binding pocket in 
T877A mutant AR was greater than the wild type.  
 
7.1.3.3. Bicalutamide 
 The AR antagonist, bicalutamide doesn't bind with T877A AR and has low 
binding energy with wild type AR (dock score = -2.54 kcal/mol). Bicalutamide 
has the highest binding energy with W741L mutated AR (dock score = -10.27 
kcal/mol). In W741L mutated AR, the nitrile group of bicalutamide formed H-
Bond interactions with Arg752, Gln711, HOH108, and Met745. The amine and 
hydroxyl group formed H-Bond interaction with Leu704 and Asn705 respectively 
(Figure 16).  
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Figure 16: Binding interactions of bicalutamide and enzalutamide with AR 
 
Bicalutamide forms H-Bond interaction with Arg752, Gln711, Leu704, Met745 (bridged 
through HOH) and Asn705 in W741L mutated AR. Enzalutamide forms H-Bond 
interactions with Arg752 and Gln711 with helix-12 truncated AR. 
7.1.3.4. Enzalutamide 
 Enzalutamide doesn't have binding affinity with wild, T877A and W741L 
ARs. The enzalutamide has binding affinity only with helix-12 truncated AR 
(dock score = -8.426 kcal/mol). The nitrile group of enzalutamide forms H-Bond 
interactions with Arg752 and Gln711 (Figure 16).  
7.1.3.4. Validation of docking and homology model 
 The docking studies were validated by calculating the RMSD between the 
crystal and docked conformation of co-crystallized ligands. The maximum RMSD 
between the predicted and crystal structure poses of the ligand was 1.28 Å. The 
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maximum allowable limit is 2 Å. Hence the docking procedures that were 
followed were a valid one. The homology model was validated in the structural 
analysis and verification server (SAVES). The amino acids in the favorable, 
allowed and disallowed regions were identified by Ramachandran plot. The 
stereochemistry of the amino acids in the homology model was evaluated by 
PROCHECK. The 3D compatibility of the homology model was validated by 
VERIFY_3D.  The homology model passed all the criteria for a good protein 
structure. The percentage of amino acids in the favorable region, allowed region 
and disallowed regions were 96.2%, 3.8% and zero respectively.  
7.1.4. Elucidation of the binding mechanism of AR antagonists 
In case of W741L mutant AR, the mutated leucine amino acid (W741L) is 
much smaller in size than the tryptophan amino acid, so we tried to compare the 
binding mode of bicalutamide in presence of leucine (W741L AR) and 
tryptophan. The conformational difference in the bicalutamide was evaluated by 
superimposing the bicalutamide bound helix -12 negative AR and W741L AR 
(Figure 17). The helix-12 negative AR has wild type tryptophan amino acid. The 
B ring of bicalutamide attains a different conformation in the presence of 
tryptophan and leucine. In the presence of tryptophan, the B ring of bicalutamide 
was shifted nearer to helix-12 amino acid Ile 899, indicating a possible steric clash 
with it.  In the presence of leucine (mutated AR) the B ring of bicalutamide was 
well inside the ligand binding pocket and far from the helix-12.  
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Figure 17: Binding conformation of bicalutamide with wild (helix-12 
negative) and W741L mutated AR 
 
Figure represents the superimposition of the wild (green colored carbon) and W741L 
mutated (red colored carbon) ARs and the difference in binding mode of bicalutamide.  
Note the lack of steric clashes of bicalutamide with helix-12 in the mutated type, which 
in turn leads to resistance. 
 
7.2. To develop a pharmacophore model for wild and mutant AR antagonists 
and to identify difference between the pharmacophore models 
7.2.1. Purpose of the study  
The purpose of the study is to construct a pharmacophore (3D-QSAR) for 
in-silico virtual screening and identification of hit molecules. There is no AR in 
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antagonist bound conformation in PDB. Hence it was not possible to identify hit 
molecules through structure based virtual screening techniques. Even though a 
homology model could be built, it would not be a reliable method for the 
identification of the hit molecule in the first hand. Hence the pharmacophore 
generation is essential for the identification of the hit molecules. Constructing 
pharmacophore for wild, T877A and full antagonist was never done before and it 
could give or augment the results obtained in the docking studies. 
7.2.2. Data set preparation for wild, T877A and full antagonists (wild and T877A) 
 Selection of training molecules is an important step for developing a 3D-
QSAR model with good predictive power. The activity (IC50) for wild type AR 
was evaluated in VCaP cell line. The activity for T877A mutant AR was evaluated 
in LNCaP cell line. The majority of the molecules were active in wild and T877A 
mutant AR expressing cell lines. However, the activity of the molecules varied 
between the cell lines. This is because the molecules exhibit different efficacy 
with wild and mutant T877A ARs. Hence, the IC50 values evaluated in the VCaP 
cell line was used in developing the 3D-QSAR model for wild type AR. Similarly, 
the IC50 values evaluated in LNCaP cell line was used in developing the 3D-
QSAR model for T877A mutant AR. The separation of datasets as mentioned 
above will lead to the identification of preferential but not absolute 3D-QSAR for 
respective AR antagonists. Also, the molecules for the first and second datasets 
were not filtered for resistance. This means that the molecules in the dataset may 
or may not have agonist/partial agonist activity with either / both wild or T877A 
mutant AR. The molecules for the dataset of full antagonists were carefully 
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selected by a two-step process. First, the ligands that could antagonize both wild 
and T877A mutant ARs were selected. The second step involved the filtering of 
the molecules for resistance. This means that none of the ligands in the dataset has 
agonist/partial agonist activity with either / both wild or T877A mutant AR. The 
activities of the molecules in this dataset were evaluated by luciferase reporter 
assay. 
7.2.3. Pharmacophore generation for wild, T877A and full antagonists (wild and 
T877A mutant)  
7.2.3.1. Wild type AR 
 The molecules in the dataset were defined by the following 
pharmacophore site points: hydrogen bond acceptor (A), hydrogen bond donor 
(D), hydrophobic group (H), and aromatic ring (R). The number of “must match” 
pharmacophore site points was gradually decreased from 7 to 3 until all the 
actives were matched and scored successfully. Based on the scoring; 
ADDHRR.295 was selected as the best model (Tables 16 & 17).  
Table 16: Validation of training set 
Parameters 3D-QSAR  PLS   SD  R
2
  F  P  Q
2
 
Wild ADDHRR.295 5  0.13  0.91  171.1 1.918e
-43
  0.62 
T877A AHHRR.266 5 0.11 0.94 294.5 8.649e
-56
 0.62 
Full AHRR.63 3 0.2 0.94 152.4 7.536e
-18
 0.58 
Correlation between the predicted and observed activity (R
2
), predictive ability of 
the model (Q
2
), low standard deviation (S.D), and the probability of getting an actual 
result (P value), Fischer test (F), Partial least square factor (PLS). 
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Table 17: Validation of test set 
Parameters  3D-QSAR  PLS  R
2
 r
2
m R
2
pred Pearson-R 
Wild ADDHRR.295 5 0.76 0.76 0.72 0.87 
T877A AHHRR.266 5 0.74 0.74 0.69 0.86 
Full AHRR.63 3 0.80 0.75 0.83 0.89 
The correlation between the observed and predicted activity (R
2
), predictive R2 
(R
2
pred), correlation between the observed and predicted activity with intercept set 
at zero (r
2
m), Partial least square factor (PLS) 
  
 The active groups of the best fit molecules were evaluated by cube models 
(Figure 18, Table 18). During the construction of the 3D-QSAR, a rectangular 
grid was applied by PHASE to the aligned training set molecules. The grid 
includes all the substitutions in the pharmacophore site points. Then by correlating 
the observed activity and the atoms in the grid space, the PHASE generates the 
cube models. The cube models have a score value, less than zero means the atoms 
in the grid space does not favour the activity and greater than 1 will favour the 
activity. The space occupied by the atoms which does not favour the activity is 
indicated in red colour. The space occupied by the atoms which favours the 
activity is indicated in blue colour. Hence, the blue cubes represent the favourable 
regions for activity and the red cubes represent the unfavourable regions for 
activity.  
 The 4-nitrile and 3-CF3 substitutions in ring R10 were favorable regions 
for activity. The 3-CF3 substitution at ring R11, which is the hydrophobic H7 site 
point, also favors the activity. However, the –OH group and sulphur atom in the 
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linker region between R10 and R11 were unfavorable for activity. The H atom of 
the hydroxyl group is the donor D4 site point. This indicates that although it is one 
among the pharmacophore site points, it decreases the activity. The observed and 
predicted activities of test and training set molecules are given in the table 19. 
Figure 18: Pharmacophore of wild type AR antagonist 
 
A: Represents the distances between the pharmacophore site points. B: Represents the 
best fit molecule with the 3D-QSAR. C: Represents the cube model of the best fit active 
molecule. Blue cubes represent the favourable regions for activity. The red cubes 
represent the unfavourable regions for activity. The 4-nitrile and 3-CF3 regions in ring 
R10, the 3-CF3 region at ring R11were favourable regions for activity. The –OH group 
(D4) site point and sulphur atom was unfavourable for activity. R-ring; D-donor; H-
hydrophobic; A-acceptor 
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Table 18: Angle and distances between wild type pharmacophore site points 
Site1  Site2  Site3  Angle Site1 Site2 Site3  Angle Site1  Site2 Distance 
 D4  A3  D5 45.2  A3  H7  D4 26.1  A3  D4 4.3 
 D4  A3  H7 126.4  A3  H7  D5 27.5  A3  D5 3.125 
 D4  A3  R10 98.5  A3  H7  R10 48.7  A3  H7 4.512 
 D4  A3  R11 85.2  A3  H7  R11 58.7  A3  R10 4.115 
 D5  A3  H7 110.6  D4  H7  D5 21.5  A3  R11 3.97 
 D5  A3  R10 53.4  D4  H7  R10 53.7  D4  D5 3.054 
 D5  A3  R11 68.4  D4  H7  R11 36.9  D4  H7 7.867 
 H7  A3  R10 75.8  D5  H7  R10 32.2  D4  R10 6.376 
 H7  A3  R11 45  D5  H7  R11 34.1  D4  R11 5.602 
 R10  A3  R11 60.8  R10  H7  R11 50.4  D5  H7 6.328 
 A3  D4  D5 46.6  A3  R10  D4 41.8  D5  R10 3.373 
 A3  D4  H7 27.5  A3  R10  D5 48.1  D5  R11 4.05 
 A3  D4  R10 39.7  A3  R10  H7 55.5  H7  R10 5.308 
 A3  D4  R11 44.9  A3  R10  R11 57.9  H7  R11 3.282 
 D5  D4  H7 49.5  D4  R10  D5 6.9  R10  R11 4.09 
 D5  D4  R10 7.6  D4  R10  H7 84.1 
 D5  D4  R11 44.7  D4  R10  R11 60.1 
 H7  D4  R10 42.2  D5  R10  H7 90.8 
 H7  D4  R11 20.6  D5  R10  R11 64.9 
 R10  D4  R11 39.3  H7  R10  R11 38.2 
 A3  D5  D4 88.2  A3  R11  D4 49.9 
 A3  D5  H7 41.9  A3  R11  D5 45.9 
 A3  D5  R10 78.5  A3  R11  H7 76.3 
 A3  D5  R11 65.7  A3  R11  R10 61.4 
 D4  D5  H7 108.9  D4  R11  D5 32.1 
 D4  D5  R10 165.5  D4  R11  H7 122.5 
 D4  D5  R11 103.2  D4  R11  R10 80.6 
 H7  D5  R10 57  D5  R11  H7 118.9 
 H7  D5  R11 27  D5  R11  R10 49 
 R10  D5  R11 66.1  H7  R11  R10 91.4 
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Table 19a: Observed and predicted activity of bicalutamide derivatives 
 
In 
 
Ar (B ring) X R (A ring) Wild (pIC50) T877A (pIC50) 
Observed Predicted Observed Predicted 
Bic 4-F-Ph SO2 4-CN, 3-CF3 4.16 4.69 4.34 4.38 
44e  4-CN-Ph O 4-CN, 3-CF3 4.61 4.64 4.67 4.57 
R-Bic 4-F-Ph SO2 4-CN, 3-CF3 4.28 4.29 4.34 4.29 
22c 3-CF3-Ph S 4-CN, 3-CF3 5.03 4.91 5.29 5.40 
22d 2-CF3-Ph S 4-CN, 3-CF3 5.12 5.18 5.3 5.29 
22h 4-OCF3-Ph S 4-CN, 3-CF3 4.39 4.59 4.36 4.36 
22o 4-CF3-2-Pyridine S 4-CN, 3-CF3 4.04 4.41 4.09 4.11 
23b# 4-CF3-Ph S 4-NO2, 3-CF3 4.67 4.85 4.54 4.61 
23c* 3-CF3-Ph S 4-NO2, 3-CF3 5.06 5.19 5.19 5.53 
23d* 2-CF3-Ph S 4-NO2, 3-CF3 5.35 5.35 5.32 5.43 
24a# 4-F-Ph S 4-CN, 2-CF3 4.34 4.55 4.57 4.65 
24c 3-CF3-Ph S 4-CN, 2-CF3 4.62 4.76 4.94 4.85 
24d 2-CF3-Ph S 4-CN, 2-CF3 4.73 4.65 4.96 4.81 
25a 4-F-Ph S 4-NO2, 2-CF3 4.67 4.68 4.92 4.69 
25b# 4-CF3-Ph S 4-NO2, 2-CF3 4.76 4.73 5.06 5.09 
25c 3-CF3-Ph S 4-NO2, 2-CF3 4.78 4.65 4.99 5.02 
25d 2-CF3-Ph S 4-NO2, 2-CF3 4.89 4.94 4.93 4.87 
25f 3,4-F-Ph S 4-NO2, 2-CF3 --- --- 4.08 4.66 
25g 2,4-F-Ph S 4-NO2, 2-CF3 4.77 4.74 4.95 4.85 
25i# 3-OCF3-Ph S 4-NO2, 2-CF3 4.79 4.90 5.03 5.06 
25l 2-OCF3-Ph S 4-NO2, 2-CF3 5.27 5.22 5.48 5.42 
25o* 4-CF3-2-Pyridine S 4-NO2, 2-CF3 4.76 4.63 4.95 4.84 
25p 5-CF3-2-Pyridine S 4-NO2, 2-CF3 4.76 4.93 5.25 5.17 
26c 3-CF3-Ph S 4-CF3 4.7 4.62 4.64 4.73 
26d* 2-CF3-Ph S 4-CF3 5.23 5.12 5.14 4.83 
26i 3-OCF3-Ph S 4-CF3 4.72 4.77 4.85 4.88 
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27b# 4-CF3-Ph O 4-CN, 3-CF3 5.01 4.69 5.19 5.21 
27c# 3-CF3-Ph O 4-CN, 3-CF3 5.04 4.72 5.08 4.94 
27d# 2-CF3-Ph O 4-CN, 3-CF3 4.77 4.55 5.01 4.98 
27f 3,4-F-Ph O 4-CN, 3-CF3 4.59 4.58 4.72 4.77 
27g 2,4-F-Ph O 4-CN, 3-CF3 4.41 4.42 4.42 4.60 
27h# 4-OCF3-Ph O 4-CN, 3-CF3 4.75 4.59 4.86 4.74 
27i 3-OCF3-Ph O 4-CN, 3-CF3 5 5.02 5 5.03 
28b* 4-CF3-Ph O 4-NO2, 3-CF3 4.96 5.02 4.76 5.14 
28c*,# 3-CF3-Ph O 4-NO2, 3-CF3 4.98 4.66 5 4.90 
28d# 2-CF3-Ph O 4-NO2, 3-CF3 4.56 4.49 4.64 4.63 
28e 4-CN-Ph O 4-NO2, 3-CF3 4.57 4.54 4.72 4.80 
28f* 3,4-F-Ph O 4-NO2, 3-CF3 4.72 4.75 4.83 4.76 
28g 2,4-F-Ph O 4-NO2, 3-CF3 4.67 4.68 4.94 4.87 
28h* 4-OCF3-Ph O 4-NO2, 3-CF3 4.7 4.72 4.75 4.91 
28i* 3-OCF3-Ph O 4-NO2, 3-CF3 5.01 5.07 5 5.09 
28l 2-OCF3-Ph O 4-NO2, 3-CF3 5.01 4.98 5.15 5.11 
28m* 4-CN,2-CF3-Ph O 4-NO2, 3-CF3 5.07 5.05 5.24 5.44 
28n 4-CN,3-F-Ph O 4-NO2, 3-CF3 4.9 4.97 5.11 5.13 
28o 4-CF3-2-Pyridine O 4-NO2, 3-CF3 --- --- 4.43 4.51 
29b* 4-CF3-Ph O 4-CN, 2-CF3 4.63 4.59 4.54 4.55 
29c*,# 3-CF3-Ph O 4-CN, 2-CF3 4.66 4.53 4.81 5.03 
29d* 2-CF3-Ph O 4-CN, 2-CF3 4.65 4.79 4.85 4.62 
29e 4-CN-Ph O 4-CN, 2-CF3 4.21 4.16 4.45 4.38 
29f 3,4-F-Ph O 4-CN, 2-CF3 4.32 4.28 4.45 4.44 
29g 2,4-F-Ph O 4-CN, 2-CF3 4.29 4.26 4.51 4.48 
29h* 4-OCF3-Ph O 4-CN, 2-CF3 4.65 4.66 4.55 4.58 
29i*,# 3-OCF3-Ph O 4-CN, 2-CF3 4.24 4.66 4.19 4.21 
29l*,# 2-OCF3-Ph O 4-CN, 2-CF3 4.35 4.77 4.47 4.64 
29m* 4-CN,2-CF3-Ph O 4-CN, 2-CF3 4.75 4.64 5.02 5.24 
29n 4-CN,3-F-Ph O 4-CN, 2-CF3 4.11 4.07 4.1 4.10 
30b* 4-CF3-Ph O 4-NO2, 2-CF3 4.73 4.82 4.86 4.62 
30c* 3-CF3-Ph O 4-NO2, 2-CF3 4.71 4.80 4.88 5.08 
31c 3-CF3-Ph O 4-CF3 4.72 4.81 4.74 4.96 
31d 2-CF3-Ph O 4-CF3 4.93 4.87 5.15 5.03 
31i# 3-OCF3-Ph O 4-CF3 5.36 5.41 5.66 5.42 
32b 4-CF3-Ph SO2 4-CN, 3-CF3 4.53 4.52 4.69 4.63 
32c# 3-CF3-Ph SO2 4-CN, 3-CF3 4.4 4.41 4.82 4.76 
32d#,* 2-CF3-Ph SO2 4-CN, 3-CF3 4.23 4.35 4.36 4.42 
32h,* 4-OCF3-Ph SO2 4-CN, 3-CF3 4.48 4.35 4.49 4.40 
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33b 4-CF3-Ph SO2 4-NO2, 3-CF3 4.5 4.46 4.74 4.67 
33c 3-CF3-Ph SO2 4-NO2, 3-CF3 4.51 4.35 4.79 4.74 
33d 2-CF3-Ph SO2 4-NO2, 3-CF3 4.55 4.56 4.59 4.59 
34a 4-F-Ph SO2 4-CN, 2-CF3 4.18 4.17 4.03 4.05 
34b* 4-CF3-Ph SO2 4-CN, 2-CF3 4.36 4.35 4.48 4.73 
34c 3-CF3-Ph SO2 4-CN, 2-CF3 4.34 4.43 4.49 4.55 
34d 2-CF3-Ph SO2 4-CN, 2-CF3 --- --- 4.13 4.16 
35a 4-F-Ph SO2 4-NO2, 2-CF3 4.23 4.27 4.41 4.47 
35b 4-CF3-Ph SO2 4-NO2, 2-CF3 4.32 4.46 4.53 4.51 
35c 3-CF3-Ph SO2 4-NO2, 2-CF3 4.41 4.37 4.77 4.79 
35d 2-CF3-Ph SO2 4-NO2, 2-CF3 4.41 4.36 4.68 4.58 
35f* 3,4-F-Ph SO2 4-NO2, 2-CF3 4.42 4.37 4.71 4.39 
35g 2,4-F-Ph SO2 4-NO2, 2-CF3 4.23 4.21 4.74 4.57 
35i 3-OCF3-Ph SO2 4-NO2, 2-CF3 4.69 4.63 4.91 4.77 
35l 2-OCF3-Ph SO2 4-NO2, 2-CF3 4.28 4.22 4.75 4.83 
35p 5-CF3-2-Pyridine SO2 4-NO2, 2-CF3 4.23 4.11 4.34 4.37 
42b (R) 4-CF3-Ph S 4-CN, 3-CF3 5.03 4.71 4.84 4.74 
42c (R)# 3-CF3-Ph S 4-CN, 3-CF3 5.05 4.94 4.84 4.86 
42d (R)* 2-CF3-Ph S 4-CN, 3-CF3 5.53 5.52 5.1 4.92 
42g (R) 2,4-F-Ph S 4-CN, 3-CF3 4.73 4.70 4.59 4.50 
42h (R) 4-OCF3-Ph S 4-CN, 3-CF3 4.75 4.74 4.7 4.72 
45b (R) 4-CF3-Ph SO2 4-CN, 3-CF3 4.5 4.37 4.75 4.69 
45c (R) 3-CF3-Ph SO2 4-CN, 3-CF3 4.39 4.56 4.88 4.92 
45d (R)# 2-CF3-Ph SO2 4-CN, 3-CF3 4.42 4.58 4.49 4.52 
45g (R) 2,4-F-Ph SO2 4-CN, 3-CF3 4.21 4.15 4.37 4.27 
45h (R)#,* 4-OCF3-Ph SO2 4-CN, 3-CF3 4.5 4.66 4.72 4.83 
46a (R) 4-F-Ph SO2 4-CN, 2-CF3 --- --- 4.06 4.05 
52 2-CF3-Ph S 4-NO2, 3-CF3 5.55 5.32 6.14 6.15 
24a* 3,5-CF3-Ph S 4-CN, 3-CF3 5.56 5.81 5.63 5.60 
25a* 3,5-CF3-Ph S 4-NO2, 3-CF3 5.81 5.83 5.82 5.68 
26a# 3,5-CF3-Ph S 4-CN, 2-CF3 5.17 5.12 5.11 5.01 
27a* 3,5-CF3-Ph S 4-NO2, 2-CF3 5.45 5.28 5.5 5.33 
28a 3,5-CF3-Ph S 4-CF3 5 5.12 5.01 4.95 
29b* 3-CF3-Ph S 3,5-CF3 5 4.97 5.05 4.97 
29c 2-CF3-Ph S 3,5-CF3 5.41 5.50 5.44 5.50 
29d 3-OCF3-Ph S 3,5-CF3 5.03 5.04 5.11 5.08 
29e 2-OCF3-Ph S 3,5-CF3 5.53 5.60 5.53 5.53 
30a# 3,5-CF3-Ph O 4-CN, 3-CF3 5.6 5.10 5.52 5.57 
30f# 3,5-tBu-Ph O 4-CN, 3-CF3 5.52 5.45 5.57 5.72 
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31a#,* 3,5-CF3-Ph S 4-NO2, 3-CF3 5.77 5.85 6 5.93 
32a# 3,5-CF3-Ph O 4-CN, 2-CF3 5.32 5.02 5.44 5.49 
33a* 3,5-CF3-Ph O 4-NO2, 2-CF3 4.82 4.96 4.62 4.83 
34a* 3,5-CF3-Ph O 4-CF3 5.38 5.41 5.47 5.11 
35a 3,5-CF3-Ph SO2 4-CN, 3-CF3 5.2 4.93 5.54 5.59 
36a 3,5-CF3-Ph SO2 4-NO2, 3-CF3 5.48 5.15 5.67 5.61 
38a 3,5-CF3-Ph SO2 4-NO2, 2-CF3 5.14 5.11 5.51 5.49 
39b 3-CF3-Ph SO2 3,5-CF3 5 4.82 5.02 5.04 
39c 2-CF3-Ph SO2 3,5-CF3 5.06 5.01 5.07 5.20 
39d# 3-OCF3-Ph SO2 3,5-CF3 5 4.88 5.02 4.98 
39e 2-OCF3-Ph SO2 3,5-CF3 5 5 5.09 5.15 
41 3,5-CF3-Ph S 4-CN, 3-CF3 6.07 5.81 6.1 5.92 
42 3,5-CF3-Ph SO2 4-CN, 3-CF3 5.38 5.26 5.7 5.76 
*Test set = T877A, #Test set = Wild 
Table 19b: Observed and predicted activity of enzalutamide derivatives
 
 
In R1 X R2 
Wild (pIC50) T877A (pIC50) 
Observed  Predicted  Observed  Predicted 
61b# 4-CN, 3-CF3 O 4-CF3 4.52  4.41 5.02 5.19 
62b# 4-NO2, 3-CF3 O 4-CF3 4.13  4.42 5.67 5.60 
62c 4-NO2, 3-CF3 O 3-CF3 --- --- 4.81 4.87 
63b 4-CN, 2-CF3 O 4-CF3 --- --- 5.07 5.15 
63c 4-CN, 2-CF3 O 3-CF3 --- --- 4.73 4.78 
64b 4-NO2, 2-CF3 O 4-CF3 --- --- 5.42 5.43 
64c 4-NO2, 2-CF3 O 3-CF3 4.87  5.05 5.39 5.18 
65b 3-CF3 O 4-CF3 4.14  4.26 5.22 5.24 
65c 3-CF3 O 3-CF3 4.12  4.20 5.24 5.09 
71b 4-CF3 O 3-CF3 --- --- 4.78 4.90 
71d 2-CF3 O 3-CF3 --- --- 4.54 4.80 
Enz*,# 4-CN, 3-CF3 S 3-F, 4-CONHMe 4.27 4.38 4.94 4.88 
Chapter 7: Results and Analysis 
 
PSG College of Pharmacy, Coimbatore. Page 87 
 
49 4-NO2, 3-CF3 S 3,5-CF3 4.54 4.65 5 5.05 
51 4-NO2, 2-CF3 S 3,5-CF3 4.73 4.77 5.33 5.40 
54# 3,5-CF3 S 3-F, 4-CONHMe 4.7 4.68 4.94 4.97 
*Test set = T877A, #Test set = Wild 
 
The correlation between the observed and predicted activity of the training 
set was 0.9. The model was validated by predicting the test set having wide range 
of biological activity. The correlation between the observed and predicted activity 
of the test set was 0.76 (Figure 19). Also, the ADDHRR.295 accurately predicted 
the biological value of AR antagonist, enzalutamide (residual activity =0.14).
 
Figure 19: Correlation between observed and predicted activity of wild type 
AR antagonist 
 
7.2.3.2. T877A mutated AR 
 The dataset generated A, D, H, and R pharmacophore site points. The 
hypothesis having five pharmacophore site points survived the scoring functions. 
Based on the scoring, AHHRR.266 was selected as the best model (Table 16 and 
17). The pharmacophore has one acceptor group (A), two hydrophobic groups (H) 
and two aromatic rings (R). The active groups of the best fit molecule were 
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evaluated by cube models (Figure 20, Table 20). The blue cubes represent the 
favorable regions for activity and red cubes represent the unfavorable regions for 
activity.  
Figure 20: Pharmacophore of T877A mutant AR antagonist 
 
A. Represents the distances between the pharmacophore site points. B: Represents the 
best fit molecule with the 3D-QSAR. C: Represents the cube model of the best fit active 
molecule. Blue cubes represent the favourable regions for activity. The red cubes 
represent the unfavourable regions for activity. The 4-nitro and 3-CF3 (H5 site point) 
substitution in ring R9, the 3-CF3 (H6 site point) and 5-CF3 substitution in ring R10 
were favourable regions for activity. The –OH group and sulphur atom was 
unfavourable for activity. R-ring; D-donor; H-hydrophobic; A-acceptor. 
  
The 4-nitro and 3-CF3 substitutions in ring R9 are favorable regions for 
activity. The 3-CF3 group is the hydrophobic H5 site point. The 3 and 5-CF3 
substitutions at ring R10 also favors the activity. The 3-CF3 substituent is also the 
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hydrophobic H6 site point. However, the –OH and sulphur atom in the linker 
region between R10 and R11 were unfavorable for activity. The observed and 
predicted activities of all the ligands in the training and test sets are given in Table 
19.  
Table 20: Angle and distances between T877A mutant pharmacophore site 
points 
Site1  Site2  Site3  Angle Site1 Site2 Site3  Angle Site1  Site2 Distance 
 H5  A2  H6 115.9  H5  H6  R9 9  A2  H5 6.993 
 H5  A2  R9 16  H5  H6  R10 58.3  A2  H6 8.623 
 H5  A2  R10 128.9  R9  H6  R10 54  A2  R9 4.036 
 H6  A2  R9 106.8  A2  R9  H5 144.4  A2  R10 6.164 
 H6  A2  R10 17.2  A2  R9  H6 51.7  H5  H6 13.267 
 R9  A2  R10 122.3  A2  R9  R10 35.4  H5  R9 3.305 
 A2  H5  H6 35.8  H5  R9  H6 141.3  H5  R10 11.874 
 A2  H5  R9 19.6  H5  R9  R10 145.8  H6  R9 10.525 
 A2  H5  R10 23.8  H6  R9  R10 17.2  H6  R10 3.284 
 H6  H5  R9 29.7  A2  R10  H5 27.3  R9  R10 8.995 
 H6  H5  R10 13.6  A2  R10  H6 129.2 
 R9  H5  R10 25.2  A2  R10  R9 22.3 
 A2  H6  H5 28.3  H5  R10  H6 108.1 
 A2  H6  R9 21.5  H5  R10  R9 9 
 A2  H6  R10 33.6  H6  R10  R9 108.8 
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The correlation between the observed and predicted activity of the training 
set and test set was 0.94 and 0.74, respectively (Figure 21). The model 
AHHRR.266 accurately predicted the biological activity of AR antagonist 
enzalutamide (residual activity = 0.06). The biological activity of enzalutamide 
has wide variations between wild and mutant ARs. Enzalutamide is ~5 times 
selective towards T877A mutant AR. The 3D-QSAR models for wild and T877A 
mutant AR could identify the differences in the structural features of 
enzalutamide. This indicates that these models could provide the possible 
breakthrough needed to overcome AR resistance. 
Figure 21: Correlation between observed and predicted activity of T877A 
mutant AR antagonist 
 
7.2.3.3. Wild and mutant AR antagonist (Full antagonist) 
 The corresponding dataset of the full antagonists has biological activity for 
wild type and T877A mutant AR. The dataset generated A, D, H, and R 
pharmacophore site points. The hypothesis having four pharmacophore site points 
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survived the scoring functions. Based on scoring; AHRR.63 was selected as the 
best model (Table 16 and 17).  
 Figure 22: Pharmacophore of wild and T877A AR antagonists 
 
A: Represents the distances between the pharmacophore site points. B: Represents the 
best fit molecule with the 3D-QSAR. C: Represents the cube model of the best fit active 
molecule. Blue cubes represent the favourable regions for activity. The red cubes 
represent the unfavourable regions for activity. The nitrile (A1 site point) and 3-Cl 
substitution in ring R11, the –OH group present between the two rings was favourable 
for activity. The methyl group of 4-CONHCH3 in ring R10 was favourable for activity. 
R-ring; D-donor; H-hydrophobic; A-acceptor. 
 
The pharmacophore has one H-Bond acceptor group (A), one hydrophobic 
group (H), and two aromatic rings (R). The active groups of the best fit molecule 
were evaluated by cube models as described above for the wild and mutant 
modeling (Figure 22, Table 21). The 4-nitrile (A1 site point) and 3-Cl 
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substitutions in ring R11 are favorable regions for activity. These regions are 
occupied by blue cubes. The methyl group that follows the 4-amide in ring R10 
also favors the activity. The N atom in the pyridine ring R10 and the –OH group 
in the linker region between R11 and R10 were also favorable for activity. The 
observed and predicted activities of all the molecules in the dataset are given in 
the tables 22.  
Table 21: Distance and angle between full antagonist pharmacophore site 
points 
Site1  Site2  Site3  Angle Site1 Site2 Site3 Angle Site1 Site2 Distance 
 H9  A1  R10 19.6  A1  R10  H9 36.7  A1  H9 7.764 
 H9  A1  R11 18.4  A1  R10  R11 11.8  A1  R10 10.811 
 R10  A1  R11 21.5  H9  R10  R11 31  A1  R11 4.028 
 A1  H9  R10 123.8  A1  R11  H9 143.7  H9  R10 4.358 
 A1  H9  R11 17.9  A1  R11  R10 146.6  H9  R11 4.143 
 R10  H9  R11 116.2  H9  R11  R10 32.8  R10  R11 7.217 
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Table 22a: Observed and predicted activity of 1-arylmethyl-4-phenylpyrrole 
derivatives 
 
I.D R1 X R2 R3 R4 R5 Observed 
(pIC50) 
Predicted 
(pIC50) 
1 H Bond Me CO2Et NO2 Me 6.61 6.30 
2 Me Bond Me CO2Et NO2 Me 6.30 6.18 
3
* 
Phenyl Bond Me CO2Et NO2 Me 5.36 5.38 
4a Phenyl CH2 Me CO2Et NO2 Me 6.46 6.42 
4b
* 
Phenyl CH2 Me CO2Me NO2 Me 6.52 6.43 
4d Phenyl CH2 Me CH2OH NO2 Me 5.42 5.60 
4e Phenyl CH2 Me COMe NO2 Me 5.33 5.52 
4f Phenyl CH2 Me H NO2 Me 6.30 6.25 
4g Phenyl CH2 Me CO2Me H Me 5.58 5.92 
4h
* 
Phenyl CH2 Me CO2Me CN Me 6.56 6.32 
4j Phenyl CH2 Me CN CN Me 7.39 7.24 
4l
* 
2-Chloro-5-
Methylpyridine 
CH2 Me CN CN Me 7.34 6.97 
4m
* 
(5-methylpyridin-
3-yl)methanol 
CH2 Me CN CN Me 7 7.27 
4n (2-chloro-5-
methylpyridin-3-
yl)methanol 
CH2 Me CN CN Me 7.60 7.46 
4o (2-chloro-5-
methylpyridin-3-
yl)methanol 
CH2 H CN CN Me 6.49 6.90 
4p (2-chloro-5- CH2 Me CN CN H 6.76 6.93 
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methylpyridin-3-
yl)methanol 
5
 
Cyclo-hexyl CH2 Me CO2Et NO2 Me 5.42 5.11 
6 Phenyl (CH2)2 Me CO2Et NO2 Me 5.38 5.33 
7
* 
Phenyl C=O Me CO2Et NO2 Me 5.61 5.95 
8 Phenyl SO2 Me CO2Et NO2 Me 5.32 5.32 
*Test set  
 
Table 22b: Observed and predicted activity of 4-arylmethyl-1-phenylpyrazole 
derivatives 
 
I.D R1 R2 X Observed (pIC50)  Predicted (pIC50)  
3
* 
H 4- F CH2 6.15 6.30 
28b Cl 3- CONH2 CH2 6.15 6.04 
28c Cl 4- CONH2 CH2 6.37 6.44 
28d
* 
Cl 4-CONHMe CH2 5.88 6.24 
28e Cl 4-CONMe2 CH2 5.39 5.53 
28f Cl 4-CONHtBu CH2 6.01 6.24 
28g Cl 4-CONH(CH2) 2OH CH2 5.56 5.60 
28h
* 
Cl 4-CONHCH2C(CH2) 2 OH CH2 6.22 5.71 
33 Cl 4-F Bond 5.20 5.00 
36 Cl 4-F (CH2)2 5.95 6.10 
*Test set  
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Table 22c: Observed and predicted activity of 4-aryloxy-1-phenylpyrazole 
derivatives 
 
I.D X Y R1 Observed 
(pIC50)  
Predicted 
(pIC50)  
25 CH CH F 6.17 6.06 
29a CH CH N-(2-hydroxy-2-
methylpropyl)acetamide 
5.74 5.69 
29b CH CH 1-morpholinoethanone 5.52 5.49 
44b N CH N-methylpivalamide 5.39 5.28 
45 CH N N-methylacetamide 5.14 5.18 
Table 22d: Observed and predicted activity of 3-aryl-3-hydroxy-1-
phenylpyrrolidine derivatives 
 
I.D R1 R3 R2 C-3 Observed (pIC50)  Predicted (pIC50)  
48 CONHMe Cl S-Me R 7.60 7.45 
49 CONMe2 Cl S-Me R 5.76 6.18 
50 CONHMe Cl R-Me S 5.19 5.06 
51 Pyrrolidin-2-one Cl S-Me R 7.95 7.63 
52
*
 CONHMe OMe S-Me R 7.20 7.25 
53 CONHMe H S-Me R 6.39 6.39 
54 CONHMe F S-Me R 6.53 6.70 
 *Test set 
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The correlation between the observed and predicted activity of the training 
and test sets were 0.94 and 0.79, respectively (Figure 23). This 3D-QSAR 
pharmacophore did not match with any of the existing AR antagonists (both wild 
and mutant). This indicates the hybrid nature of the full antagonist 
pharmacophore. Recall that all the marketed AR antagonists develop resistance 
during the course of the treatment. 
Figure 23: Correlation between observed and predicted activity of wild and 
T877A mutant AR antagonist pharmacophore 
   
7.2.4. Similarities and differences between the wild and T877A mutant 
pharmacophores 
 The molecules in the dataset for the construction of the 3D-QSAR models 
have common structures, which are also present in the marketed drugs (Figure 
24). All the marketed ligands have two rings (A and B) separated by a linker 
group. These two rings (A and B) were present in all the 3D-QSAR models. 
Notably, the substitutions of 4-nitro / 4-nitrile groups and 3-CF3 / 3-Cl groups in 
the A ring are favorable for activity as explained by the cube models. Similarly, 
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the hydrophobic substitutions at 3
rd
, 4
th
, and 5
th
 position in the B ring also favored 
the activity. The major difference among the 3D-QSAR models was the distance 
and angle between the A ring and B ring. Also, there is a difference in the distance 
between the two extreme pharmacophore site points. These properties describe the 
variability in the length and flexibility among the active molecules.  
Figure 24: 2D diagram representing the differences between the 
pharmacophores 
 
 The shortest distances are for wild type AR antagonist (A ring to B ring: 
4.09 Å and D4 to H7: 7.867 Å). The angle between the A ring and B ring is 
always acute (<90º), with the ordinates in the linker region (R10-D4-R11 = 39.3º, 
R10-D5-R11 = 66º, R10-A3-R11 = 60.8). The shorter distances and acute angle 
between the A ring and B ring indicate a flexible linker region among the active 
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molecules. The longest distances are for the T877A mutant antagonist (ring A to 
ring B: 8.895 Å and H5 to H6: 13.267 Å). The angle between the A ring and B 
ring is always obtuse (>90º), with the ordinates in the linker region (R10-A2-R9 = 
122.3º). The longer distances and obtuse angles between the A and B rings 
indicate a less flexible linker region among the active molecules. The distances of 
the full antagonist pharmacophore are marginally less than the T877A mutant 3D-
QSAR (ring A to ring B: 7.217 Å and A1 to R10: 10.811 Å). Also, the angle 
between the A and B rings is always obtuse (>90º), with the ordinates in the linker 
region (R10-H9-R11 = 116.2º).  
 The relatively longer distances and obtuse angles between the A and B 
rings indicate a less flexible linker region among the active molecules. Notably, 
the 3D-QSAR of full antagonists does not represent the site points for H-Bond 
interaction in the linker region. The 3D-QSAR of wild type AR favors H-bond 
interaction in the linker region when compared to the other two. This is because it 
has 3 pharmacophore points (A1, D4 and D5) in the linker region, which could 
form H-Bond interactions. 
7.3. Phase 3 - Identification of new chemical entities through in-silico drug 
design methods 
7.3.1. Purpose of the study 
The purpose of the study is to identify hit molecules through in-silico drug 
design methods. The ligand based drug design approach was followed for the 
selection of hit molecules. Then the selected ligands were studied for their 
interaction with AR through docking studies. In-silico virtual screening was very 
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useful method for identification of hit molecules. This is because we can screen 
millions of molecules in the chemical databases within short period of time. This 
method was also cost effective. The ADME properties, Lipinski rule of 5 and 
toxicity parameters were also included in the screening process for the 
identification of best fit molecule.  
7.3.2. Drug Design 
7.3.2.1. Target selection 
Figure 25: AR as central dogma in AIPC (From literature review) 
 
T887A AR: T877A mutated AR; TMPRSS2: Transmembrane protease, serine 2; ETS: 
erythroblast transformation-specific: ERG: ETS related genes; ETV1: ETS variant 1. 
 
From the evaluation of the molecular pathogenesis of prostate cancer we 
selected mutant AR as target for AIPC. The mutant AR was directly modulates 
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many cellular proliferation pathways. In this study we had used helix-12 negative 
T877A mutant AR for docking studies. As per literature the evidence, we used 
helix-12 negative AR to accommodate bulkier AR antagonist.   
7.3.2.2. Target validation 
The docking studies were validated by calculating the RMSD between the 
crystal and docked conformation of co-crystallized ligands. The RMSD between 
the predicted and crystal poses of cyproterone acetate was structure was 1.14 Å. 
The maximum allowable limit is 2 Å. Hence the docking procedures we were 
followed was valid one. The homology model was validated in the structural 
analysis and verification server (SAVES). The amino acids in the favorable, 
allowed and disallowed regions were identified by Ramachandran plot. The 
stereochemistry of the amino acids in the homology model was evaluated by 
PROCHECK. The 3D compatibility of the homology model was validated by 
VERIFY_3D.  The homology model passed all the criteria for a good protein 
structure. The percentage of amino acids in the favorable region, allowed region 
and disallowed regions were 96.2%, 3.8% and zero respectively. 
7.3.2.3. Lead identification 
The wild and T877A mutated AR antagonist pharmacophore was used to 
find matches in the SPECS database and synthesized compounds from Shasun 
Research Center, Chennai (>1 million compounds). The pharmacophore matched 
ligands (1001 ligands) were ranked according to the fitness score (maximum of 3). 
The ligands with fitness score >2 (666 ligands) were subjected to structure based 
screening. Initially, the ligands were screened for optimum bulkiness by docking 
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with helix-12 positive AR. The ligands that did not have binding affinity for helix-
12 positive AR were selected for the next step. This filtering eliminated the less 
bulky / highly flexible ligands and reduced the total ligands to 192. The remaining 
ligands were docked with helix-12 negative AR by extra precision (XP) glide 
docking method. The molecules that form H-Bond interaction with amino acids 
such as Arg752, Gln711 and Asn705 were selected. Further, the ligands were 
manually evaluated for ADME and toxicity and we selected the ligands that have 
β-iminoenamine-BF2 complex with either 1, 2 dihydronaphthalene or 2H-
chromene groups (Figure 26). We obtained a total 9 compounds from the β-
iminoenamine-BF2 series from Shasun Research Centre, Chennai, for in-vitro 
screening. 
Figure 26: Pharmacophore matched compounds 
ARA1, fitness score - 2.009 3b: ARA3, Fitness score - 2.025
 
7.3.2.4. β-iminoenamine-BF2 complex ligands 
The β-iminoenamine BF2 complex ligands also have 4-nitro-phenyl or 4-
methoxy-phenyl or 4-fluoro-phenyl nucleus. The bulky ring that makes the β-
iminoenamine BF2 complex is either 2H-chromene or 1, 2-dihydronapthalene 
group. These molecules were synthesized and obtained from Shasun Research 
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Centre [129]. The docking studies have further shown that these molecules have 
affinity for the AR and formed essential H-Bond interactions with AR.  
Figure 27: In-silico - Drug design workflow 
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7.3.2.5. Ligand/AR binding interactions 
The enzalutamide had the best glide score (-8.426 kcal/mol) followed by 
test ligand, ARA3 (-8.295 kcal/mol). Most of the test ligands had similar glide 
scores as of bicalutamide (-7.624 kcal/mol) (Table 23). The enzalutamide and 
bicalutamide formed H-Bond interactions with Gln711, HOH108, Arg752, and 
Asn705 with helix-12 truncated AR. Bicalutamide had binding affinity for helix-
12 uncut AR (-8.930 kcal/mol) but enzalutamide did not bind with it. Similar to 
enzalutamide, the test ligands (ARA1-ARA9) had binding affinity for helix-12 
truncated AR, but did not bind with helix-12 uncut AR. The ligands (ARA1 - 
ARA4 and ARA6) formed H-Bond interaction with Gln711, HOH108, and 
Arg752 (bridged). The oxygen atom of the methoxy-phenyl group in ARA1 and 
ARA3 functions as H-Bond acceptor and mediates this H-bond interaction (Figure 
28). Similarly, the oxygen atom of the nitro-phenyl group in ARA2, ARA4, and 
ARA6 forms H-Bond interactions with Gln711, HOH-108, and Arg752 (bridged). 
The ligands ARA5, ARA7 to ARA9 form H-Bond interactions with amino acid 
Asn705. The oxygen atom of the 2H-chromene group mediates this H-Bond 
interaction. 
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Table 23: Docking score and H-Bond interactions of tested and standard 
ligands 
Ligand H-Bond interaction Glide score 
kcal/mol Gln711 Arg752 HOH108* Asn705 
ARA1     -7.869 
ARA2     -7.646 
ARA3     -8.295 
ARA4     -5.367 
ARA5     -7.942 
ARA6     -6.386 
ARA7     -7.737 
ARA8     -7.414 
ARA9     -7.686 
Bicalutamide     -7.624 
Enzalutamide     -8.426 
Flutamide     -6.591 
 
Figure 28: Docking interactions of best hit molecules
 
ARA3 forms H-Bond interactions with Gln711, HOH108, and Arg752 (bridged through 
HOH108). The 1, 2-dihydronaphthalene ring overlaps with Met895 of helix-12. The 
fluorine atom in    1, 2-dihydronaphthalene ring was closely located near Phe891. 2d: 
ARA1 forms H-Bond interactions with Gln711, HOH108, and Arg752 (bridged through 
HOH108). The oxygen atom of the 2H-chromene group was closely located with Met895 
of helix-12. 
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7.4. In-vitro anti prostate cancer activity of the new chemical entities to 
identify the hit molecules 
7.4.1. Purpose of the study 
The purpose of the study is to select the best hit molecules of the series 
and to and to evaluate the anti-prostate cancer activity of the tested (ARA1 -ARA 
9) and standard (bicalutamide) ligands. The tested (ARA1-ARA9) and standard 
molecules were screened in AR positive (LNCaP, MDA MB 453, MCF-7), AR 
negative (PC3), and non-cancerous (3T3) cell lines through anti-proliferation 
assay (Modified MTT assay, refer section 7.4.3). This type of screening will 
identify the ligands which are selective to AR expressing cell line. The 
measurement of DHT stimulated mRNA expression of AR response elements 
(PSA, TMPRSS2) by real-time PCR will confirm the anti-prostate activity of the 
compounds was mediated through AR. 
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7.4.2. Structure of different cells and their morphology 
Figure 29: Morphology of the AR positive and negative cell lines 
 
The figure represents the morphology of AR positive and negative cell lines. The 
prostate cancer cells LNCaP and PC3 is needle shaped while the breast cancer cells 
MDA MB 453 and MCF-7 has irregular shape. 
 
7.4.3. Evaluation of anti-proliferation activity in AR positive and negative cell 
lines 
 The bicalutamide was ~1.5 fold selective towards AR positive cell lines 
(LNCaP, MCF-7, & MDA MB-453) than the AR negative cell line, PC3. The test 
ligands, ARA1 – ARA4 and ARA6 have better selectivity (>1.5 fold) for AR 
positive cell lines than bicalutamide (Tables 24 and 25). The ARA3 is the best 
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active molecule of the series and was ~7.6 fold selective towards AR positive cell 
lines. The dose response curve of ARA3 is given in figure 30. The test and 
standard AR antagonist does not have any agonist/partial agonist activity (Figure 
30). The best active molecule ARA3 was the most potent molecule and was ~8.8 
fold selective towards T877A mutant AR positive cell line than bicalutamide. 
Selective antagonist to each type of ARs will be intricate because the mutation 
retains the binding but only changes the activity. 
Figure 30: Bioactivity of tested and standard compounds 
 
A: Dose response curve of ARA3. B: Agonist/Partial agonist activity of test and standard 
compounds treated with 1µM for 48 hours. The experiments were conducted in 
triplicates and the average value was represented as mean ± S.D.
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Table 24: Bioactivity of tested and standard compounds 
 
Ligand X R1 R2 R3 LNCaP  
(T877A AR) 
MCF-7 (AR) MDA MB 453 
(Q875H AR) 
PC3 
(AR -) 
3T3 
(non-cancer) 
ARA1 O H H OMe 14.1 ± 0.64 13.8 ± 2.2 17.7 ± 0.41 51.2 ± 2.87 56.1 ± 0.66 
ARA2 CH2 F H NO2 8.4 ± 0.7 12.9 ± 0.45 11.2 ± 0.26 44.6 ±0.32 47.8 ± 1.26 
ARA3 CH2 F H OMe 4.8 ± 0.03 6.2 ± 0.02 7.4 ± 0.38 45.6 ± 3.56 54.3 ± 0.7 
ARA4 CH2 H H NO2 17.5 ± 1.09 16.9 ± 0.43 14.9 ± 1.05 48.2 ±3.78 54.2 ± 1.68 
ARA5 O H H H 33.6 ± 6.15 40.8 ± 5.07 32.1 ± 0.73 56.1 ± 2.48 52.7 ± 1.06 
ARA6 O H H NO2 21.6 ± 4.84 18.2 ± 1.85 28.5 ± 2.89 42.4 ± 3.88 40.1 ± 2.03 
ARA7 O H H F 31.6 ± 1.59 33.5 ± 2.72 34.7 ± 1.90 36.9 ± 2.29 53.6 ± 2.13 
ARA8 O H F H 33.1 ± 2.79 38.8 ± 4 36.1 ± 7.87 52.9 ± 1.17 84.3 ± 2.75 
ARA9 O F H I 7.1 ± 4.97 8.8 ± 0.39 17.8 ± 1.02 12 ± 0.86 10.8 ± 0.55 
(R)-BIC     42.7 ± 3.05 45.5 ± 5 41.6 ± 6.17 66.83 ± 6.9 63.1 ± 5.9 
The experiments were conducted in triplicates and the average value was represented as mean ± S.D. The IC50 were represented in µM 
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Table 25: Selectivity of tested and standard compounds 
Ligand Selectivity for cancer cells Selectivity for AR+ cells 
3T3/T877A 3T3/WT AR 3T3/Q865H 3T3/AR (-) PC3/T877A PC3/WT AR PC3/Q865H Mean 
ARA1 3.9 4.1 3.1 1.1 3.6 3.7 2.8 3.3 
ARA2 5.6 3.7 4.2 1.07 5.3 3.4 3.9 4.2 
ARA3 11.3 8.7 7.3 1.2 9.5 7.3 6.1 7.6 
ARA4 3.0 3.2 3.6 1.1 2.7 2.8 3.2 2.9 
ARA5 1.5 1.3 1.6 0.9 1.6 1.3 1.7 1.5 
ARA6 1.8 2.2 1.4 0.9 1.9 2.3 1.4 1.8 
ARA7 1.7 1.6 1.5 1.4 1.1 1.1 1 1 
ARA8 2.5 2.2 2.3 1.6 1.5 1.3 1.4 1.4 
ARA9 1.5 1.2 0.6 0.9 1.6 1.3 0.6 1.1 
(R)-BIC 1.4 1.3 1.5 0.9 1.5 1.4 1.6 1.5 
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7.4.4. Structural activity relationship 
 The ARA1 and ARA3 have methoxy substitution at R3 position. The 
oxygen atom of the methoxy group forms H-Bond interaction with Gln711, 
HOH108 and Arg752 (bridged). The ARA2, ARA4 and ARA6 have nitro 
substitution at R3. The oxygen atom of the nitro group forms H-Bond interaction 
with Gln711, HOH108, and Arg752 (bridged). Substitution of hydrogen or 
fluorine atom at R3 (ARA5 to ARA8) decreased the activity. Substitution of 
iodine at R3 (ARA9) was found to be toxic because ARA9 did not have 
selectivity and inhibited the proliferation of AR negative (PC3) and non-
cancerous (3T3) cell lines. The compounds (ARA5 to ARA9) could not form H-
Bond interaction with Gln711 and HOH108 because of the absence of H-Bond 
acceptor group at R3 position. This indicates that H-Bond acceptor group at R3 is 
essential for activity. 
 The substitution of fluorine atom at R1 increases the activity. The ligand 
ARA3 has better activity than ARA1. Similarly, ARA2 has better activity than 
ARA4 and ARA6. The substitution of oxygen atom at position X decreased the 
activity. ARA3, which has 1, 2-dihydronaphthalene group (X = CH2), was more 
potent than ARA1, which has 2H-chromene group (X = O). Similarly, the 
compounds ARA2 and ARA4, which have 1, 2-dihydronaphthalene group, were 
more potent than ARA6, which has 2H-chromene group. Since the two 
substitutions were in the bulky region of the ligand and was oriented towards 
helix-12, we evaluated the binding position of these two substitutions with respect 
to helix-12 by superimposing helix-12 truncated and uncut AR (Figure 28). The 1, 
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2-dihydronaphthalene of ARA3 overlaps with the helix-12 amino acid Met895. 
The fluorine atom was also located nearer to Phe891, which was present in turn 
before the helix-12. Hence, it might not be possible for the helix-12 to attain 
agonist conformation when ARA3 binds to the AR (12th helix closed towards the 
ligand binding pocket for agonist activity). The 1, 2-dihyronaphthalene ring is 
more bulky than the chromene ring; so the naphthalene ring possibly exhibits 
better steric clash with helix-12 amino acid Met895. 
 The H-Bond acceptor group at R3 was essential for activity. The bulky 
substituent should attain optimal conformation in order to push the helix-12 away 
from the ligand binding domain. Substitution in the bulky groups might augment 
the steric clash with helix-12 and possibly increase the activity. 
7.4.5. Gene expression of AR response elements 
 The mRNA expression of the androgen receptor response elements PSA 
and TMPRSS2 genes were evaluated in LNCaP cells The DHT significantly 
increased the mRNA expression of PSA (~9.8 fold) and TMPRSS2 (~3.6 fold) 
genes when compared to solvent treated (control). The Bicalutamide (10 µM) and 
ARA3 (1 µM) treatment significantly decreased the DHT stimulated mRNA 
expressions of PSA and TMPRSS2 genes (Figure 31).  
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Figure 31: Gene expression of AR response elements with melt curves 
 
The experiments were conducted in triplicates and the average value was represented as 
mean ± S.D. The significance (P<0.05) was obtained by applying one way ANOVA, followed 
by post hoc turkey test. (***P<0.001, **P<0.01, *P<0.05). The # indicates the comparison 
between control and negative control (1 nM DHT). The * indicates the comparison between 
1nM DHT treatment with either ARA3 (1 µM) or R-BIC (10 µM) treatment. Single peak 
indicates the formation of single product (amplicon). There is no amplification in the 
negative control as observed from the melt curve. This indicates the amplification is because 
of the mRNA in the sample and not the dimers formed by primers.   
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7.5. Phase 4 - Elucidation of the mechanism of action of the best active 
molecule 
7.5.1. Purpose of the study 
The purpose of the study is to identify the mechanism of action of ARA3. 
This will help to identify potential novel targets. The AR is a nuclear receptor and 
increases the transcriptional process of the prostate cells. So, we evaluated the 
gene expressions of androgen stimulated oncogenes such as c-myc, cyclin d1 and 
ETV1. The LNCaP cells also express low levels of estrogen receptors. Hence, we 
quantified the mRNA expression of estrogen receptor response element PS2 to 
confirm the activity of the ARA3 was mediated through AR. The protein 
expression of AR, p-AR 213, AKT and p-AKT 473 was also quantified to check 
the effect of the ARA3 in non-nuclear mediated mechanisms. The apoptosis was 
confirmed by quantifying bax/bcl2 ratio as well as caspase 3 activities and 
fluorescence staining techniques. 
7.5.2. Gene expression of androgen induced oncogenes 
 The mRNA expression of androgen stimulated oncogenes such as ETV1, 
c-myc, cyclin d1, AR and PS2 were measured in LNCaP cells by qPCR (Figures 
32 and 33). The DHT treatment significantly increased the expression of 
oncogenes such as cyclin d1 (~3.9 fold), c-myc (~2.6 fold), ETV1 (~6 fold), and 
PS2 (~2.4 fold) in comparison to the control. The DHT decreased the expression 
of AR (~0.73 fold) in comparison to the control. The Bicalutamide (10 µM) did 
not significantly change the mRNA expression of c-myc, cyclin d1, AR and PS2 
genes. The ARA3 (1 µM) significantly decreased the DHT stimulated mRNA 
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expression of oncogenes such as c-myc, cyclin d1 and ETV1 genes. Hence, 
contrary to bicalutamide, ARA3 significantly decreased the androgen stimulated 
expression of oncogenes such as cyclin d1, and c-myc. ARA3 did not affect the 
mRNA expression of AR and PS2. 
Figure 32: Gene expression of oncogenes with melt curves 
 
The experiments were conducted in triplicates and the average value was represented as 
mean ± S.D. The significance (P<0.05) was obtained by applying one way ANOVA, 
followed by post hoc turkey test. (***P<0.001, **P<0.01, *P<0.05). The # indicates the 
comparison between control and negative control (1nM DHT). The * indicates the 
comparison between 1nM DHT treatment with either ARA3 (1µM) or R-BIC (10µM) 
treatment. Single peak indicates the formation of single product (amplicon). There is no 
amplification in the negative control as observed from the melt curve. This indicates the 
amplification is because of the mRNA in the sample and not the dimers formed by 
primers.  
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Figure 33: Gene expression of AR and PS2 with melt curves
 
 
The experiments were conducted in triplicates and the average value was represented as 
mean ± S.D. The significance (P<0.05) was obtained by applying one way ANOVA, followed 
by post hoc turkey test. (***P<0.001, **P<0.01, *P<0.05). The # indicates the comparison 
between control and negative control (1 nM DHT). The * indicates the comparison between 1 
nM DHT treatment with either ARA3 (1 µM) or R-BIC (10 µM) treatment. Single peak 
indicates the formation of single product (amplicon). There is no amplification in the 
negative control as observed from the melt curve. This indicates the amplification is because 
of the mRNA in the sample and not the dimers formed by primers. 
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7.5.3. Protein expression of AR and AKT1
 
 The DHT significantly increased the protein expression of AR (~1.3 fold) 
and p-AR
213
 (~1.5 fold) compared to control (Figure 34). Bicalutamide (10 µM) 
and ARA3 (1 µM) significantly decreased the DHT stimulated AR and p-AR
213
 
protein expression. The ARA3 significantly decreased the DHT induced protein 
expression of p-AKT1
473
 (~0.8 fold). The bicalutamide treatment does not have 
significant effect on p-AKT1
473
 (Figure 34).  
Figure 34: Protein expression of AR and AKT1 
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The experiments were conducted in triplicates and the average value was represented as 
mean ± S.D. The significance (P<0.05) was obtained by applying one way ANOVA, 
followed by post hoc turkey test. (***P<0.001, **P<0.01, *P<0.05). The # indicates the 
comparison between control and negative control (1 nM DHT). The * indicates the 
comparison between 1 nM DHT treatment with either ARA3 (1 µM) or R-BIC (10 µM) 
treatment.
 
7.5.4. Apoptotic assays 
 The apoptosis was confirmed in LNCaP cells by quantifying the 
BAX/Bcl2 mRNA ratio, procaspase-3 protein level, caspase-3 enzyme activity, 
and ethidium bromide/acridine orange (EB/AO) staining. 
7.5.4.1. Gene expression of bax/bcl2  
The treatment of LNCaP cells with DHT (1 nM) and bicalutamide (10 
µM) did not affect the mRNA ratio of anti-apoptotic protein, bcl2 and 
proapoptotic protein BAX. The ARA3 significantly increased (~3 fold) the 
BAX/Bcl2 ratio when compared to the solvent control [Figure 35].  
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Figure 35: BAX/Bcl2 mRNA ratio with melt curves 
 
 The significance (P<0.05) was obtained by applying one way ANOVA, followed by post 
hoc turkey test. (***P<0.001, **P<0.01, *P<0.05). The # indicates the comparison 
between control and negative control (1 nM DHT). The * indicates the comparison 
between 1 nM DHT treatment with either ARA3 (1 µM) or R-BIC (10 µM) treatment. 
Single peak indicates the formation of single product (amplicon). There is no 
amplification in the negative control as observed from the melt curve. This indicates the 
amplification is because of the mRNA in the sample and not the dimers formed by 
primers. The experiments were conducted in triplicates and the average value was 
represented as mean ± S.D. 
7.5.4.2. Caspase activity 
The DHT and bicalutamide did not affect the expression of procaspase-3 
and hence there is no significant increase in caspase-3 activity when compared to 
control. The ARA3 significantly decreased the protein expression procaspase-3 
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(~0.7 fold) and so the ARA3 significantly increased the caspase 3 activity at 16
th
 
and 24
th
 hour (Figure 36). 
Figure 36: Caspase activity 
 
The significance (P<0.05) was obtained by applying one way ANOVA, followed by post 
hoc turkey test. (***P<0.001, **P<0.01, *P<0.05). The # indicates the comparison 
between control and negative control (1 nM DHT). The * indicates the comparison 
between 1 nM DHT treatment with either ARA3 (1 µM) or R-BIC (10 µM) treatment. 
 
7.5.4.3. Ethidium bromide/Acridine orange staining 
 The LNCaP cells were cultured in RPMI medium supplemented with 10% 
charcoal stripped FBS. The cells were treated for different time points (4 hour, 16 
hour and 24 hour) with ARA3 (4.8 µM) in the absence of 1 nM DHT (Figures 37 
and 38). The morphology of the ARA3 treated cells was different from the control 
cells. The density of the cells in the ARA3 treated wells were less when compared 
to control wells. Further, the cytoplasm of the ARA3 treated cells appear bulged 
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and the cells have irregular shape when compared to control. The apoptotic nuclei 
were visible in the 16 and 24 hour treatment. The apoptotic nuclei were condensed 
and stained bright green. The late apoptotic cells stain bright orange. The late 
apoptotic cells were seen in 4, 16 and 24 hour treatment.   
Figure 37: Fluorescence image of ARA3 treated LNCaP cells 
 
The figure (20X) represents the EB/AO fluorescent images of LNCaP cells treated with 
4.8 µM of ARA3. The live cells (LC) stain normal green. The early apoptotic (EA) cells 
have a condensed or fragmented nucleus and stains bright green. The nucleus of the late 
apoptotic (LA) cells appears condensed or fragmented and stained yellow-orange. The 
nucleus of the necrotic cells uniformly stains red. 
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Figure 38: Phase contrast image of ARA3 treated LNCaP cells 
 
The images (20X) represent the phase contrast images of EB/AO stained cells. The cells 
were treated with 4.8 µM of ARA3 for 4, 16 and 24 hours. There is a change in the 
morphology of treated cells when compared to untreated control. The treated cells 
appear bulged with irregular morphology 
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8. DISCUSSION 
Mutant AR is responsible for androgen independent prostate cancer progression  
 The expression of the point mutation in the ligand binding domain of the 
AR was one of the major reasons behind the development of androgen 
independent prostate cancer [130]. The cells of androgen independent prostate 
cancer do not dependent on androgens for proliferation [131]. This is because the 
mutation in the ligand binding domain of the AR widens the ligand specificity 
such that the steroidal hormones such as oestrogen, progesterone and 
glucocorticoids activate the mutant AR [132, 133]. Additionally, the mutant AR 
leads to the withdrawal of AR antagonist from the regimen because the mutant 
AR converts the AR antagonist into an agonist [134, 135]. The mutations, T877A, 
W741L/C and F876L are some of the mutations that are identified in androgen 
independent prostate cancer patients [135]. Recent studies have indicated that the 
constitutive activation of mutant AR could be reversed by designing a potent AR 
antagonist that lacks resistance with mutant AR [136, 137]. Hence, we decided to 
target mutant AR for drug design and development to treat androgen independent 
prostate cancer.  
 The entire non-steroidal AR antagonist in clinical use has common anilide 
pharmacophore. There is no diverse structural element in the marketed non-
steroidal AR antagonist. Hence there is possibility of cross resistance within the 
molecules and because of that the entire AR antagonist had developed resistance 
for one or another mutation [134, 135]. Structurally diverse AR antagonist could 
possibly resist those mutations that occur during the course of treatment. In the 
Chapter 8: Discussion 
 
PSG College of Pharmacy, Coimbatore. Page 123 
 
preliminary studies we found that the crystal structures of AR ligand binding 
domain in the protein data bank are in agonist conformation. Therefore we 
decided to identify novel AR antagonist through ligand based drug design.    
Ligand/receptor interactions in wild and mutant AR 
As a preliminary investigation we decided to study the interactions of non-
steroidal AR antagonist (flutamide, bicalutamide and enzalutamide) with wild, 
T877A mutant and W741L mutant using docking studies. In the docking studies, 
we observed that the enzalutamide did not have binding affinity with the wild, 
T877A and W741L mutant ARs. Similarly the bicalutamide also did not have 
binding affinity with the wild type and T877A mutant ARs. As discussed earlier 
the crystal structures of the wild and mutated ARs in the PDB are in agonist 
conformation. Hence it was not possible for an AR antagonist to have affinity for 
the ARs in agonist conformation. Altimari and co-workers [138] had indentified 
novel AR antagonist by rigid docking studies with AR in agonist conformation. 
The identified triazole derivatives did not have potent activity against mutant AR 
Hence, identification of molecules by docking using ARs in agonist conformation 
might lead to the identification of less potent ligands with partial agonistic type 
activity.  
Another major observation in the docking studies is that the volume of the 
ligand binding pocket of the mutant ARs (T877A and W741L) was larger than the 
wild type AR. This is because the mutations were from higher molecular weight 
amino acids to lower molecular weight ones. It is well established that the AR 
antagonist are bigger molecules than the agonist [139]. To accommodate the 
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additional bulkier groups of AR antagonist, the helix-12 of the AR attains an 
extended conformation from the binding pocket [140]. This new conformation of 
the AR prevents it from binding with co-activators [141]. Hence the mutations in 
the AR could be deliberate to prevent the AR antagonist from affecting the agonist 
conformation of helix-12 (helix-12 closed towards binding pocket). From the 
docking results and literature review we hypothesized that the bulkier AR 
antagonist could be fitted in helix-12 negative AR. So, we constructed a homology 
of AR without the helix-12. We again carried out docking studies using the 
homology model. The entire non-steroidal AR antagonist including enzalutamide 
had binding affinity for the helix-12 negative AR. This proves that the bulkiness 
in AR antagonist prevent it from binding with the AR in agonist conformation. 
Therefore, to identify a potent AR antagonist, the helix-12 positive AR (agonist 
conformation) could be used to eliminate the less bulky ligands. 
Selection of ligand based drug design method for lead identification 
The modelling of a pharmacophore or 3D-QSAR and identification of hits 
is a ligand based approach. Here, a 3D-representation of the essential descriptors 
or functional groups will be derived from the reported active molecules [142]. The 
previous studies from our laboratory had demonstrated that the ligand based drug 
design methods will more likely provide the hit molecules than the docking 
studies. This was the direct result of the more amounts of calculations and 
validation processes involved in 3Q-QSAR generation [143, 144].  
In our study we constructed three pharmacophore models. The first 
pharmacophore was constructed from molecules that antagonize wild type AR. 
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The second pharmacophore was constructed from molecules that antagonize 
T877A mutant AR. The dataset molecules in the first two pharmacophore models 
are bicalutamide and enzalutamide derivatives. The third pharmacophore was 
constructed from ligands that antagonize wild and T877A mutant AR. The 
molecules in this dataset do not have any partial agonist/agonist activity with wild 
and/or T877A mutant AR. The hit molecules were identified from the third 
pharmacophore because this pharmacophore was derived from molecules that do 
not have resistance with wild or T877A mutant AR. The first two pharmacophores 
where compared with each other to identify the difference between wild and 
T877A mutant AR.  
Differences between the wild and T877A mutant AR antagonist pharmacophore 
The descriptors such as hydrogen bond acceptor (A), hydrogen bond donor 
(D), hydrophobic group (H), aromatic ring (R), positively charged group (P) and 
negatively charged group (N) are used for the construction of pharmacophore 
[145]. The molecules in the dataset for the construction of the 3D-QSAR models 
have common structures, which are also present in the marketed drugs. All the 
marketed ligands have two aromatic rings (A and B) separated by a linker group. 
These two rings (A and B) were also present in all the 3D-QSAR models. The 
major difference among the 3D-QSAR models was the distance and angle 
between the A ring and B ring. Also, there is a difference in the distance between 
the two extreme pharmacophore site points. These properties describe the 
variability in the length and flexibility among the active molecules.  
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The distance between the A and B ring of wild type (A ring to B ring: 4.09 
Å) was shorter than the T877A mutant AR (ring A to ring B: 8.895 Å) 
pharmacophore. Additionally the angle between the A and B ring was acute in 
wild type and obtuse in T877A mutant AR pharmacophore. The distances and 
angle for wild and mutant AR pharmacophore was more or less similar to that of 
T877A mutant AR. The distances between A and B ring was 7.217 Å and the 
angle between them was obtuse. The relatively longer distances and obtuse angles 
between the A and B rings indicate a less flexible linker region among the active 
molecules of T877A mutant AR antagonist. Ohta and co-workers [146] have 
shown that bulky carborane pharmacophore is essential for AR antagonistic 
activity in T877A mutant AR. This bulky group is shown to occupy a position in 
the ligand binding pocket that overlaps with the helix-12 amino acids. The T877A 
mutant AR pharmacophore from our study also indicates that the rigid and less 
flexible structures were essential for AR antagonistic activity against T877A 
mutant AR. From these 3D-QSAR models, we could possibly deduce that smaller 
and/ or flexible molecules could be sufficient to block wild type AR. For T877A 
mutant AR, a bigger molecule in length plus less flexibility would be required to 
block it. 
In-silico virtual screening and identification of β-iminoenamine BF2 ligands as 
novel AR antagonist 
The β-iminoenamine BF2 ligands were identified through pharmacophore 
based screening approach. The wild and T877A mutant AR pharmacophore is 
used for screen the databases for the identification of matches. Voet and co-
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workers [147] had followed the pharmacophore based approach for the 
identification of novel AR antagonist. The pharmacophore in that study was 
constructed using bio-active conformation of bicalutamide. The identified ligands 
(ARAN – 4, 51 and 53) were found to be less potent than the standard AR 
antagonist. The major reason for the decreased activity of the test ligands was 
because of the selection of bicalutamide for the construction of the 
pharmacophore. It is well known that the bicalutamide has resistance with W741L 
mutant AR [148]. In our study, the wild and T877A mutant AR pharmacophore 
was derived from molecules that does not have resistance with T877A and W741L 
mutant AR. Hence our pharmacophore is more likely to provide a potent lead 
molecule against mutant ARs. Additionally, to improve the efficacy of molecules 
against mutant ARs we included a structure based elimination process to eliminate 
the flexible and less bulky ligands. Here, we eliminated the pharmacophore 
matched ligands which has binding affinity for helix-12 positive AR (agonist 
conformation) and selected the ligands which had binding affinity only with helix-
12 negative AR. This process of selection will lead to the elimination of the 
flexible ligands.  
The β-iminoenamine BF2 ligands have 2H-Chromene or 1, 2-
Dihydronaphthalene as bulky group. As discussed earlier, the entire standard non-
steroidal AR antagonist has a common anilide scaffold which was resistant to one 
or another mutation. The ARN-509 was a recently approved AR antagonist for 
phase 4 clinical trials and has the common anilide pharmacophore. Consequently, 
reports have shown that the ARN-509 exhibits cross resistance with the F876L 
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mutant AR [149]. The F876L mutation was originally indentified in the 
enzalutamide treated prostate cancer cells. Hence the anilide scaffold could lead to 
the cross resistance among the AR antagonists. A recently identified clinical trial 
candidate ODM-201 does not share the common anilide scaffold and was better 
active than enzalutamide [150]. Therefore, the identification of novel scaffold is 
essential to avoid cross resistance and to improve the potency against mutant ARs. 
The β-iminoenamine BF2 is a novel scaffold and so these ligands might not be 
affected by cross resistance with mutant ARs.  
In-vitro screening and structural activity relationship of β-iminoenamine BF2 
complex ligands 
 The test ligands (ARA1 - ARA9) and standard bicalutamide were screened 
in AR positive (LNCaP, MCF-7, & MDA MB-453) and negative cell line (PC3) 
through anti-proliferative assay. Previous studies have shown that the AR positive 
and AR negative cell lines could be used in the screening process to identify AR 
specific ligands [151]. In our study we observed that the ligands, ARA1 – ARA4 
and ARA6 have better selectivity towards AR positive cell lines than the 
bicalutamide. The ligands, ARA1 – ARA4 and ARA6 formed H-Bond interaction 
with amino acids Gln711 and Arg752 (bridged through HOH108) in docking 
studies with the helix-12 negative AR. The remaining tested ligands (ARA5, 
ARA7 – ARA9) have formed H-Bond interaction with Asn705 and have low 
selectivity to AR positive cell lines than the bicalutamide. 
Literature survey has indicated that the H-Bond interactions with the 
amino acids Arg752, G1n711, HOH108, Leu704, Asn705, and Thr877 is essential 
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for specific binding of ligands to the AR [152]. The amino acids Arg752, Gln711 
and HOH108 are present deep inside the binding pocket. The amino acids Thr877 
and Asn705 are present nearer to helix-12. Guo and co-workers [106] had 
indicated that the molecules that preferentially form H-Bond interaction with the 
deep residues exhibits better AR antagonist potency than the ones that form H-
Bond interaction with Asn705 and Thr877. This is because the amino acids 
Asn705 and Thr877 are present near to helix-12 and H-Bond interaction with 
them might prevent the molecules from abutting (steric clash) the helix-12.  
 The interaction of best hit molecule ARA3 with helix-12 amino acids was 
evaluated by superimposing the helix-12 negative (ARA3 bound) and helix-12 
positive ARs. We observed that the bulky 2H-chromene group of ARA3 was 
oriented towards the helix-12 of the AR and overlaps with the amino acid Met895 
of helix-12. Söderholm and co-workers [153] have identified novel diphenyl and 
phenylpyridine derivatives and these molecules do not have resistance with 
mutant ARs. Further, induced fit docking studies had shown that these molecules 
had interacted with the Met895 of helix-12 and extended the helix-12 away from 
the binding pocket. Hence, in our case also it may not possible for the helix-12 of 
the AR to attain an agonist conformation with ARA3. From the structural activity 
relationship, we conclude that the H-Bond acceptor group should bind deeply into 
the binding pocket to form H-Bond interaction with Arg752 and Gln711. The 
proper orientation of the bulky groups towards the helix-12 amino acids, in 
particular Met895 favors the activity.   
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The best active molecule ARA3 decreases the androgen dependant protein 
expression of AR and gene expression of PSA and TMPRSS2  
 In our study we used the LNCaP cell line for the elucidation of the anti-
prostate cancer mechanism of ARA3. This is because the LNCaP cell line 
expresses T877A mutant AR and TMPRSS2-ETV1 gene fusion, which are the 
major contributing factors for the development of androgen independent prostate 
cancer [154]. The androgen dependant activity of the ARA3 was elucidated by 
measuring the protein expression of AR and p-AR
213
 and gene expression of PSA 
and TMPRSS2. The binding of androgens to AR causes phosphorylation of AR at 
several sites. The p-AR
213
 is one of the active phosphorylated forms of the AR 
[155]. We observed that the bicalutamide and ARA3 treatment prevented the 
activation of AR to p-AR
213
. The previous reports have shown that the prevention 
of the phosphorylation of AR is essential to decrease the AR mediated genomic 
activity [156]. The decrease in the AR mediated genomic activity will 
subsequently decrease the expression of genes regulated by AR.  
 The PSA and TMPRSS2 are widely accepted biomarkers for prostate 
cancer [157]. The expression of these AR response elements is found to be 
increased in prostate cancer patients [158]. Recently, the TMPRSS2 has gained 
more attention because of the fusion of ETS (ERG - ETV1) genes with 
TMPRSS2. This gene fusion has active role in the androgen independent prostate 
cancer progression [159]. The ETS family of transcriptional factors are oncogenes 
and stimulates the cell division, metastasis, angiogenesis, etc in cancer cells [160]. 
We observed that the ARA3 and bicalutamide are almost equipotent in reducing 
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the DHT stimulated gene expression of PSA and TMPRSS2. Hence our new 
molecule, ARA3 has anti-prostate cancer activity mediated through AR similar to 
that of bicalutamide.   
The ARA3 reduces the expression of oncogenes and induces apoptosis in 
LNCaP cells    
 The LNCaP cells were naturally resistant to apoptosis because of the 
constitutive activation of PI3K/AKT survival pathway and leads to the over 
expression of oncogenes such as c-myc and cyclin D1 [161, 162]. The c-myc 
expression was 50 times higher in LNCaP cell than the normal prostate cells 
[163]. A recent study has reported that, novel isoindolinediones based AR 
antagonist decreased the gene expression of c-myc and cyclin d1. Those 
compounds had prevented the G1/S cell cycle transition and induced apoptosis in 
LNCaP cells [164]. In our study we quantified the gene expression of oncogenes 
(c-myc and cyclin d1) in ARA3 and bicalutamide treated LNCaP cells. Here, the 
ARA3 alone had decreased the gene expression of oncogenes and not the standard 
bicalutamide. Hence, the ARA3 is better than bicalutamide and could also prevent 
the G1/S cell cycle transition. 
 The induction of apoptosis in LNCaP cells by ARA3 was confirmed by 
measuring the bax/bcl2 mRNA ratio, procaspase-3 protein expressions and 
caspase-3 enzyme activities. Previous studies have shown that increase in the 
bax/bcl2 ratio leads to the cleavage of procaspase-3 into active caspase-3 [165]. 
The activated caspase-3 cleaves many proteins and induces the apoptosis in the 
normal and cancer cells [166]. In the androgen independent prostate cancer cells 
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the bax/bcl2 ratio was found to be decreased and it is one of the contributing 
factors for androgen independent prostate cancer progression [167]. The 
expression of anti-apoptotic factor bcl2 was found to be elevated in androgen 
independent prostate cancer cells and this was responsible for the decrease in 
bax/bcl2 ratio [167]. We observed that the ARA3 increased the bax/bcl2 mRNA 
ratio but the bicalutamide did not increase the bax/bcl2 mRNA ratio. Browne and 
co-workers [168] has demonstrated that the bicalutamide had increased the 
expression of anti-apoptotic factor bcl2 in LNCaP transfected nude mice model. 
This is exactly the opposite effect that was required for anti-cancer activity. 
Hence, our new molecule ARA3 was better than the bicalutamide because 
induction of apoptosis is required to control the cancer cell proliferation. 
The anti-cancer activity of ARA3 was mediated through PI3K/AKT pathway  
 The PI3K/AKT pathway could be activated by AR through genomic and 
non-genomic pathways in androgen independent prostate cancer cells. In the AR 
mediated genomic pathway, the transcription of TMPRSS2-ETV1 gene fusion 
product was responsible for the PI3K/AKT activation [154]. The over expression 
of ETV1 contributes to the down regulation of PTEN and mitigates the control of 
PTEN over PI3K/AKT pathway [154]. The PTEN is a tumor suppressor gene and 
prevents the constitutive activation of PI3K/AKT pathway [169]. In the AR 
mediated non genomic pathway, the agonist bound AR (AR-DHT/Agonist) 
directly interacts with the AKT and activates it in the cytoplasm [170]. Therefore 
we decided to quantify the protein expression of p-AKT1
473
 (active form of 
AKT1) and gene expression of ETV1 in LNCaP cells.  
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We observed that the ARA3 and bicalutamide decreased the DHT induced 
gene expression of ETV1. However the biological activity of ARA3 and 
bicalutamide varies with AKT1. The ARA3 decreased the activation of AKT1 to 
pAKT
473
 but the bicalutamide did not prevent the activation of AKT1 protein. 
Therefore, the suppression of AR mediated ETV1 gene expression did not 
significantly affect the AKT1 activation. As a result of this, the ARA3 could 
possibly reduce the activation of AKT1 to p-AKT1
473
 through AR mediated non-
genomic pathway. Hence, from the above experimental evidences we propose that 
the test ligand ARA3 decreases the gene expression of oncogenes (c-myc and 
cyclin d1) and promotes the apoptosis in LNCaP cells through AR mediated non-
genomic inhibition of AKT activation. The bicalutamide prevents the androgen 
mediated genomic activity but it could not prevent the androgen mediated non-
genomic activation of AKT. Hence, the bicalutamide could not decrease the 
oncogenes of the PI3K/AKT survival pathway to induce the apoptosis. The 
proposed mechanism of action of ARA3 is given in figure (Figure 39).  
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Figure 39: Anti-prostate cancer mechanism of ARA3 in AIPC 
 
 
Figure represents the mechanism of action of ARA3. Androgen deprivation increases the 
expression of AR protein and enzymes involved in the synthesis of androgen. This 
increases the expression of AR and the intracrine androgen concentration. Since the 
LNCaP cells express T877A mutant AR, the AR could be activated by androgens and 
non-androgens (AR antagonist, estrogen, progesterone etc). ARA3 and bicalutamide 
decreases the DHT stimulated AR and p-AR213 protein expression in LNCaP cells. This 
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further leads to the decrease in AR mediated genomic activity. The AR-Agonist complex 
could also activate AKT, which leads to the expression of oncogenes such as c-myc and 
cyclin D1. The activated AKT also increases the expression of AR which leads to a 
vicious cycle. ARA3, but not bicalutamide, decreases the AR-Agonist mediated AKT 
activation. This is the major difference between the bicalutamide and ARA3. The 
attenuation of AKT activation by ARA3 decreases the transcription of oncogenes and 
increased the ratio of BAX/Bcl2 mRNA, which leads to the induction of apoptosis in 
LNCaP cells.
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9. SUMMARY AND CONCLUSION 
 The point mutation in the AR increases the volume of the ligand binding 
pocket to neutralize the bulky functional groups in the AR antagonist. The bulky 
functional groups of the AR antagonists affect the conformation of the helix-12 of 
the AR. The helix-12 was essential for the binding with the co-activators. The 
helix-12 negative and helix-12 positive ARs were used to select new chemical 
entities among the pharmacophore matched ligands. This led to the identification 
of ligands having bulky β-iminoenamine groups. The test ligand ARA3 was 
bulkier and less flexible than the bicalutamide and has improved potency against 
mutant ARs. The improved potency against mutant AR had led to the effective 
control of the AR mediated non-genomic phosphorylation and activation of the 
AKT. The decrease in the activation of AKT had further prevented the over 
expression of oncogenes such as c-myc, cyclin d1 and bcl2. Bicalutamide did not 
significantly decrease the gene expression of oncogenes because of its inability to 
control the phosphorylation and activation of AKT. This is because the 
bicalutamide has lesser efficacy against mutant AR expressing cell lines. From the 
study we conclude that, the different handling of AR mediated non-genomic 
pathway by ARA3 resulted in the induction of apoptosis. 
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10. IMPACT OF THE STUDY 
 Adenocarcinoma of prostate gland is the second most frequent cancer and 
sixth leading cause of mortality in males. The mutation at amino acid 
Thr877 was frequently expressed in androgen independent prostate cancer 
patients.  
 The point mutations were specific to the AR antagonists and convert them 
into an agonist, which leads to the withdrawal of the antagonist from the 
treatment regimen. 
 In-silico docking and pharmacophore studies had indicated that the 
interaction with helix-12 of AR was essential to antagonize mutant AR. 
 Through in-silico drug design methods, we have identified a novel hit AR 
antagonist bearing β-iminoenamine BF2 complex. The ARA3 is the best 
hit molecule of the series.  
 The mechanism by which the ARA3 induces the apoptosis is novel. The 
androgen/AR mediated activation of AKT is unexplored and ARA3 
induces the apoptosis by preventing the activation of AKT by 
androgen/AR complex.  
 The ARA3 was also active in breast cancer cell lines (MCF-7 & MDA MB 
453) that expresses AR. Therefore, the ligands in this chemical class are 
also eligible candidates for the treatment of prostate cancer.  
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ABSTRACTProstate cancer is the second most frequent and sixth leading cause of mortality among male population. Androgen receptor antagonist is one of the regimens for prostate cancer. The relapsed prostate cancer patients were found to express point mutations in the ligand binding domain of the androgen receptor. The mutations at amino acids, threonine 877 and tryptophan 741 were frequently expressed among the androgen independent prostate cancer patients. These point mutations were responsible for the development of resistance against androgen receptor 
antagonist. Identification of novel androgen receptor antagonist was hampered because of the expression of different types of point mutation and the lack of insight into the binding mode of the androgen receptor antagonist with the mutated receptor. In this study, we have discussed the method adopted by us in designing a novel androgen receptor antagonist that could tolerate the point mutations. We also discussed the role of the point mutations in the development of resistance against androgen receptor antagonist. 
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Keywords: Prostate cancer; Androgen receptor; Resistance; T877A; W741L
Abbreviations: Prostate Cancer (PCa); Androgen Receptor (AR); Castration Resistant Prostate Cancer (CRPC); Androgen Independent Prostate Cancer (AIPC); Heat Shock Protein 
(HSP); Androgen Receptor Response Elements (AREs); Steroid Receptor Co-activator (SRC); Transcriptional Intermediary Factor (TIF); cAMP Response Element Binding (CREB); CREB Binding Protein (CBP); Dihydrotestosterone (DHT); Androgen Deprivation Therapy (ADT); Combined Androgen Blockade (CAB); Gonadotropin Releasing Hormone (GnRH); Phosphatase and Tensin Homolog (PTEN); E26 Transformation Specific (ETS); Transmembrane Protease Serine 2 (TMPRSS2); Mirror-Image Polydactyly Gene 1 Protein (MIPOL); Threonine to Alanine 
(T877A); Threonine to Serine (T877S); Valine to Methionine (V715M); Alanine to Threonine 
(A721T); Asparagine to Aspartic Acid (N756D); Histidine to Tyrosine (H874Y); Tryptophan to Cysteine (W741C); Tryptophan to Leucine (W741L); Aspartic Acid to Glycine (D879G); Protein Data Bank (PDB); Hydrogen Bond (H-Bond).
INTRODUCTION
Prostate CancerThe growth, development, and homeostasis of the prostate gland are under the control of 
androgens. The growth of prostate gland occurs significantly during puberty and after that, the androgens continue to play an important role in its function. In some men, with increasing age, androgen dependant proliferation of the prostate gland resumes, resulting in benign prostatic hyperplasia or malignant prostate cancer [1]. Most of the Prostate Cancer (PCa) relapses within 18 to 24 months of hormonal therapy. The relapsed PCa would be either Castration Resistant Prostate Cancer (CRPC) or Androgen Independent Prostate Cancer (AIPC) [2]. The enzymes involved in the synthesis of Dihydrotestosterone (DHT) are over expressed in CRPC resulting in the relapse. The CRPC could be controlled by including the drugs which inhibit the enzymes involved in the synthesis of DHT [3]. Unlike CRPC, the AIPC doesn’t depend on androgens for proliferation; instead it adapts various mechanisms to neutralize the hormonal 
therapy. Clinically, AIPC is defined as the ability of the PCa cells to grow in the castrated plasma levels of androgen. Point mutation in the ligand binding domain of the Androgen Receptor (AR) is one of the major reasons behind the androgen independent proliferation of the PCa cells [4,5]. 
Androgen ReceptorHuman AR is a nuclear receptor encoded by a single gene located on human X-chromosome at Xq11-12 region that spans more than 90kb and has 8 exons [6]. AR is a 900-920 amino acid protein and its variations are due to the polymorphism in the length of polyglutamine (CAG 
repeats) and polyglycine (GGN repeats) tracts in the first exon [7]. Like other nuclear receptors, AR is also divided into 4 regions: variable N-terminal domain or Activation Function 1 (AF-1), DNA binding domain, hinge region, and ligand binding domain or Activation Function 2 (AF-2). 
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The ligand binding domain of AR is coded by exons 6, 7, 8, and c-terminal part of exon 5. The ligand binding domain of AR has 12α helixes and a β sheet that fold to form a hydrophobic ligand binding pocket to which the androgens bind [8]. Helix 4, 5, and 10 are the primary contact sites for androgens. The binding of androgens with AR majorly involves hydrophobic interactions with amino acids Val746, Met742, Gln711, Met745, Leu707, Leu704, and Trp741. The hydrogen bond 
interactions also play a critical role in the specific binding of androgens to AR [9]. 
Androgen Dependant Androgen Receptor Activation Androgen is required for the maximum activation of the AR. The AR predominantly resides in cytoplasm, associated with Heat Shock Protein (HSP) and chaperons. The HSP also has an active role, HSP90 bind to AR and keeps it in an active conformation that is necessary for androgens to bind [10]. The nuclear localization signal of the AR resides within amino acids 742 to 817, which keeps the AR within the cytoplasm in the resting state. The nuclear localization signal is dominant over the nuclear export signal in the resting state [11]. The ligands bind to the ligand binding domain of the AR. The helix-12 of the ligand binding domain attains different conformation with agonist and antagonist. Androgen binding causes the helix-12 to lie over the ligand binding pocket, which will reveal the domain for intramolecular AF-1 
and AF-2 interaction (N/C terminal interaction). The N/C terminal interaction is specific to AR. The AF-2 region of the other nuclear receptors will preferentially interact with leucine rich LxxLF motifs in the co-activators. The AF-2 region of the AR interacts with phenylalanine rich FxxLF motifs in the AF-1 region. The N/C terminal interaction will lead to cascade of events like phosphorylation, 
dimerization, nuclear translocation, binding to specific androgen receptor response elements, co-activator recruitment, and initiation of transcription [12,13]. Class 1 family of co-activators, Steroid Receptor Co-activator (SRC)-1, Transcriptional Intermediary Factor-2 (TIF2), SRC-3, and class 2 family of co-activators, which are also known as transcriptional integrators, p300/CREB (cAMP Response Element Binding) binding protein, regulate the transcriptional activity of AR [14]. The co-activators decondense the chromatin and facilitate the binding of RNA polymerase for the initiation of transcriptional activity. The AR co-activators preferentially interact with the glutamine rich region (1053 - 1123) in the AF-1. Mutant AR that doesn’t have this glutamine region is inactive [13]. Antagonist binding displaces the helix-12 away from the ligand binding pocket and unveils the binding surface for co-repressor NcoR/SMRT interaction, which leads to the inhibition of the AR mediated transcriptional activity [15]. 
Androgen Independent Androgen Receptor Activation
The aim of the treatment in metastatic PCa is to reduce the plasma levels of prostate specific antigen and androgen. This can be established by either Androgen Deprivation Therapy (ADT) or Combined Androgen Blockade Therapy (CAB). ADT includes surgical or pharmacological castration. Surgical castration involves bilateral orchiectomy (removal of testes) and the standard castrate level of testosterone could be achieved within 12hr. Pharmacological castration can be 
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achieved by either Gonadotropin Releasing Hormone (GnRH) receptor agonist or GnRH receptor antagonist. There will be an initial rise in the testosterone concentration by using GnRH receptor agonist but after 2 to 4 weeks, castration levels of testosterone will be achieved. In CAB therapy, in addition to castration (surgical or pharmacological), AR antagonist or 5α reductase inhibitors are used to prevent AR activation by adrenal androgens [16,17]. 
The hormonal therapy has beneficial outcome for 18-24 months but the PCa relapses because of many other pathological conditions. Some of the major reasons are, over expression of enzymes involved in DHT synthesis and subsequent rise in intracraine androgen level [18], down regulation of enzymes involved in DHT catabolism [19], somatic point mutations in the ligand binding domain of AR [4,5], AR over expression [20], truncation of AR ligand binding domain, and constitutive activation of AF-1 region [21], Phosphatase and Tensin homolog (PTEN) loss [22], increased telomerase activity [23], mutations in p53 [24], down regulation of E-Cadherin and over expression of N-Cadherin which increases the heterotypic cell adhesion and metastasis [25], 
translocation and fusion of E26 Transformation Specific (ETS) genes with androgen responsive genes like Transmembrane Protease Serine 2 (TMPRSS2) or prostate specific Mirror-Image Polydactyly gene 1 protein (MIPOL1) gene [26,27]. 
The fusion between androgen responsive and ETS genes were identified in 40 to 70% of aggressive PCa cases [27]. The ETS family of transcriptional factors is oncogenic and controls the cell differentiation, cell division, metastasis, angiogenesis etc. The fusion of ETS genes with androgen responsive genes results in the over expression of ETS genes whenever AR is activated. 
Somatic point mutation in the ligand binding domain of AR was also frequently identified in drug resistance PCa patients [4,5]. The mechanism by which the AR mutates was unknown and 
many point mutations were identified among AIPC patients. The mutated AR does not depend on androgen for activation; instead it can be activated by other steroidal hormones like estradiol, progesterone, and AR antagonists. For the ETS to over-express, it requires AR activation, since it was fused with an AR responsive genes. The hormonal therapy decreases the plasma testosterone level but the mutated AR does not require androgen for activation. Consequently, the mutated AR could activate the expression of ETS genes without androgen. The AR mutation and ETS chromosomal rearrangement in conjunction could co-ordinate the AIPC progression and drug resistance for AR antagonist and cytotoxic drugs. A novel AR antagonist that resists the mutations and decreases the expression of ETS genes could well be the future for PCa treatment. 
Mutations in the Ligand Binding Domain of Androgen Receptor
The somatic point mutations can be broadly classified into two types
Mutations expressed in flutamide treated patientsThe mutations, T877A (Threonine to Alanine), T877S (Threonine to Serine), V715M (Valine to Methionine), A721T (Alanine to Threonine), N756D (Asparagine to Aspartic acid), and H874Y 
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(Histidine to Tyrosine) were identified in AIPC patients who underwent flutamide containing 
therapy [5,28,29]. These mutations cause resistance to flutamide treatment and these mutant 
ARs are activated by flutamide.
Mutations expressed in bicalutamide treated patientsThe mutations, W741C (Tryptophan to Cysteine), W741L (Tryptophan to Leucine), and 
D879G (Aspartic acid to Glycine) were identified in AIPC patients who underwent bicalutamide containing therapy [28,30]. These mutations were responsible for bicalutamide resistance and these mutant ARs are activated by bicalutamide.
In general, these mutations broaden the ligand specificity of the receptor. For example, the 
T877 amino acid mutated AR was activated by non androgens like cyproterone acetate, flutamide, estrogens, glucocorticoids, progesterone etc., whereas, bicalutamide antagonizes the T877 mutant AR. Similarly the W741 amino acid mutated AR was activated by non androgens like bicalutamide, 
estrogens, glucocorticoids, progesterone etc., whereas, flutamide antagonizes the W741 mutant AR [30,31,32,33,34].
COMPUTATIONAL METHODS
DockingThe ligands for the docking studies were prepared using LigPrep, Schrödinger. The ligands 
were geometrically refined and assigned appropriate protonation state at pH 7.0 ± 2.0. The energy 
minimization was carried out by OPLS 2005 force field [35]. The proteins (PDB: 2AMA, 2AX6, 1Z95 & helix-12 truncated ARs) were prepared using protein preparation wizard in Maestro, Schrödinger [36]. The preprocessed protein was then used to generate the grid for docking. The grid was assigned by picking the ligand as the center of the grid and the grid box was generated by applying default parameters. The docking was carried out using GLIDE, Schrödinger. GLIDE XP (extra precision) method was followed for docking calculations [37].
Homology ModellingThe helix-12 truncated AR was generated using PRIME, Schrodinger [38]. The Prime suite was used for protein structure prediction, side chain optimization, loop prediction, active site 
refinement and energy minimization. The amino acid sequence of the ligand binding domain of AR was obtained from NCBI (Protein accession No: P10275.2).
The template protein was identified through blast search. The AR crystal structure, 2AMA was the template for wild type AR and 2OZ7 was the template for T877A mutated AR. The alignment between the target and template sequence was carried out by clustalW method. ClustalW could be used when there is a high sequence identity between the target and template. Prime allows us to build the homology model in two different types, either knowledge based or energy based. We used a knowledge based method were it uses the structure information from the template for gaps 
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and insertions. As default, the side chains were only optimized for the residues that are not from 
the template. The ligand and a water molecule (HOH-108) were retained in the final model. The 
homology model was then energy minimized (OPLS 2005) by VSGB solvation and we also refined the active site (5Å from the ligand) of the model.
CASE STUDY
Target SelectionIt is impossible to consider all those mutations while designing an AR antagonist. The 
mutations in T877 amino acid occur frequently among the flutamide treated patients [34]. At 
present, flutamide was largely replaced with bicalutamide and there was no report of T877A/S mutation among bicalutamide treated patients. Mutations in W741 predominate among the bicalutamide treated patients [28,30]. The T877A mutated AR was expressed in LNCaP cell line. The LNCaP could also express the W741L/C mutation upon incubation with bicalutamide in an 
androgen depleted medium for 6-13 weeks [30]. So, the mutations are treatment specific and might keep on piling up depending on the antagonist. Targeting the wild type AR for drug designing is essential because the mutations occur during the course of treatment and as discussed above, 
the mutations are treatment specific. Understanding the mechanism by which these mutations convert an antagonist to agonist is essential because a novel AR antagonist should tolerate these types of mutations that might occur during the course of treatment. The crystal structure of the wild type and some of the mutated ARs are available in Protein Data Bank (PDB). Unfortunately, none of them are in antagonist bound conformation. Generally, the steroidal receptor antagonist has bulkier groups than the endogenous agonist. Antagonist form similar H-Bond interaction like agonist but due to their bulkier nature, they displace the helix-12 away from the ligand binding pocket [39,40]. The helix-12 of the ligand binding domain adapts closed and open conformation in response to agonist and antagonist respectively [41,42]. Consequently, we modelled an AR that lacks helix-12 for the structure based virtual screening. The truncated receptor has 671-881 amino acids instead of 671-919 amino acids. 
Docking StudiesDocking studies were carried out to evaluate the role of the point mutation in converting an AR antagonist to agonist. We chose 4 different types of AR: wild type (PDB: 2AMA), T877A (PDB: 2AX6), W741L (PDB: 1Z95), and helix-12 truncated ARs (homology model). The ligands were 
DHT, testosterone, non steroidal AR antagonist flutamide, bicalutamide, and enzalutamide.
Androgen
The androgen, DHT, has binding affinity towards all the ARs but did not form H-Bond interaction with T877A mutated AR (Table1). The DHT and testosterone have similar type H-Bond interactions with wild type AR (Figure 1). The keto group of DHT and testosterone formed H-Bond interaction with Arg752, while the 17β hydroxyl group formed H-Bond interaction with Asn705 
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and Thr877. Testosterone did not bind with the T877A mutated AR and didn’t form any H-Bond interaction with W741L mutated AR. The binding energy of the androgens was less in the mutated ARs than the wild type AR. The DHT has a dock score of -10.80 kcal/mol with wild type AR but the dock score had decreased with T877A (-5.84 kcal/mol) and W741L (-6.71 kcal/mol) mutated ARs. Similarly the testosterone has a dock score of -10.68 kcal/mol with wild type AR but the dock score had decreased with T877A (no binding) and W741L (-5.95 kcal/mol) mutated ARs. This indicates that the mutations might affect the binding of the androgens with AR. Ligand binding 
assay also proved that the mutations could decrease the binding affinity of androgens [43]. 
Figure 1: Binding interactions of androgens.
1a: DHT forms H-Bond interaction with Arg752, Asn705 and Thr877 with wild type AR. 1b: Testosterone forms H-Bond interaction with Arg752, Asn705 and Thr877 with wild type AR.
8Software and Techniques for Bio-Molecular Modelling | www.austinpublishinggroup.com/ebooks
Copyright  Ramanathan M. This book chapter is open access distributed under the Creative Commons Attribu-
tion 4.0 International License, which allows users to download, copy and build upon published articles even for 
commercial purposes, as long as the author and publisher are properly credited. 
Table 1: Docking score and H-Bond interaction of androgen receptor ligands.
Ligands
Wild type T877A W741L Truncated
Dock Score1 H-Bond Dock Score H-Bond Dock Score H-Bond Dock Score H-Bond
DHT -10.80
Arg752, 
Asn705, 
Thr877
-5.84  -6.71
Arg752, 
Gln711, 
Thr877, 
HOH108
-7.26 HOH108, Asn705
Testosterone -10.68
Arg752, 
Asn705, 
Thr877
  -5.95  -7.17 HOH108, Asn705
Flutamide -7.76 Asn705, Thr877 -8.25
Arg752, 
Gln711, 
Asn705, 
Leu704, 
HOH108*, 
HOH213#
-7.22
Arg752, 
Gln711, 
Leu704, 
Asn705, 
HOH108
-6.22
Arg752, 
Gln711, 
Asn705, 
HOH108
Bicalutamide -2.548    -10.27
Arg752, 
Gln711, 
Leu704, 
Asn705, 
HOH108
-9.22
Arg752, 
Gln711, 
Asn705
Enzalutamide       -5.87 Arg752, Gln7111Dock score in kcal/mol.*HOH108 could form bridged H-Bond interactions with Arg752, Gln711 and Met745. #HOH213 could form bridged H-Bond interaction with Leu873.
Flutamide
Flutamide has binding affinity for all the AR types used in this study. Flutamide has the highest binding energy with T877A mutated AR (dock score = -8.25 kcal/mol). Flutamide has a dock score of -7.76 kcal/mol and -7.22 kcal/mol with wild and W741L mutated ARs, respectively. As 
discussed above, T877A mutation causes resistance specifically to flutamide. In wild type AR, 
the hydroxyl group of flutamide forms H-Bond interactions with Thr877 and Asn705 (Figure 2). 
In T877A mutated AR, the nitro group of flutamide formed H-Bond interactions with Gln711, 
Arg752, HOH108, and Met745. The hydroxyl group of flutamide, in the absence of Thr877 amino acid, formed H-Bond interaction only with Asn705. The keto group of the amide formed H-Bond interaction with Leu873 mediated through a water molecule (HOH213) and the amino group of the amide formed H-Bond interaction with Leu704. The exact mechanism by which the T877A 
mutation converts the flutamide from antagonist to agonist was unknown, but we could observe that the size of the ligand binding pocket in T877A was bigger than the wild type AR (Figure 
2). The binding conformation of flutamide with wild and T877A mutated ARs was also different. Flutamide attained a bent conformation when bound to T877A mutated AR. It is possible that the T877A mutation could increase the space within the ligand binding pocket to accommodate for larger ligands without disturbing the closing of helix-12.
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Figure 2: Binding interactions of flutamide.
2a: Flutamide forms H-Bond interaction with Thr877, Asn705 and forms ionic interaction with Arg752 in wild type AR. 2b: Flutamide forms H-Bond interactions with Arg752 (ionic and H-Bond), Gln711, Leu704, Leu873 (bridged through HOH) and Met745 (bridged through HOH) in T877A mutant AR.
BicalutamideThe AR antagonist, bicalutamide doesn’t bind with T877A AR and has low binding energy with wild type AR (dock score = -2.54 kcal/mol). Bicalutamide is an antagonist to wild and T877A mutated ARs. This reveals that the bicalutamide was bulky enough so that it couldn’t bind with AR which has helix-12 in agonist conformation. Bicalutamide has the highest binding energy with W741L mutated AR (dock score = -10.27 kcal/mol) and this mutation causes resistance 
specifically to bicalutamide. In W741L mutated AR, the nitrile group of bicalutamide formed H-Bond interactions with Arg752, Gln711, HOH108, and Met745. The amine and hydroxyl group formed H-Bond interaction with Leu704 and Asn705 respectively (Figure 3a). It is obvious that the mutated leucine amino acid (W741L) is much smaller in size than the tryptophan amino acid, so we tried to compare the binding mode of bicalutamide in presence of leucine (W741L AR) and tryptophan (wild type AR). The binding comparison was carried out by superimposing the bound conformation of bicalutamide in W741L and wild type (helix-12 truncated) ARs (Figure 3b). The truncated AR has wild type tryptophan amino acid. The B ring of bicalutamide attains a different conformation in the presence of tryptophan and leucine. In the presence of tryptophan, the B ring of bicalutamide was shifted nearer to helix-12 amino acid Ile 899, indicating a possible 
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steric clash with it. In the presence of leucine (mutated AR) the B ring of bicalutamide was well inside the ligand binding pocket and far from the helix-12. This indicates that the W741L mutation also keeps the bulky B ring of bicalutamide within the binding pocket so that it could switch the antagonist activity of bicalutamide into an agonist.
The unexplained mystery of the mutations T877A and W741L was that flutamide, which is comparatively a smaller ligand than bicalutamide, could antagonize W741L mutated AR but not the T877A AR. Similarly bicalutamide could antagonize T877A mutated AR but not the W741L 
mutated AR. The possible explanation to this is, the mutations might be specific to the binding conformation of their respective antagonist. For instance, the B ring of bicalutamide was involved in steric interference with helix-12. So, the W741L mutation could be deliberate to keep the B ring 
of the bicalutamide away from the helix-12. In case of flutamide, there could be some other group 
involved in the steric interference with helix-12 and hence flutamide works as an antagonist in W741L mutated AR. 
Figure 3: Binding mode of bicalutamide.
3a: Bicalutamide forms H-Bond interaction with Arg752, Gln711, Leu704, Met745 (bridged through HOH) and Asn705 in W741L mutated AR. 3b: Figure represents the superimposition of the wild (green colored carbon) and W741L mutated (red colored carbon) ARs and the difference in binding mode of bicalutamide.  Note the lack of steric clashes of bicalutamide with helix-12 in the mutated type, which in turn leads to resistance.
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EnzalutamideEnzalutamide is a novel AR antagonist which was recently approved and doesn’t have the 
resistance with T877A and W741L mutated ARs. Enzalutamide doesn’t have binding affinity with wild, T877A and W741L, which all have helix-12 in agonist conformation. The enzalutamide has 
binding affinity only with helix-12 truncated AR (dock score = -5.87 kcal/mol). This reveals that enzalutamide has enough bulk that prevents it from binding with ARs that has helix-12 in agonist conformation. The nitrile group of enzalutamide forms H-Bond interactions with Arg752 and Gln711 (Figure 4). This also proves that the truncated helix-12 model is a viable way to identify novel AR antagonists by structure based virtual screening method. 
Figure 4: Binding interactions of enzalutamide.Enzalutamide forms H-Bond interactions with Arg752 and Gln711 with helix-12 truncated AR.
Derivation of Structure Based Drug Design MethodThe mutation increases the space within the ligand binding pocket so that it could accommodate for larger molecules without disturbing the helix-12 [44]. The 12th helix truncated AR model 
could then be used to screen chemical databases (ZINC, SPECS etc) for the identification of novel AR antagonist scaffold. The AR with helix-12 closed conformation could also be included in the docking process to eliminate the ligands that also have good binding score with helix-12 truncated 
AR. This step will eliminate the less bulk and highly flexible ligands so that the identified ligands might overcome the space increasing mutations that occur in the ligand binding pocket. This way, we can also differentiate between an AR agonist/partial agonist from pure antagonist.
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The novel AR antagonist should also form essential H-Bond interactions with the AR for specific binding. In general, the AR ligands could form H-Bond interactions with amino acids Arg752, G1n711, Met745, Leu704, Asn705, and Thr877. The amino acids Arg752, Gln711, and Met745 are present deep inside the binding pocket. The amino acids Thr877 and Asn705 are present nearer to helix-12. An AR antagonist should preferentially form H-Bond with the deep residues, Arg752, Gln711, and Met745 either directly or mediated through a water molecule (bridged H-Bond). The H-Bond interactions with Asn705 and Thr877 might prevent the antagonist from 
abutting (steric clash) the helix-12 [45]. In the docking studies, flutamide and bicalutamide which exhibit resistance with the mutated AR had formed H-Bond interaction with Asn705 and Thr877 amino acids. Enzalutamide, which doesn’t have resistance with Thr877 or W741L mutated ARs, formed H-Bond interaction with Arg752 and Gln711 and didn’t form H-Bond interaction with either Asn705 or Thr877. 
CONCLUSION
The point mutations in AR increase the binding affinity for the antagonist and decrease the 
binding affinity for agonist androgens. The mutation converts the antagonist into agonist, which promotes the growth of the cancer cells. Hence, it is essential to design an antagonist that will tolerate the point mutation that may occur during the course of the treatment. This is possible by designing AR antagonists that possess optimal bulk. The bulky groups should also attain optimal conformation in order to abut helix-12. The method described in this manuscript is capable of identifying new chemical entities that remain impervious to mutation in the AR ligand binding domain.
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ABSTRACT
Androgen﻿ increases﻿ the﻿proliferation﻿of﻿prostate﻿cancer﻿cells﻿by﻿activating﻿ the﻿androgen﻿receptor﻿
(AR).﻿AR﻿antagonists﻿block﻿the﻿androgen﻿mediated﻿proliferation﻿and﻿are﻿used﻿to﻿treat﻿prostate﻿cancer.﻿
Antagonist﻿resistance﻿occurs﻿due﻿to﻿the﻿expression﻿of﻿mutations﻿in﻿AR.﻿One﻿particular﻿mutation,﻿
T877A,﻿was﻿frequently﻿expressed﻿in﻿relapsed﻿patients.﻿Presently,﻿there﻿is﻿no﻿antagonist﻿in﻿the﻿market﻿
without﻿the﻿problem﻿of﻿resistance﻿developing﻿over﻿the﻿period﻿of﻿treatment.﻿A﻿plausible﻿reason﻿for﻿this﻿
shortcoming﻿could﻿be﻿the﻿lack﻿of﻿designing﻿because﻿of﻿the﻿unavailability﻿of﻿AR-crystal﻿structure﻿in﻿
antagonist﻿bound﻿conformation.﻿Hence,﻿3D-QSAR﻿becomes﻿a﻿major﻿tool﻿in﻿identification﻿of﻿novel﻿
AR﻿antagonists.﻿Three﻿models,﻿ADDHRR.295,﻿AHHRR.266,﻿and﻿AHRR.63﻿were﻿designed﻿for﻿wild﻿
type,﻿T877A﻿mutant,﻿and﻿full﻿(active﻿at﻿both﻿wild﻿and﻿mutant﻿types)﻿AR﻿antagonists﻿respectively.﻿
There﻿is﻿a﻿major﻿difference﻿in﻿the﻿angles﻿and﻿lengths﻿of﻿the﻿pharmacophore﻿site﻿points﻿among﻿the﻿
3D-QSAR﻿models.﻿The﻿generated﻿pharmacophore﻿for﻿full﻿antagonists﻿was﻿then﻿used﻿for﻿screening﻿
the﻿SPECS﻿database﻿with﻿filters﻿for﻿identifying﻿hits.
KeyWoRDS
3D-QSAR, Androgen Receptor Antagonist, Mutation, Pharmacophore, Prostate Cancer, Resistance, T877A, 
Virtual Screening
INTRoDUCTIoN
Activation﻿of﻿AR﻿(androgen﻿receptor)﻿by﻿androgen﻿leads﻿to﻿the﻿proliferation﻿of﻿prostate﻿cells.﻿AR﻿
antagonists﻿inhibit﻿the﻿binding﻿of﻿androgens﻿with﻿AR﻿and﻿prevent﻿the﻿proliferation﻿of﻿prostate﻿cells﻿
(Gao﻿et﻿al.,﻿2010).﻿However,﻿the﻿AR﻿develops﻿resistance﻿for﻿its﻿antagonists﻿after﻿a﻿treatment﻿median﻿
of﻿12-24﻿months.﻿This﻿is﻿because﻿of﻿the﻿expression﻿of﻿point﻿mutations﻿in﻿the﻿ligand﻿binding﻿domain﻿of﻿
the﻿AR﻿(Tilley﻿et﻿al.,﻿1996,﻿Feldman﻿et﻿al.,﻿2001).﻿The﻿T877A﻿mutation﻿was﻿most﻿frequently﻿expressed﻿
among﻿prostate﻿cancer﻿patients﻿(Feldman﻿et﻿al.,﻿2001,﻿Balk﻿et﻿al.,﻿2002).﻿The﻿mutant﻿AR﻿converts﻿the﻿
antagonist﻿into﻿agonist﻿(Fenton﻿et﻿al.,﻿1997).﻿Furthermore,﻿the﻿mutated﻿AR﻿could﻿also﻿be﻿activated﻿
by﻿steroidal﻿hormones,﻿estrogens,﻿progesterone,﻿etc.﻿(Fenton﻿et﻿al.,﻿1997).﻿This﻿leads﻿to﻿the﻿failure﻿of﻿
androgen﻿deprivation﻿therapy﻿because﻿of﻿the﻿activation﻿of﻿AR﻿by﻿non-androgens.
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Previously,﻿we﻿had﻿designed﻿and﻿synthesized﻿novel﻿oxbenzimidazole﻿derivatives﻿targeting﻿AR﻿
(Elencheran﻿ et﻿ al.,﻿ 2016).﻿However,﻿most﻿ of﻿ the﻿molecules﻿were﻿ non﻿ selective﻿ and﻿ inhibited﻿ the﻿
proliferation﻿of﻿AR﻿negative﻿and﻿positive﻿prostate﻿cancer﻿cell﻿lines.﻿Therefore,﻿in﻿order﻿to﻿overcome﻿
this﻿issue,﻿we﻿decided﻿to﻿study﻿the﻿pharmacophoric﻿features﻿of﻿AR﻿antagonists.﻿In﻿this﻿study,﻿we﻿have﻿
developed﻿three﻿3D-QSAR﻿models.﻿These﻿models﻿represent﻿the﻿pharmacophore﻿site﻿points﻿of﻿wild﻿
type﻿AR﻿antagonist,﻿T877A﻿mutant﻿AR﻿antagonist,﻿and﻿the﻿full﻿antagonist.﻿The﻿full﻿antagonist,﻿for﻿the﻿
purposes﻿of﻿this﻿study,﻿is﻿defined﻿as﻿a﻿molecule﻿that﻿will﻿not﻿function﻿as﻿an﻿agonist﻿or﻿partial﻿agonist﻿
with﻿either﻿wild﻿or﻿mutant﻿ARs.﻿The﻿difference﻿between﻿the﻿full﻿antagonist﻿and﻿partial﻿agonist﻿is﻿that﻿
the﻿full﻿antagonist﻿will﻿behave﻿as﻿an﻿antagonist﻿irrespective﻿of﻿the﻿AR﻿mutation.﻿The﻿activity﻿of﻿the﻿
partial﻿agonist﻿is﻿facultative﻿and﻿depends﻿on﻿the﻿presence﻿of﻿mutation.﻿The﻿partial﻿agonist﻿functions﻿as﻿
an﻿agonist﻿in﻿the﻿presence﻿of﻿T877A﻿mutation﻿and﻿acts﻿an﻿antagonist﻿in﻿the﻿absence﻿of﻿the﻿mutation.﻿
A﻿good﻿example﻿in﻿this﻿regard﻿is﻿Flutamide.﻿The﻿3D-QSAR﻿models﻿were﻿compared﻿for﻿differences﻿
among﻿them.﻿This﻿study﻿could﻿potentially﻿provide﻿the﻿insight﻿into﻿the﻿necessary﻿structural﻿properties﻿
of﻿AR﻿antagonists﻿to﻿avoid﻿resistance﻿developing﻿during﻿treatment.
MATeRIALS AND MeTHoDS
Dataset Preparation
The﻿molecules﻿ for﻿ the﻿datasets﻿were﻿obtained﻿ from﻿ literature﻿ (Ferla,﻿ et﻿ al.,﻿2016,﻿Bassetto﻿et﻿ al.,﻿
2016,﻿Yamamoto﻿et﻿al.,﻿2013,﻿Yamamoto﻿et﻿al.,﻿2012,﻿Yamamoto﻿et﻿al.,﻿2012).﻿The﻿ligands﻿were﻿then﻿
grouped﻿into﻿three﻿datasets.﻿The﻿first﻿dataset﻿consists﻿of﻿ligands﻿that﻿antagonize﻿the﻿wild﻿type﻿AR.﻿The﻿
ligands﻿for﻿this﻿dataset﻿were﻿obtained﻿from﻿Ferla﻿et﻿al.,﻿2016﻿and﻿Bassetto﻿et﻿al.,﻿2016.﻿The﻿methods﻿
adopted﻿in﻿these﻿papers﻿were﻿the﻿same﻿and﻿the﻿experiments﻿were﻿conducted﻿in﻿the﻿same﻿laboratory.﻿
The﻿antagonist﻿activity﻿was﻿measured﻿in﻿VCaP﻿cell﻿line,﻿which﻿expresses﻿wild﻿type﻿AR.﻿The﻿second﻿
dataset﻿consists﻿of﻿ligands﻿that﻿antagonize﻿the﻿T877A﻿mutant﻿AR.﻿The﻿ligands﻿for﻿this﻿dataset﻿were﻿
also﻿obtained﻿from﻿Ferla﻿et﻿al.,﻿2016﻿and﻿Bassetto﻿et﻿al.,﻿2016.﻿The﻿methods﻿adopted﻿in﻿these﻿papers﻿
were﻿also﻿the﻿same.﻿The﻿antagonist﻿activity﻿was﻿measured﻿in﻿LNCaP﻿cell﻿line,﻿which﻿expresses﻿T877A﻿
mutant﻿AR.﻿The﻿third﻿dataset﻿consists﻿of﻿ligands﻿that﻿antagonize﻿both﻿wild﻿and﻿T877A﻿mutant﻿AR﻿
without﻿any﻿agonist﻿/﻿partial﻿agonist﻿effect﻿on﻿either﻿of﻿these﻿receptors.﻿The﻿ligands﻿for﻿this﻿dataset﻿
were﻿obtained﻿from﻿Yamamoto﻿et﻿al.,﻿2013,﻿Yamamoto﻿et﻿al.,﻿2012,﻿and﻿Yamamoto﻿et﻿al.,﻿2012.﻿The﻿
methods﻿adopted﻿in﻿these﻿papers﻿were﻿the﻿same﻿and﻿the﻿experiments﻿were﻿conducted﻿in﻿the﻿same﻿
laboratory.﻿The﻿antagonist﻿and﻿partial﻿agonist﻿activity﻿were﻿measured﻿by﻿a﻿transfection﻿assay.
As﻿mentioned﻿above,﻿the﻿biological﻿activity﻿of﻿each﻿dataset﻿was﻿obtained﻿in﻿different﻿cell﻿lines.﻿
Hence,﻿ there﻿ is﻿ a﻿ difference﻿ in﻿ the﻿ biological﻿ activity﻿ range﻿ among﻿ the﻿ datasets.﻿The﻿ active﻿ and﻿
inactive﻿molecules﻿were﻿selected﻿depending﻿on﻿the﻿activity﻿range﻿among﻿the﻿dataset﻿molecules.﻿The﻿
active﻿molecules﻿are﻿the﻿ones﻿which﻿will﻿have﻿the﻿least﻿IC50﻿and﻿the﻿inactive﻿molecules﻿will﻿have﻿the﻿
higher﻿IC50﻿values﻿among﻿the﻿dataset﻿molecules.﻿Hence,﻿the﻿inactive﻿molecules﻿are﻿more﻿precisely﻿
described﻿as﻿less﻿actives﻿rather﻿than﻿absolutely﻿inactives.﻿This﻿selection﻿method﻿was﻿followed﻿to﻿yield﻿
an﻿optimal﻿numbers﻿of﻿active﻿and﻿inactive﻿molecules﻿in﻿the﻿training﻿and﻿test﻿sets.﻿This﻿is﻿absolutely﻿
essential﻿ for﻿validating﻿ the﻿3D-QSAR﻿with﻿an﻿external﻿ test﻿ set﻿which﻿ should﻿have﻿equal﻿ activity﻿
distribution﻿like﻿training﻿set.
The﻿first﻿dataset﻿(wild﻿type)﻿has﻿122﻿molecules﻿and﻿was﻿randomly﻿split﻿into﻿training﻿(75%)﻿and﻿
test﻿(25%)﻿sets.﻿The﻿molecules﻿in﻿the﻿dataset﻿represent﻿similarity﻿with﻿AR﻿antagonists﻿enzalutamide﻿
and﻿bicalutamide.﻿The﻿molecules﻿having﻿IC50<4μM﻿were﻿designated﻿as﻿actives﻿and﻿molecules﻿having﻿
IC50>50μM﻿were﻿designated﻿as﻿inactives.﻿The﻿second﻿dataset﻿(T877A﻿AR)﻿has﻿132﻿molecules﻿and﻿the﻿
dataset﻿was﻿divided﻿randomly﻿into﻿training﻿(75%)﻿and﻿test﻿(25%)﻿sets.﻿The﻿extra﻿10﻿molecules﻿in﻿the﻿
mutant﻿(second)﻿dataset﻿do﻿not﻿have﻿any﻿defined﻿activity﻿values﻿in﻿the﻿wild﻿type﻿and﻿consequently﻿
were﻿not﻿included﻿in﻿the﻿wild﻿type﻿pharmacophore﻿generation.﻿The﻿molecules﻿in﻿the﻿dataset﻿represent﻿
similarity﻿with﻿AR﻿antagonists﻿enzalutamide﻿and﻿bicalutamide﻿(Figure﻿1).﻿The﻿molecules﻿having﻿
IC50<3μM﻿were﻿designated﻿as﻿actives﻿and﻿molecules﻿having﻿IC50>32μM﻿were﻿designated﻿as﻿inactives.﻿
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The﻿third﻿data﻿set﻿(full﻿antagonist)﻿had﻿42﻿molecules﻿and﻿the﻿dataset﻿was﻿randomly﻿divided﻿into﻿training﻿
(75%)﻿and﻿test﻿(25%)﻿sets.﻿The﻿molecules﻿in﻿the﻿dataset﻿have﻿different﻿types﻿of﻿basic﻿nuclei﻿comprising,﻿
1-arylmethyl-4-phenylpyrrole,﻿ 4-arylmethyl-1-phenylpyrazole,﻿ 4-aryloxy-1-phenylpyrazole,﻿ and﻿
3-aryl-3-hydroxy-1-phenylpyrrolidine﻿derivatives﻿(Figure﻿1).﻿The﻿ligands﻿having﻿IC50<0.10μM﻿were﻿
designated﻿as﻿actives﻿and﻿ligands﻿having﻿IC50>3μM﻿were﻿designated﻿as﻿inactives.
Common Pharmacophore Hypotheses and 3D-QSAR
Common﻿pharmacophore﻿hypotheses﻿(CPH)﻿identification﻿and﻿3D-QSAR﻿modelling﻿were﻿performed﻿
using﻿PHASE,﻿Schrödinger﻿(v3.9).﻿The﻿ligands﻿were﻿geometrically﻿refined﻿and﻿assigned﻿appropriate﻿
protonation﻿states﻿for﻿pH-7.0﻿±﻿0.2﻿by﻿LigPrep﻿(v3.1).﻿The﻿IC50﻿values﻿were﻿entered﻿as﻿pIC50.﻿The﻿
conformers﻿(maximum﻿of﻿1000)﻿ for﻿each﻿ ligand﻿were﻿generated﻿by﻿mixed﻿Monte﻿Carlo﻿Multiple﻿
Minimum/Low﻿Mode﻿rapid﻿sampling﻿method.﻿The﻿generated﻿conformers﻿were﻿energy﻿minimized﻿
using﻿OPLS﻿2005﻿force﻿field﻿(Dixon﻿et﻿al.,﻿2006).﻿The﻿OPLS﻿2005﻿force﻿field﻿is﻿one﻿of﻿the﻿preferable﻿
force﻿fields﻿for﻿biological﻿systems﻿and﻿organic﻿molecules.﻿It﻿has﻿improved﻿solvation﻿free﻿energies﻿in﻿
comparison﻿to﻿other﻿systems﻿like﻿AMBER﻿or﻿CHARMM﻿force﻿fields﻿(Shivakumar﻿et﻿al.,﻿2010).﻿The﻿
cutoff﻿value﻿for﻿conformer﻿redundancy﻿was﻿set﻿at﻿1Å﻿RMSD.﻿The﻿maximum﻿number﻿of﻿PLS﻿factors﻿
that﻿could﻿be﻿used﻿for﻿calculations﻿was﻿N/5,﻿where﻿N﻿is﻿the﻿number﻿of﻿molecules﻿in﻿the﻿training﻿set.﻿A﻿
PLS﻿factor﻿value﻿of﻿5﻿was﻿used﻿to﻿validate﻿the﻿wild﻿and﻿T877A﻿mutant﻿AR﻿antagonist.﻿A﻿PLS﻿factor﻿
value﻿of﻿3﻿was﻿used﻿for﻿full﻿antagonist.﻿Atom﻿based﻿3D-QSAR﻿method﻿was﻿followed﻿by﻿applying﻿
default﻿parameters.
Figure 1. Representation of the scaffolds used in the construction of 3D-QSAR models
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Homology Modelling and Docking
Schrodinger﻿PRIME﻿(v3.7)﻿was﻿used﻿for﻿protein﻿structure﻿prediction,﻿side﻿chain﻿optimization,﻿loop﻿
prediction,﻿active﻿site﻿refinement,﻿and﻿energy﻿minimization.﻿The﻿amino﻿acid﻿sequence﻿of﻿the﻿T877A﻿
mutant﻿AR﻿was﻿obtained﻿from﻿NCBI.﻿The﻿T877A﻿mutant﻿AR﻿(PDB:﻿2OZ7)﻿was﻿used﻿as﻿the﻿template.﻿
This﻿was﻿co-crystallized﻿with﻿antagonist﻿cyproterone﻿acetate﻿and﻿has﻿a﻿resolution﻿of﻿1.80﻿Å.﻿Regarding﻿
the﻿homology﻿modeled﻿AR,﻿its﻿ligand﻿binding﻿domain﻿has﻿671-881﻿amino﻿acids﻿instead﻿of﻿671-919﻿
amino﻿acids﻿(Guo﻿et﻿al.,﻿2012).﻿The﻿homology﻿modelled﻿AR﻿thereby﻿lacks﻿the﻿helix-12﻿amino﻿acids.﻿
The﻿alignment﻿between﻿the﻿target﻿and﻿template﻿sequence﻿was﻿carried﻿out﻿by﻿Clustalw﻿method.﻿The﻿
sequence﻿identity﻿between﻿the﻿target﻿and﻿template﻿was﻿100%.﻿The﻿ligand﻿(cyproterone﻿acetate)﻿and﻿a﻿
water﻿molecule﻿(HOH-108)﻿were﻿retained﻿in﻿the﻿final﻿model.﻿The﻿homology﻿model﻿was﻿then﻿energy﻿
minimized﻿(OPLS﻿2005)﻿and﻿the﻿active﻿site﻿was﻿further﻿refined.
The﻿ligands﻿for﻿docking﻿studies﻿were﻿prepared﻿using﻿LigPrep,﻿Schrödinger.﻿The﻿ligands﻿were﻿
geometrically﻿ refined﻿ and﻿ assigned﻿ appropriate﻿ protonation﻿ states﻿ at﻿ pH﻿7.0﻿±﻿0.2.﻿The﻿ energy﻿
minimization﻿was﻿carried﻿out﻿by﻿OPLS﻿2005﻿force﻿field.﻿The﻿AR﻿proteins:﻿T877A﻿mutant﻿(2OZ7),﻿
and﻿homology﻿model﻿(truncated﻿helix-12)﻿were﻿used﻿for﻿visualizing﻿the﻿dockings﻿into﻿their﻿respective﻿
active﻿sites.﻿The﻿proteins﻿were﻿prepared﻿using﻿the﻿protein﻿preparation﻿wizard.﻿The﻿grid﻿was﻿assigned﻿
by﻿picking﻿the﻿ligand﻿as﻿the﻿center﻿and﻿applying﻿default﻿parameters.﻿The﻿docking﻿was﻿carried﻿out﻿
using﻿GLIDE,﻿Schrödinger.﻿GLIDE﻿XP﻿(extra﻿precision),﻿and﻿SP﻿(standard﻿precision)﻿methods﻿were﻿
followed﻿for﻿the﻿docking﻿calculations.
The﻿homology﻿model﻿was﻿validated﻿in﻿the﻿structural﻿analysis﻿and﻿verification﻿server﻿(SAVES)﻿
(Messaoudi﻿et﻿al.,﻿2013).﻿The﻿amino﻿acids﻿in﻿the﻿favorable,﻿allowed﻿and﻿disallowed﻿regions﻿were﻿
identified﻿by﻿Ramachandran﻿plot.﻿The﻿stereochemistry﻿of﻿the﻿amino﻿acids﻿in﻿the﻿homology﻿model﻿
was﻿ evaluated﻿by﻿PROCHECK.﻿The﻿3D﻿compatibility﻿ of﻿ the﻿homology﻿model﻿was﻿validated﻿by﻿
VERIFY_3D.﻿The﻿homology﻿model﻿passed﻿all﻿the﻿criteria﻿for﻿a﻿good﻿protein﻿structure.﻿The﻿percentage﻿
of﻿amino﻿acids﻿in﻿the﻿favorable﻿region,﻿allowed﻿region﻿and﻿disallowed﻿regions﻿were﻿96.2%,﻿3.8%﻿and﻿
zero﻿respectively.﻿The﻿docking﻿studies﻿were﻿validated﻿by﻿calculating﻿the﻿root﻿mean﻿square﻿deviation﻿
(RMSD)﻿of﻿the﻿crystal﻿and﻿docked﻿conformation﻿of﻿cyproterone﻿acetate.﻿The﻿RMSD﻿between﻿the﻿
predicted﻿and﻿crystal﻿structure﻿was﻿0.46﻿Å.﻿The﻿maximum﻿allowable﻿limit﻿is﻿2﻿Å﻿(Tripathi﻿et﻿al.,﻿2013).
ReSULTS AND DISCUSSIoN
Dataset Preparation
Selection﻿of﻿training﻿molecules﻿is﻿an﻿important﻿step﻿for﻿developing﻿a﻿3D-QSAR﻿model﻿with﻿good﻿
predictive﻿power.﻿The﻿activity﻿(IC50)﻿for﻿wild﻿type﻿AR﻿was﻿evaluated﻿in﻿VCaP﻿cell﻿line.﻿The﻿activity﻿
for﻿T877A﻿mutant﻿AR﻿was﻿evaluated﻿in﻿LNCaP﻿cell﻿line.﻿The﻿majority﻿of﻿the﻿molecules﻿were﻿active﻿
in﻿wild﻿and﻿T877A﻿mutant﻿AR﻿expressing﻿cell﻿lines.﻿However,﻿the﻿activity﻿of﻿the﻿molecules﻿varied﻿
between﻿the﻿cell﻿lines.﻿This﻿is﻿because﻿the﻿molecules﻿exhibit﻿different﻿efficacy﻿with﻿wild﻿and﻿mutant﻿
T877A﻿ARs.﻿Hence,﻿ the﻿ IC50﻿values﻿evaluated﻿ in﻿ the﻿VCaP﻿cell﻿ line﻿was﻿used﻿ in﻿developing﻿ the﻿
3D-QSAR﻿model﻿for﻿wild﻿type﻿AR.﻿Similarly,﻿the﻿IC50﻿values﻿evaluated﻿in﻿LNCaP﻿cell﻿line﻿was﻿used﻿
in﻿developing﻿the﻿3D-QSAR﻿model﻿for﻿T877A﻿mutant﻿AR.﻿The﻿separation﻿of﻿datasets﻿as﻿mentioned﻿
above﻿will﻿lead﻿to﻿the﻿identification﻿of﻿preferential﻿but﻿not﻿absolute﻿3D-QSAR﻿for﻿respective﻿AR﻿
antagonists.﻿Also,﻿the﻿molecules﻿for﻿the﻿first﻿and﻿second﻿datasets﻿were﻿not﻿filtered﻿for﻿resistance.﻿
This﻿means﻿that﻿the﻿molecules﻿in﻿the﻿dataset﻿may﻿or﻿may﻿not﻿have﻿agonist/partial﻿agonist﻿activity﻿
with﻿either﻿/﻿both﻿wild﻿or﻿T877A﻿mutant﻿AR.﻿The﻿molecules﻿for﻿the﻿dataset﻿of﻿full﻿antagonists﻿were﻿
carefully﻿selected﻿by﻿a﻿two-step﻿process.﻿First,﻿the﻿ligands﻿that﻿could﻿antagonize﻿both﻿wild﻿and﻿T877A﻿
mutant﻿ARs﻿were﻿selected.﻿The﻿second﻿step﻿involved﻿the﻿filtering﻿of﻿the﻿molecules﻿for﻿resistance.﻿
This﻿means﻿that﻿none﻿of﻿the﻿ligands﻿in﻿the﻿dataset﻿has﻿agonist/partial﻿agonist﻿activity﻿with﻿either﻿/﻿
both﻿wild﻿or﻿T877A﻿mutant﻿AR.﻿The﻿activities﻿of﻿the﻿molecules﻿in﻿this﻿dataset﻿were﻿evaluated﻿by﻿
luciferase﻿reporter﻿assay.
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Selection and Validation of the Models
The﻿best﻿3D-QSAR﻿model﻿was﻿selected﻿based﻿on﻿high﻿correlation﻿between﻿the﻿predicted﻿and﻿observed﻿
activity﻿(R2),﻿predictive﻿ability﻿of﻿the﻿model﻿(Q2),﻿low﻿standard﻿deviation﻿(SD),﻿and﻿the﻿probability﻿
of﻿getting﻿an﻿actual﻿result﻿(p﻿value)﻿of﻿the﻿training﻿set﻿(Durdagi﻿et﻿al.,﻿2011).﻿The﻿model﻿was﻿also﻿
validated﻿by﻿predicting﻿a﻿test﻿set﻿having﻿wide﻿range﻿of﻿biological﻿activity.﻿The﻿correlation﻿between﻿
the﻿observed﻿and﻿predicted﻿activity﻿of﻿the﻿test﻿set﻿(R2),﻿Pearson-R,﻿Predictive﻿R2﻿(R2pred),﻿and﻿the﻿
correlation﻿between﻿the﻿observed﻿and﻿predicted﻿activity﻿of﻿the﻿test﻿set﻿with﻿intercept﻿set﻿at﻿zero﻿(r2m)﻿
were﻿used﻿to﻿evaluate﻿the﻿predictivity﻿of﻿the﻿models.﻿The﻿models﻿having﻿the﻿highest﻿(at﻿least>0.5)﻿
value﻿for﻿Q2,﻿R2pred,﻿and﻿r2m﻿were﻿considered﻿for﻿selection﻿(Pratim﻿et﻿al.,﻿2009).﻿From﻿this﻿selection,﻿
the﻿model﻿that﻿had﻿the﻿highest﻿R2﻿value﻿for﻿training﻿and﻿test﻿set﻿molecules,﻿Q2,﻿R2pred,﻿and﻿r2m﻿was﻿
considered﻿as﻿the﻿best.
Wild Type AR
The﻿molecules﻿in﻿the﻿dataset﻿were﻿defined﻿by﻿the﻿following﻿pharmacophore﻿site﻿points:﻿hydrogen﻿
bond﻿acceptor﻿(A),﻿hydrogen﻿bond﻿donor﻿(D),﻿hydrophobic﻿group﻿(H),﻿and﻿aromatic﻿ring﻿(R).﻿The﻿
number﻿of﻿“must﻿match”﻿pharmacophore﻿site﻿points﻿were﻿gradually﻿decreased﻿from﻿7﻿to﻿3﻿until﻿all﻿
the﻿actives﻿were﻿matched﻿and﻿scored﻿successfully.﻿The﻿hypothesis﻿having﻿six﻿pharmacophore﻿site﻿
points﻿survived﻿the﻿scoring﻿functions.﻿PHASE﻿generates﻿CPH﻿by﻿comparing﻿the﻿pharmacophore﻿site﻿
points﻿from﻿two﻿or﻿more﻿active﻿ligands﻿(Almerico﻿et﻿al.,﻿2010).﻿Therefore,﻿the﻿pharmacophore﻿site﻿
points﻿in﻿the﻿3D-QSAR﻿represent﻿the﻿spatial﻿arrangement﻿of﻿the﻿common﻿pharmacophore﻿features﻿
that﻿are﻿present﻿among﻿the﻿active﻿ligands.﻿Based﻿on﻿the﻿scoring;﻿ADDHRR.295﻿was﻿selected﻿as﻿the﻿
best﻿model﻿(Table﻿1).﻿The﻿3D-QSAR﻿has﻿one﻿acceptor﻿group﻿(A),﻿two﻿hydrogen﻿bond﻿donor﻿groups﻿
(D),﻿one﻿hydrophobic﻿group﻿(H),﻿and﻿two﻿aromatic﻿rings﻿(R)﻿(Figure﻿2).
The﻿active﻿groups﻿of﻿the﻿best﻿fit﻿molecules﻿were﻿evaluated﻿by﻿cube﻿models﻿(Figure﻿3﻿and﻿Figure﻿
4).﻿During﻿the﻿construction﻿of﻿the﻿3D-QSAR,﻿a﻿rectangular﻿grid﻿is﻿applied﻿by﻿PHASE﻿to﻿the﻿aligned﻿
training﻿set﻿molecules.﻿The﻿grid﻿comprises﻿all﻿the﻿substitutions﻿in﻿the﻿pharmacophore﻿site﻿points.﻿
Then﻿by﻿correlating﻿the﻿observed﻿activity﻿and﻿the﻿atoms﻿in﻿the﻿grid﻿space,﻿the﻿PHASE﻿generates﻿the﻿
cube﻿models.﻿The﻿cube﻿models﻿have﻿a﻿score﻿value,﻿which﻿being﻿less﻿than﻿zero﻿means﻿the﻿atoms﻿in﻿the﻿
grid﻿space﻿does﻿not﻿favor﻿the﻿activity﻿and﻿greater﻿than﻿1﻿will﻿favor﻿the﻿activity.﻿The﻿space﻿occupied﻿
by﻿the﻿atoms﻿which﻿does﻿not﻿favor﻿the﻿activity﻿is﻿indicated﻿in﻿red﻿color.﻿The﻿space﻿occupied﻿by﻿the﻿
atoms﻿which﻿favors﻿the﻿activity﻿is﻿indicated﻿in﻿blue﻿color﻿(Dixon﻿et﻿al.,﻿2006).﻿Hence,﻿the﻿blue﻿cubes﻿
represent﻿the﻿favorable﻿regions﻿for﻿activity﻿and﻿the﻿red﻿cubes﻿represent﻿the﻿unfavorable﻿regions﻿for﻿
activity.﻿The﻿4-nitrile﻿and﻿3-CF3﻿substitutions﻿in﻿ring﻿R10﻿were﻿favorable﻿regions﻿for﻿activity.﻿The﻿3-CF3﻿
substitution﻿at﻿ring﻿R11,﻿which﻿is﻿the﻿hydrophobic﻿H7﻿site﻿point,﻿also﻿favors﻿the﻿activity.﻿However,﻿
the﻿–OH﻿group﻿and﻿sulphur﻿atom﻿in﻿the﻿linker﻿region﻿between﻿R10﻿and﻿R11﻿were﻿unfavorable﻿for﻿
activity.﻿The﻿H﻿atom﻿of﻿the﻿hydroxyl﻿group﻿is﻿the﻿donor﻿D4﻿site﻿point.﻿This﻿indicates﻿that﻿although﻿
it﻿is﻿one﻿among﻿the﻿pharmacophore﻿site﻿points,﻿it﻿decreases﻿the﻿activity.﻿The﻿observed﻿and﻿predicted﻿
activities﻿of﻿test﻿and﻿training﻿set﻿molecules﻿are﻿given﻿in﻿the﻿supplementary﻿data﻿(Tables﻿S1﻿and﻿S2)﻿
(https://doi.org/10.4018/ijqspr.2017070105).﻿The﻿ correlation﻿between﻿ the﻿observed﻿and﻿predicted﻿
activity﻿of﻿the﻿training﻿set﻿was﻿0.9.﻿The﻿model﻿was﻿validated﻿by﻿predicting﻿the﻿test﻿set﻿having﻿wide﻿
range﻿of﻿biological﻿activity.﻿The﻿correlation﻿between﻿the﻿observed﻿and﻿predicted﻿activity﻿of﻿the﻿test﻿
set﻿was﻿0.76.﻿Also,﻿the﻿ADDHRR.295﻿accurately﻿predicted﻿the﻿biological﻿value﻿of﻿AR﻿antagonist,﻿
enzalutamide﻿(residual﻿activity﻿=﻿0.14).
T877A Mutant AR
The﻿ dataset﻿ generated﻿A,﻿D,﻿H,﻿ and﻿R﻿ pharmacophore﻿ site﻿ points.﻿The﻿ hypothesis﻿ having﻿ five﻿
pharmacophore﻿site﻿points﻿survived﻿the﻿scoring﻿functions.﻿Based﻿on﻿the﻿scoring,﻿AHHRR.266﻿was﻿
selected﻿as﻿the﻿best﻿model﻿(Table﻿1).﻿The﻿pharmacophore﻿has﻿one﻿acceptor﻿group﻿(A),﻿two﻿hydrophobic﻿
groups﻿(H)﻿and﻿two﻿aromatic﻿rings﻿(R)﻿(Figure﻿5).﻿The﻿active﻿groups﻿of﻿the﻿best﻿fit﻿molecule﻿were﻿
evaluated﻿by﻿cube﻿models﻿(Figures﻿6﻿and﻿7).﻿The﻿blue﻿cubes﻿represent﻿the﻿favorable﻿regions﻿for﻿activity﻿
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Table 1. Statistics of the 3D-QSAR models
Training Test
In ID PLS SD R2 F P Q2 R2 r2m R2pred Pearson-R
Wild ADDHRR.295 5 0.13 0.91 171.1 1.918e-43 0.62 0.76 0.76 0.72 0.87
T877A AHHRR.266 5 0.11 0.94 294.5 8.649e-56 0.62 0.74 0.74 0.69 0.86
Full AHRR.63 3 0.2 0.94 152.4 7.536e-18 0.58 0.80 0.75 0.83 0.89
Figure 2. Representation of the distances between the pharmacophore site points of wild type AR
Figure 3. Representation of the best fit molecule with the wild type 3D-QSAR
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and﻿red﻿cubes﻿represent﻿the﻿unfavorable﻿regions﻿for﻿activity.﻿The﻿4-nitro﻿and﻿3-CF3﻿substitutions﻿in﻿
ring﻿R9﻿are﻿favorable﻿regions﻿for﻿activity.﻿The﻿3-CF3﻿group﻿is﻿the﻿hydrophobic﻿H5﻿site﻿point.﻿The﻿
3﻿ and﻿5-CF3﻿ substitutions﻿ at﻿ ring﻿R10﻿ also﻿ favors﻿ the﻿ activity.﻿The﻿3-CF3﻿ substituent﻿ is﻿ also﻿ the﻿
hydrophobic﻿H6﻿site﻿point.﻿However,﻿the﻿–OH﻿and﻿sulphur﻿atom﻿in﻿the﻿linker﻿region﻿between﻿R10﻿
and﻿R11﻿were﻿unfavorable﻿for﻿activity.﻿The﻿observed﻿and﻿predicted﻿activities﻿of﻿all﻿the﻿ligands﻿in﻿the﻿
training﻿and﻿test﻿sets﻿are﻿given﻿in﻿Supplementary﻿section﻿(Tables﻿S1﻿and﻿S2).﻿The﻿correlation﻿between﻿
Figure 4. Representation of the cube model of the wild type 3D-QSAR best fit molecule
Figure 5. Representation of the distances between the pharmacophore site points of T877A mutant AR
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the﻿observed﻿and﻿predicted﻿activity﻿of﻿the﻿training﻿set﻿and﻿test﻿set﻿was﻿0.94﻿and﻿0.74,﻿respectively.﻿
The﻿model﻿AHHRR.266﻿accurately﻿predicted﻿the﻿biological﻿activity﻿of﻿AR﻿antagonist﻿enzalutamide﻿
(residual﻿activity﻿=﻿0.06).﻿The﻿biological﻿activity﻿of﻿enzalutamide﻿has﻿wide﻿variations﻿between﻿wild﻿
and﻿mutant﻿ARs.﻿Enzalutamide﻿is﻿~5﻿times﻿selective﻿towards﻿T877A﻿mutant﻿AR.﻿The﻿3D-QSAR﻿
models﻿for﻿wild﻿and﻿T877A﻿mutant﻿AR﻿could﻿identify﻿the﻿differences﻿in﻿the﻿structural﻿features﻿of﻿
enzalutamide.﻿This﻿indicates﻿that﻿these﻿models﻿could﻿provide﻿the﻿possible﻿breakthrough﻿needed﻿to﻿
overcome﻿AR﻿resistance.
Figure 6. Representation of the best fit molecule with the T877A mutant 3D-QSAR
Figure 7. Representation of the cube model of the T877A mutant 3D-QSAR best fit molecule
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Full Antagonist
The﻿corresponding﻿dataset﻿has﻿activities﻿of﻿ the﻿ full﻿ antagonists﻿ listed﻿ for﻿both﻿ the﻿wild﻿ type﻿and﻿
the﻿mutant﻿AR.﻿We﻿chose﻿the﻿dataset﻿for﻿the﻿wild﻿type﻿because﻿the﻿resistance﻿develops﻿only﻿during﻿
the﻿course﻿of﻿the﻿treatment.﻿The﻿dataset﻿generated﻿A,﻿D,﻿H,﻿and﻿R﻿pharmacophore﻿site﻿points.﻿The﻿
hypothesis﻿having﻿four﻿pharmacophore﻿site﻿points﻿survived﻿ the﻿scoring﻿functions.﻿The﻿ list﻿of﻿ the﻿
entire﻿CPH﻿in﻿their﻿rank﻿order﻿is﻿given﻿in﻿the﻿Supplementary﻿section.﻿Based﻿on﻿scoring;﻿AHRR.63﻿
was﻿selected﻿as﻿the﻿best﻿model﻿(Table﻿1).﻿The﻿pharmacophore﻿has﻿one﻿H-Bond﻿acceptor﻿group﻿(A),﻿
one﻿hydrophobic﻿group﻿(H),﻿and﻿two﻿aromatic﻿rings﻿(R)﻿(Figure﻿8).﻿The﻿active﻿groups﻿of﻿the﻿best﻿fit﻿
molecule﻿were﻿evaluated﻿by﻿cube﻿models﻿as﻿described﻿above﻿for﻿the﻿wild﻿and﻿mutant﻿modeling﻿(Figure﻿
9﻿and﻿Figure﻿10).﻿The﻿4-nitrile﻿(A1﻿site﻿point)﻿and﻿3-Cl﻿substitutions﻿in﻿ring﻿R11﻿are﻿favorable﻿regions﻿
for﻿activity.﻿These﻿regions﻿are﻿occupied﻿by﻿blue﻿cubes.﻿The﻿methyl﻿group﻿that﻿follows﻿the﻿4-amide﻿
in﻿ring﻿R10﻿also﻿favors﻿the﻿activity.﻿The﻿N﻿atom﻿in﻿the﻿pyridine﻿ring﻿R10﻿and﻿the﻿–OH﻿group﻿in﻿the﻿
linker﻿region﻿between﻿R11﻿and﻿R10﻿were﻿also﻿favorable﻿for﻿activity.﻿The﻿observed﻿and﻿predicted﻿
activities﻿of﻿all﻿the﻿molecules﻿in﻿the﻿dataset﻿are﻿given﻿in﻿the﻿supplementary﻿data﻿(Tables﻿S3﻿–﻿S6).﻿The﻿
correlation﻿between﻿the﻿observed﻿and﻿predicted﻿activity﻿of﻿the﻿training﻿and﻿test﻿sets﻿were﻿0.94﻿and﻿0.79,﻿
respectively.﻿This﻿3D-QSAR﻿pharmacophore﻿did﻿not﻿match﻿with﻿any﻿of﻿the﻿existing﻿AR﻿antagonists﻿
(both﻿wild﻿and﻿mutant).﻿This﻿indicates﻿the﻿hybrid﻿nature﻿of﻿the﻿full﻿antagonist﻿pharmacophore.﻿Recall﻿
that﻿all﻿the﻿marketed﻿AR﻿antagonists﻿develop﻿resistance﻿during﻿the﻿course﻿of﻿the﻿treatment.
Similarity and Difference Between the 3D-QSAR Models
The﻿molecules﻿in﻿the﻿dataset﻿for﻿the﻿construction﻿of﻿the﻿3D-QSAR﻿models﻿have﻿common﻿structures,﻿
which﻿are﻿also﻿present﻿in﻿the﻿marketed﻿drugs﻿(Figure﻿11).﻿All﻿the﻿marketed﻿ligands﻿have﻿two﻿rings﻿
(A﻿and﻿B)﻿separated﻿by﻿a﻿linker﻿group.﻿These﻿two﻿rings﻿(A﻿and﻿B)﻿were﻿present﻿in﻿all﻿the﻿3D-QSAR﻿
models.﻿Notably,﻿the﻿substitutions﻿of﻿4-nitro﻿/﻿4-nitrile﻿groups﻿and﻿3-CF3﻿/﻿3-Cl﻿groups﻿in﻿the﻿A﻿ring﻿
are﻿favorable﻿for﻿activity﻿as﻿explained﻿by﻿the﻿cube﻿models.﻿Similarly,﻿the﻿hydrophobic﻿substitutions﻿
at﻿3rd,﻿4th,﻿and﻿5th﻿position﻿in﻿the﻿B﻿ring﻿also﻿favored﻿the﻿activity.﻿The﻿major﻿difference﻿among﻿the﻿
3D-QSAR﻿models﻿was﻿the﻿distance﻿and﻿angle﻿between﻿the﻿A﻿ring﻿and﻿B﻿ring.﻿Also,﻿there﻿is﻿a﻿difference﻿
in﻿the﻿distance﻿between﻿the﻿two﻿extreme﻿pharmacophore﻿site﻿points.﻿These﻿properties﻿describe﻿the﻿
variability﻿in﻿the﻿length﻿and﻿flexibility﻿among﻿the﻿active﻿molecules.﻿The﻿shortest﻿distances﻿are﻿for﻿
wild﻿type﻿AR﻿antagonist﻿(A﻿ring﻿to﻿B﻿ring:﻿4.09﻿Å﻿and﻿D4﻿to﻿H7:﻿7.867﻿Å).﻿The﻿angle﻿between﻿the﻿
A﻿ring﻿and﻿B﻿ring﻿is﻿always﻿acute﻿(<90º),﻿with﻿the﻿ordinates﻿in﻿the﻿linker﻿region﻿(R10-D4-R11﻿=﻿
39.3º,﻿R10-D5-R11﻿=﻿66º,﻿R10-A3-R11﻿=﻿60.8).﻿The﻿shorter﻿distances﻿and﻿acute﻿angle﻿between﻿
the﻿A﻿ring﻿and﻿B﻿ring﻿ indicate﻿a﻿ flexible﻿ linker﻿ region﻿among﻿ the﻿active﻿molecules.﻿The﻿ longest﻿
distances﻿are﻿for﻿the﻿T877A﻿mutant﻿antagonist﻿(ring﻿A﻿to﻿ring﻿B:﻿8.895﻿Å﻿and﻿H5﻿to﻿H6:﻿13.267﻿Å).﻿
The﻿angle﻿between﻿the﻿A﻿ring﻿and﻿B﻿ring﻿is﻿always﻿obtuse﻿(>90º),﻿with﻿the﻿ordinates﻿in﻿the﻿linker﻿
Figure 8. Representation of the distances between the pharmacophore site points of full antagonist
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region﻿(R10-A2-R9﻿=﻿122.3º).﻿The﻿longer﻿distances﻿and﻿obtuse﻿angles﻿between﻿the﻿A﻿and﻿B﻿rings﻿
indicate﻿a﻿less﻿flexible﻿linker﻿region﻿among﻿the﻿active﻿molecules.﻿The﻿distances﻿of﻿the﻿full﻿antagonist﻿
pharmacophore﻿are﻿marginally﻿less﻿than﻿the﻿T877A﻿mutant﻿3D-QSAR﻿(ring﻿A﻿to﻿ring﻿B:﻿7.217﻿Å﻿
and﻿A1﻿to﻿R10:﻿10.811﻿Å).﻿Also,﻿the﻿angle﻿between﻿the﻿A﻿and﻿B﻿rings﻿is﻿always﻿obtuse﻿(>90º),﻿with﻿
the﻿ordinates﻿in﻿the﻿linker﻿region﻿(R10-H9-R11﻿=﻿116.2º).﻿The﻿relatively﻿longer﻿distances﻿and﻿obtuse﻿
angles﻿between﻿the﻿A﻿and﻿B﻿rings﻿indicate﻿a﻿less﻿flexible﻿linker﻿region﻿among﻿the﻿active﻿molecules.﻿
Notably,﻿the﻿3D-QSAR﻿of﻿full﻿antagonists﻿does﻿not﻿represent﻿the﻿site﻿points﻿for﻿H-Bond﻿interaction﻿
in﻿the﻿linker﻿region.﻿The﻿3D-QSAR﻿of﻿wild﻿type﻿AR﻿favors﻿H-bond﻿interaction﻿in﻿the﻿linker﻿region﻿
Figure 9. Representation of the best fit molecule with the full antagonist 3D-QSAR
Figure 10. Representation of the cube model of the full antagonist 3D-QSAR best fit molecule
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when﻿compared﻿to﻿the﻿other﻿two.﻿This﻿is﻿because﻿it﻿has﻿3﻿pharmacophore﻿points﻿(A1,﻿D4﻿and﻿D5)﻿in﻿
the﻿linker﻿region,﻿which﻿could﻿form﻿H-Bond﻿interactions.
The﻿ identified﻿ similarities﻿ and﻿ differences﻿ of﻿ the﻿ pharmacophore﻿ site﻿ points﻿ and﻿ favorable﻿
substitutions﻿were﻿evaluated﻿for﻿their﻿interactions﻿with﻿the﻿AR.﻿This﻿is﻿essential﻿because﻿most﻿of﻿the﻿
functional﻿groups﻿will﻿be﻿involved﻿in﻿interactions﻿with﻿AR,﻿which﻿decides﻿the﻿efficacy﻿and﻿resistance﻿
of﻿the﻿molecules.﻿The﻿favorable﻿regions,﻿4-nitro﻿or﻿4-nitrile﻿substitutions﻿in﻿the﻿A﻿ring﻿participate﻿in﻿
the﻿H-Bond﻿interaction﻿with﻿amino﻿acids﻿Arg752,﻿Gln711,﻿and﻿HOH108﻿(Bohl﻿et﻿al.,﻿2005).﻿These﻿
interactions﻿with﻿AR﻿are﻿essential﻿for﻿specific﻿binding.﻿The﻿B﻿ring﻿of﻿the﻿AR﻿antagonist﻿interacts﻿with﻿
the﻿helix-12﻿region,﻿which﻿in﻿turn,﻿determines﻿the﻿agonist﻿and﻿antagonist﻿proclivities﻿of﻿the﻿ligands.﻿
The﻿ligands,﻿which﻿could﻿displace﻿the﻿helix-12﻿away﻿from﻿the﻿binding﻿pocket,﻿will﻿block﻿the﻿activation﻿
of﻿the﻿AR﻿and﻿function﻿as﻿antagonists.﻿The﻿ligands,﻿which﻿do﻿not﻿affect﻿the﻿conformation﻿of﻿helix-12,﻿
will﻿function﻿as﻿an﻿agonist/partial﻿agonist.﻿The﻿mutations﻿in﻿AR﻿increase﻿the﻿space﻿within﻿the﻿ligand﻿
binding﻿pocket﻿to﻿accommodate﻿for﻿ligands﻿without﻿the﻿displacement﻿of﻿helix-12﻿from﻿the﻿binding﻿
pocket﻿(Bohl﻿et﻿al.,﻿2005,﻿Osguthorpe﻿et﻿al.,﻿2011).﻿This﻿displacement﻿of﻿helix-12﻿away﻿from﻿the﻿
ligand﻿binding﻿pocket,﻿unveils﻿the﻿binding﻿surface﻿for﻿co-repressor﻿NcoR/SMRT﻿interaction,﻿which﻿
leads﻿to﻿the﻿inhibition﻿of﻿the﻿AR﻿mediated﻿transcriptional﻿activity﻿(Hodgson﻿et﻿al.,﻿2008).﻿All﻿our﻿
models﻿have﻿shown﻿that﻿the﻿hydrophobic﻿substitution﻿at﻿3rd﻿or﻿4th﻿or﻿5th﻿position﻿in﻿the﻿B﻿ring﻿favored﻿
the﻿antagonistic﻿activity.﻿This﻿could﻿be﻿because﻿those﻿ligands﻿could﻿increase﻿the﻿steric﻿clash﻿between﻿
the﻿ligand﻿and﻿helix-12﻿amino﻿acids,﻿thereby﻿favoring﻿the﻿antagonist﻿activity.﻿From﻿these﻿3D-QSAR﻿
models,﻿we﻿could﻿possibly﻿deduce﻿ that﻿ smaller﻿and/﻿or﻿ flexible﻿molecules﻿could﻿be﻿ sufficient﻿ to﻿
block﻿wild﻿type﻿AR.﻿For﻿T877A﻿mutant﻿AR,﻿a﻿bigger﻿molecule﻿in﻿length﻿plus﻿less﻿flexibility﻿would﻿
be﻿required﻿to﻿block﻿it.
Figure 11. The 2D diagram representing the essential features of pharmacophore
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Ligand and Structure Based Screening
The﻿3D-QSAR﻿of﻿full﻿antagonist﻿was﻿used﻿for﻿screening﻿the﻿SPECS﻿database﻿for﻿the﻿identification﻿
of﻿possible﻿matches﻿(Darshit﻿et﻿al.,﻿2014).﻿Searching﻿for﻿hits﻿using﻿the﻿3D-QSAR﻿model﻿generated﻿
by﻿ the﻿wild﻿ type﻿may﻿ lead﻿ to﻿ identification﻿of﻿ smaller﻿and﻿ /﻿or﻿highly﻿ flexible﻿molecules.﻿Those﻿
molecules﻿ could﻿be﻿kept﻿within﻿ the﻿binding﻿pocket﻿when﻿ the﻿binding﻿pocket﻿ becomes﻿bigger﻿ as﻿
in﻿ the﻿ case﻿of﻿mutation.﻿We﻿also﻿ chose﻿not﻿ to﻿use﻿T877A﻿mutant﻿3D-QSAR﻿model﻿because﻿ the﻿
mutation﻿is﻿specific﻿to﻿flutamide﻿treatment﻿(Hara﻿et﻿al.,﻿2003).﻿Moreover,﻿the﻿AR﻿antagonist﻿will﻿be﻿
administered﻿when﻿there﻿is﻿no﻿mutation﻿in﻿AR﻿and﻿the﻿mutation﻿only﻿occurs﻿during﻿the﻿treatment.﻿
Hence,﻿the﻿hits﻿were﻿identified﻿from﻿full﻿antagonist﻿pharmacophore.﻿This﻿will﻿identify﻿ligands﻿with﻿
optimal﻿bulk,﻿which﻿will﻿efficiently﻿antagonize﻿wild﻿type﻿AR﻿and﻿could﻿possibly﻿resist﻿the﻿mutations.﻿
The﻿full﻿antagonist﻿cannot﻿access﻿the﻿binding﻿pocket﻿with﻿helix-12﻿in﻿agonist﻿conformation.﻿The﻿AR﻿
antagonist,﻿enzalutamide,﻿did﻿not﻿have﻿binding﻿affinity﻿for﻿with﻿helix-12﻿positive﻿AR.﻿Therefore,﻿a﻿
homology﻿model﻿receptor﻿was﻿built﻿without﻿helix-12.﻿The﻿ligands﻿which﻿could﻿bind﻿with﻿helix-12﻿
positive﻿AR﻿might﻿not﻿be﻿full﻿antagonists.﻿Those﻿ligands﻿could﻿be﻿easily﻿converted﻿into﻿agonist﻿when﻿
mutation﻿occurs.﻿The﻿H-Bonding﻿pattern﻿also﻿influences﻿the﻿resistance﻿to﻿some﻿extent.﻿There﻿are﻿two﻿
sets﻿of﻿H-Bond﻿interactions﻿that﻿could﻿occur﻿between﻿a﻿ligand﻿and﻿AR.﻿The﻿amino﻿acids﻿Arg752,﻿
Gln711﻿and﻿HOH108﻿are﻿present﻿deep﻿inside﻿the﻿binding﻿pocket.﻿The﻿amino﻿acids﻿Leu704,﻿Thr877﻿
and﻿Asn705﻿are﻿present﻿laterally﻿to﻿the﻿helix-12.﻿Preferential﻿H-Bond﻿interaction﻿with﻿amino﻿acids﻿
near﻿helix-12﻿prevents﻿the﻿ligand﻿from﻿clashing﻿with﻿the﻿same﻿(Guo﻿et﻿al.,﻿2012).﻿Hence,﻿the﻿ligands﻿
should﻿preferentially﻿form﻿H-Bond﻿interactions﻿only﻿with﻿the﻿deep﻿residues.
Hits Identification
The﻿3D-QSAR﻿model﻿of﻿full﻿antagonist﻿was﻿used﻿to﻿find﻿matches﻿in﻿the﻿SPECS﻿database﻿(>1﻿million﻿
compounds).﻿The﻿pharmacophore﻿matched﻿ligands﻿(1001﻿ligands)﻿were﻿ranked﻿according﻿to﻿the﻿fitness﻿
score﻿(maximum﻿of﻿3).﻿The﻿ligands﻿with﻿fitness﻿score﻿>2﻿(666﻿ligands)﻿were﻿subjected﻿to﻿structure﻿
based﻿screening.﻿Initially,﻿the﻿ligands﻿were﻿screened﻿for﻿optimum﻿bulkiness﻿by﻿docking﻿with﻿helix-12﻿
positive﻿AR.﻿The﻿ligands﻿that﻿did﻿not﻿have﻿binding﻿affinity﻿for﻿helix-12﻿positive﻿AR﻿were﻿selected﻿
for﻿the﻿next﻿step.﻿This﻿filtering﻿will﻿thus﻿eliminate﻿the﻿less﻿bulky﻿/﻿highly﻿flexible﻿ligands﻿and﻿reduce﻿
the﻿total﻿ligands﻿to﻿192.﻿These﻿remaining﻿ligands﻿were﻿docked﻿with﻿helix-12﻿negative﻿AR﻿by﻿extra﻿
precision﻿(XP)﻿glide﻿docking﻿method.﻿Here﻿we﻿selected﻿molecules﻿that﻿form﻿H-Bond﻿interaction﻿with﻿
deep﻿residues﻿(Arg752,﻿Gln711,﻿etc.)﻿and﻿not﻿with﻿ones﻿present﻿near﻿the﻿helix-12﻿(Asn705,﻿Leu704,﻿
etc.).﻿Only﻿one﻿molecule﻿passed﻿ the﻿H-Bond﻿query.﻿The﻿ ligand﻿(SPECS﻿ID:﻿88/32738047)﻿has﻿a﻿
fitness﻿score﻿of﻿2.002/3﻿(Figure﻿12).﻿The﻿interaction﻿between﻿the﻿hit﻿molecule﻿and﻿AR﻿is﻿given﻿in﻿the﻿
Supplementary﻿section﻿(Figure﻿S1).﻿The﻿hit﻿molecule﻿has﻿two﻿nitro﻿groups﻿which﻿may﻿cause﻿toxicity.﻿
This﻿is﻿because﻿the﻿nitro-aromatic﻿compounds﻿could﻿be﻿bio-activated﻿in﻿the﻿liver﻿and﻿could﻿cause﻿
hepatotoxicity﻿(Boelsterli﻿et﻿al.,﻿2006).﻿The﻿AR﻿antagonist﻿flutamide﻿also﻿exhibited﻿hepatotoxicity﻿
possibly﻿ because﻿ of﻿ the﻿ presence﻿ of﻿ nitro-aryl﻿ group.﻿We﻿ also﻿ ran﻿ the﻿ generated﻿ full﻿ antagonist﻿
pharmacophore﻿with﻿the﻿compounds﻿in﻿the﻿first﻿two﻿data﻿sets﻿(wild﻿and﻿mutant)﻿and﻿also﻿among﻿the﻿
compounds﻿from﻿our﻿previous﻿study﻿(Elencheran﻿et﻿al.,﻿2016).﻿But﻿none﻿of﻿the﻿compounds﻿displayed﻿
a﻿fitness﻿value﻿over﻿the﻿threshold﻿of﻿2.﻿Thus,﻿the﻿output﻿generated﻿by﻿this﻿screening﻿should﻿give﻿more﻿
clues﻿and﻿directions﻿in﻿designing﻿novel﻿molecules﻿for﻿resistant﻿AR﻿proteins.
CoNCLUSIoN
In﻿this﻿study,﻿we﻿have﻿identified﻿the﻿pharmacophore﻿from﻿three﻿different﻿AR﻿antagonist﻿datasets.﻿The﻿
models﻿of﻿wild﻿and﻿T877A﻿mutated﻿ARs﻿could﻿be﻿used﻿to﻿differentiate﻿or﻿identify﻿the﻿structural﻿features﻿
of﻿the﻿respective﻿antagonists.﻿The﻿full﻿antagonist﻿3D-QSAR﻿model﻿could﻿be﻿used﻿to﻿designing﻿aspects﻿
for﻿the﻿identification﻿of﻿hit﻿molecules.﻿The﻿differences﻿in﻿the﻿pharmacophore﻿indicate﻿that﻿a﻿major﻿
change﻿in﻿the﻿bulk﻿and﻿flexibility﻿of﻿the﻿existing﻿AR﻿antagonist﻿was﻿required﻿to﻿overcome﻿resistance.﻿
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Other﻿relevant﻿filters﻿were﻿also﻿employed﻿for﻿the﻿identification﻿of﻿hits.﻿This﻿led﻿to﻿the﻿identification﻿
of﻿only﻿one﻿hit﻿starting﻿with﻿>1﻿million﻿compounds﻿in﻿the﻿database.﻿Combining﻿the﻿3D-QSAR﻿and﻿
docking﻿studies,﻿we﻿propose﻿ that﻿ the﻿AR﻿antagonist﻿ should﻿preferably﻿ form﻿H-Bond﻿ interactions﻿
with﻿deep﻿amino﻿acid﻿residues﻿(Gln711,﻿Arg752,﻿HOH108)﻿in﻿the﻿active﻿site.﻿Since﻿the﻿mutations﻿
increase﻿the﻿space﻿within﻿the﻿ligand﻿binding﻿pocket,﻿the﻿AR﻿antagonist﻿should﻿have﻿additional﻿bulky﻿
group(s)﻿and﻿has﻿to﻿attain﻿an﻿optimal﻿conformation﻿in﻿order﻿to﻿push﻿the﻿12th﻿helix﻿away﻿from﻿the﻿ligand﻿
binding﻿pocket.﻿The﻿antagonist﻿that﻿could﻿overcome﻿the﻿mutations﻿will﻿thus﻿be﻿a﻿relatively﻿flat﻿and﻿
rigid﻿molecule﻿that﻿resists﻿bending.﻿This﻿is﻿because﻿the﻿flexible﻿ligands﻿might﻿be﻿packed﻿within﻿the﻿
mutated﻿receptor﻿binding﻿pocket.﻿Hence,﻿the﻿bulky﻿group(s)﻿in﻿the﻿flexible﻿ligands﻿would﻿not﻿reach﻿
the﻿12th﻿helix﻿to﻿induce﻿the﻿steric﻿clash.﻿The﻿helix-12﻿positive﻿and﻿negative﻿ARs﻿could﻿be﻿effectively﻿
used﻿to﻿differentiate﻿AR﻿antagonists﻿from﻿agonists﻿and﻿partial﻿agonists.﻿Agonists﻿and﻿partial﻿agonists﻿
bind﻿to﻿the﻿ligand﻿binding﻿pocket﻿while﻿the﻿12th﻿helix﻿is﻿in﻿closed﻿conformation.﻿The﻿pure﻿antagonist﻿
will﻿not﻿bind﻿to﻿the﻿receptor﻿binding﻿site﻿in﻿12th﻿helix﻿closed﻿conformation﻿and﻿will﻿only﻿access﻿it﻿in﻿
the﻿absence﻿of﻿12th﻿helix.﻿This﻿hypothesis﻿could﻿then﻿be﻿used﻿in﻿the﻿further﻿structure﻿based﻿screening﻿
for﻿AR﻿antagonists﻿that﻿overcomes﻿resistance.
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Figure 12. Representation of the pharmacophore match of the identified hit
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Abstract:Androgen receptor (AR) is an attractive target for the treatment of prostate cancer.
Structural modification and molecular docking­based virtual screening approaches were imposed to
identify the novel 1,3­thiazolidine­2,4­diones (TZDs) by using Schrödinger (Maestro 9.5). The best fit
molecules (3­12 & 23­31) were synthesized and characterized using spectroscopic techniques, then in
vitro antioxidant and anti­prostate cancer activities were evaluated. Further, the structure of the
intermediate (18) was confirmed by single crystal XRD analysis. Of these compounds, 29, 30 and 31
showed comparatively significant antioxidant activity and better antiproliferative activity against PC­3 &
LNCaP cell lines. Also, a very low cytotoxicity was observed in the non­cancerous cell (3T3). The
mechanism studies were performed through the gene expression for the compounds,
dihydrotestosterone, R­bicalutamide, 29, 30 and 31. The compounds, 29, 30 and 31 significantly
decreased the mRNA expression of AR­stimulated genes, PSA and TMPRSS2 which explains their
anti­prostate cancer activity. ADME/T properties prediction of the compounds (3­12 & 23­31) showed
the promising drug­likeness and pharmacokinetic parameters without any toxicity. Moreover, DFT
calculations were apparently confirmed the stable conformer of the compound, 31. These findings
may provide the essential information for the development of anti­prostate cancer agents.
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